

0001628280-24-03479110-Q MEDIFAST INC 2024080520240805165048165049165049 0 0001628280-24-034791 10-Q 59 20240630 20240805 20240805 MEDIFAST INC 0000910329 2090 133714405 DE 1231 10-Q 34 0001-31573 241175648 11445 CRONHILL DRIVE OWINGS MILLS MD 21117 7327640619 11445 CRONHILL DRIVE OWINGS MILLS MD 21117 HEALTHRITE INC 19951120 XX 19950619 00 19950619 10-Q 1 med-20240630.htm 10-Q med-20240630000091032912-312024Q3FALSEXbrii:sharesiso4217:USDiso4217:USDXbrii:sharesxbrii:pure00009103292024-01-012024-06-3000009103292024-07-2900009103292024-04-012024-06-3000009103292023-04-012023-06-3000009103292023-01-012023-06-3000009103292023-12-3100009103292022-12-3100009103292022-06-300000910329us-gaap:CommonStockMember2023-12-310000910329us-gaap:AdditionalPaidInCapitalMember2023-12-310000910329us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000910329us-gaap:RetainedEarningsMember2023-12-310000910329us-gaap:TreasuryStockCommonMember2023-12-310000910329us-gaap:RetainedEarningsMember2024-01-012024-03-3100009103292024-01-012024-03-310000910329us-gaap:CommonStockMember2024-01-012024-03-310000910329us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000910329us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000910329us-gaap:CommonStockMember2024-03-310000910329us-gaap:AdditionalPaidInCapitalMember2024-03-310000910329us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000910329us-gaap:RetainedEarningsMember2024-03-310000910329us-gaap:TreasuryStockCommonMember2024-03-3100009103292024-03-310000910329us-gaap:RetainedEarningsMember2024-04-012024-06-300000910329us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000910329us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000910329us-gaap:CommonStockMember2024-06-300000910329us-gaap:AdditionalPaidInCapitalMember2022-12-310000910329us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000910329us-gaap:RetainedEarningsMember2022-12-310000910329us-gaap:TreasuryStockCommonMember2022-12-310000910329us-gaap:RetainedEarningsMember2023-01-012023-03-3100009103292023-01-012023-03-310000910329us-gaap:CommonStockMember2023-01-012023-03-310000910329us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000910329us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000910329us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000910329us-gaap:CommonStockMember2023-03-310000910329us-gaap:AdditionalPaidInCapitalMember2023-03-310000910329us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000910329us-gaap:RetainedEarningsMember2023-03-310000910329us-gaap:TreasuryStockCommonMember2023-03-3100009103292023-03-310000910329us-gaap:RetainedEarningsMember2023-04-012023-06-300000910329us-gaap:CommonStockMember2023-04-012023-06-300000910329us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000910329us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000910329us-gaap:CommonStockMember2023-06-300000910329us-gaap:AdditionalPaidInCapitalMember2023-06-300000910329us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000910329us-gaap:RetainedEarningsMember2023-06-300000910329us-gaap:TreasuryStockCommonMember2023-06-300000910329us-gaap:RestrictedStockMember2024-04-012024-06-300000910329us-gaap:RestrictedStockMember2023-04-012023-06-300000910329us-gaap:RestrictedStockMember2024-01-012024-06-300000910329us-gaap:RestrictedStockMember2023-01-012023-06-300000910329us-gaap:EmployeeStockOptionMember2024-01-012024-06-300000910329us-gaap:RestrictedStockMember2024-01-012024-06-300000910329us-gaap:RestrictedStockMember2023-12-310000910329us-gaap:RestrictedStockMember2022-12-310000910329us-gaap:RestrictedStockMember2023-01-012023-06-300000910329us-gaap:RestrictedStockMember2024-06-300000910329us-gaap:RestrictedStockMember2023-06-300000910329us-gaap:PerformanceSharesMembersrt:MinimumMember2024-01-012024-06-300000910329us-gaap:PerformanceSharesMembersrt:MaximumMember2024-01-012024-06-300000910329us-gaap:PerformanceSharesMemberbermed:GrantedInMarch2022Member2023-01-012023-03-310000910329med:MarketAndPerformanceBasedShareMemberbermed:GrantedInOctober2021Member2024-04-012024-06-300000910329med:MarketAndPerformanceBasedShareMember2024-01-012024-06-300000910329med:MarketAndPerformanceBasedShareMember2023-01-012023-06-300000910329med:OptionsAndRestrictedStockMember2024-04-012024-06-300000910329med:OptionsAndRestrictedStockMember2023-04-012023-06-300000910329med:GrantedIn2024Memberus-gaap:PerformanceSharesMember2024-04-012024-06-300000910329med:GrantedIn2024Memberus-gaap:PerformanceSharesMember2023-04-012023-06-300000910329med:MarketAndPerformanceBasedShareMemberbermed:GrantedIn2023Member2024-04-012024-06-300000910329med:MarketAndPerformanceBasedShareMemberbermed:GrantedIn2023Member2023-04-012023-06-300000910329med:GrantedIn2022Memberbermed:MarketAndPerformanceBasedShareMember2024-04-012024-06-300000910329med:GrantedIn2022Memberbermed:MarketAndPerformanceBasedShareMember2023-04-012023-06-300000910329us-gaap:PerformanceSharesMemberbermed:GrantedIn2021Member2023-04-012023-06-300000910329us-gaap:PerformanceSharesMemberbermed:GrantedIn2020Member2023-04-012023-06-300000910329med:OptionsAndRestrictedStockMember2024-01-012024-06-300000910329med:OptionsAndRestrictedStockMember2023-01-012023-06-300000910329med:GrantedIn2024Memberus-gaap:PerformanceSharesMember2024-01-012024-06-300000910329med:GrantedIn2024Memberus-gaap:PerformanceSharesMember2023-01-012023-06-300000910329med:MarketAndPerformanceBasedShareMemberbermed:GrantedIn2023Member2024-01-012024-06-300000910329med:MarketAndPerformanceBasedShareMemberbermed:GrantedIn2023Member2023-01-012023-06-300000910329med:GrantedIn2022Memberbermed:MarketAndPerformanceBasedShareMember2024-01-012024-06-300000910329med:GrantedIn2022Memberbermed:MarketAndPerformanceBasedShareMember2023-01-012023-06-300000910329us-gaap:PerformanceSharesMemberbermed:GrantedIn2021Member2023-01-012023-06-300000910329us-gaap:PerformanceSharesMemberbermed:GrantedIn2020Member2023-01-012023-06-300000910329med:MarketAndPerformanceBasedShareMember2024-06-300000910329us-gaap:PerformanceSharesMember2024-06-300000910329med:OperatingLeaseArrangementForRealEstateMembersrt:MinimumMember2024-06-300000910329med:OperatingLeaseArrangementForRealEstateMembersrt:MaximumMember2024-06-300000910329srt:MinimumMemberbermed:OperatingLeaseArrangementForEquipmentMember2024-06-300000910329med:CashAndCashEquivalentsExcludingMoneyMarketFundsMember2024-06-300000910329us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2024-06-300000910329us-gaap:FairValueInputsLevel1Member2024-06-300000910329us-gaap:FairValueInputsLevel1Member2024-01-012024-06-300000910329us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2024-06-300000910329med:CashAndCashEquivalentsExcludingMoneyMarketFundsMember2023-12-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-12-310000910329us-gaap:FairValueInputsLevel1Member2023-12-310000910329us-gaap:FairValueInputsLevel1Member2023-01-012023-12-310000910329us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2023-12-310000910329med:LifeMDMember2023-10-012023-12-310000910329med:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementInitialMilestonePaymentMemberbermed:LifeMDMember2023-12-310000910329med:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementSecondMilestonePaymentMemberbermed:LifeMDMember2024-03-180000910329med:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementSecondMilestonePaymentMemberbermed:LifeMDMember2024-01-012024-03-310000910329med:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementSecondMilestonePaymentMemberbermed:LifeMDMember2024-04-012024-06-300000910329med:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementFinalMilestonePaymentMemberbermed:LifeMDMember2024-06-050000910329med:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementFinalMilestonePaymentMemberbermed:LifeMDMember2024-04-012024-06-300000910329med:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementFinalMilestonePaymentMembersrt:ScenarioForecastMemberbermed:LifeMDMember2024-07-012024-09-300000910329med:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2021-04-130000910329med:AmendedCreditAgreementMemberus-gaap:LetterOfCreditMember2021-04-130000910329med:AmendedCreditAgreementMemberbermed:UncommittedIncrementalFacilityMember2021-04-130000910329med:AmendedCreditAgreementMembersrt:MinimumMember2021-04-132021-04-130000910329med:AmendedCreditAgreementMembersrt:MaximumMember2021-04-132021-04-130000910329med:AmendedCreditAgreementMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2024-01-012024-06-300000910329us-gaap:BaseRateMemberbermed:AmendedCreditAgreementMember2024-01-012024-06-300000910329med:AmendedCreditAgreementMember2021-04-130000910329med:AmendedCreditAgreementMember2024-06-30Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORM 10-Qx QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended June 30, 2024Or Transition Report PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _____ to _____.Commission File Number: 001-31573Medifast, Inc. (Exact name of registrant as specified in its charter)Delaware13-3714405(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)100 International DriveBaltimore, Maryland 21202Telephone Number: (410) 581-8042(Address of Principal Executive Offices, Zip Code and Telephone Number, Including Area Code)Securities registered pursuant to Section 12(b) of the Act:Title of each classTrading SymbolName of each exchange on which registeredCommon Stock, par value \$0.001 per shareMEDNew York Stock ExchangeIndicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes x No oIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes x No oIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company  Emerging growth company  If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. oIndicate by checkmark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes o No xIndicate the number of shares outstanding of each of the issuers classes of common stock, as of the latest practicable date.The number of shares of the registrants common stock outstanding at JulyA 29, 2024 was 10,937,418. Table of ContentsMedifast, Inc. and SubsidiariesIndexPart 1  Financial InformationItem 1  Financial StatementsCondensed Consolidated Statements of Operations (unaudited) for the Three and Six Months Ended June 30, 2024 and 2023Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) for the Three and Six Months Ended June 30, 2024 and 2023Condensed Consolidated Balance Sheets (unaudited) as of June 30, 2024 and December 31, 2023Condensed Consolidated Statements of Cash Flows (unaudited) for the Six Months Ended June 30, 2024 and 2023Condensed Consolidated Statements of Changes in Stockholders Equity (unaudited) for the Three and Six Months Ended June 30, 2024 and 2023Notes to Condensed Consolidated Financial Statements (unaudited)Item 2  Managements Discussion and Analysis of Financial Condition and Results of Operations15Item 3  Quantitative and Qualitative Disclosures about Market Risk26Item 4  Controls and Procedures26Part II  Other InformationItem 1  Legal Proceedings28Item 1A  Risk Factors28Item 2  Unregistered Sales of Equity Securities and Use of Proceeds28Item 6  Exhibits291Table of Contents MEDIFAST, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)(U.S. dollars in thousands, except per share amounts & dividend data)Three months ended June 30, Six months ended June 30,2024202320242023Revenues168,558969,188\$343,297\$645,170Cost of sales45,12085,473\$2,567\$188,065Gross profit123,438210,715\$250,824\$457,105Selling, general, and administrative131,314172,009250,66364,887Income (loss) from operations(7,876)38,7066492,180Other income (expense)Interest income1,2964622,159181Other expense(4,070)(51)(1,647)(53)(2,774)411872228Income (loss) from operations before income taxes(10,650)39,11793692,446Provision (benefit) for income taxes(2,496)8,83777322,198Net income (loss)\$(8,154)\$30,280\$163\$70,248Earnings (loss) per share - basics\$(0.75)\$2.78\$0.01\$6.43Earnings (loss) per share - diluted\$(0.75)\$2.77\$0.01\$6.43Weighted average shares outstandingBasic10,93710,88810,92310,876Diluted10,93710,96710,923Cash dividends declared per share\$\$1.65\$\$3.30The accompanying notes are an integral part of these condensed consolidated financial statements.2Table of ContentsMEDIFAST, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)(U.S. dollars in thousands)Three months ended June 30, Six months ended June 30,2024202320242023Net income (loss)\$(8,154)\$30,280\$163\$70,248Other comprehensive income (loss), net of tax:Foreign currency translation32A 904399Unrealized losses on investment securities(28)(265)4A 90(22)99Comprehensive income (loss)\$(8,150)\$30,370\$(59)\$70.347The accompanying notes are an integral part of these condensed consolidated financial statements.3Table of ContentsMEDIFAST, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)(U.S. dollars in thousands, except par value)June 30, 2024December 31, 2023ASSETSCurrent AssetsCash and cash equivalents\$108,016\$94,440Inventories39,603\$54,591Investments55,489\$65,601Income taxes, prepaid, 728\$7,727Prepaid expenses and other current assets12,47910,670Total current assets224,315224,029Property, plant and equipment - net of accumulated depreciation39,921\$51,467Right-of-use assets13,417\$15,645Other assets11,77014,650Deferred tax assets4,1084,117TOTAL ASSETS\$293,531\$309,908LIABILITIES AND STOCKHOLDERS' EQUITYCurrent LiabilitiesAccounts payable and accrued expenses\$69,148\$86,415Current lease obligations,031\$5,885Total current liabilities75,179\$92,300Lease obligations, net of current lease obligations13,06916,127Total liabilities88,248108,427Stockholders' EquityCommon stock, par value \$0.001 per share: 20,000 shares authorized; 10,937 and 10,896 issued and outstandingat JuneA 30, 2024 and DecemberA 31, 2023, respectively1111Additional paid-in capital30,40126,573Accumulated other comprehensive income26248Retained earnings 174,845174,649Total stockholders' equity205,283201,481TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY\$293,531\$309,908The accompanying notes are an integral part of these condensed consolidated financial statements.4Table of ContentsMEDIFAST, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)(U.S. dollar in thousands)Six months ended June 30, 20242023Operating ActivitiesNet income\$163\$70.248Adjustments to reconcile net income to cash provided by operating activitiesDepreciation and amortization 6,3286,342Non-cash lease expense2,2525,514Share-based compensation4,6253,120Loss on sale or disposal of property, plant and equipment51619Realized gain on sale of investment securities(74)Amortization of discount on investment securities(372)Deferred income taxes9800Unrealized loss on equity investment securities1,752Non-cash charges for supply chain optimization11,689Change in operating assets and liabilities:Inventories14,98849,960Prepaid expenses and other current assets(1,809)3,721Other assets206(2,142)Accounts payable and accrued expenses (19,430)(31,851)Income taxes

[illegible]

Companyâ€™s operating lease liabilities as of June 30, 2024 (in thousands):2024 (excluding the six months ended June 30, 2024)\$3,171A 20256,462A 20264,783A 20272,553A 20282,618A Thereafter240A Total lease payments\$19,827A Less: imputed interest(727)Total \$19,100A 6. ACCUMULATED OTHER COMPREHENSIVE INCOMEThe following table sets forth the components of accumulated other comprehensive income, net of tax where applicable (in thousands):June 30, 2024December 31, 2023Foreign currency translation\$(5)(48)Unrealized net gains on investment securities31A 296A Accumulated other comprehensive income\$26A \$248A 7. INVESTMENTSCertain financial assets and liabilities are accounted for at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy prioritizes the inputs used to measure fair value:Level 1 â€” Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an on-going basis.Level 2 â€” Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.Level 3 â€” Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in managementâ€™s best estimate of fair value from the perspective of a market participant.12Table of ContentsThe following tables present the Companyâ€™s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):June 30, 2024CostUnrealized Gains (Losses)Accrued InterestEstimated FairValueCash & CashEquivalentsInvestmentSecuritiesCash and cash equivalents, excluding money market accounts\$102,982\$â€”\$â€”\$102,982\$102,982\$â€”Level 1:Money market accounts5,034â€”â€”â€”5,0345,034â€”Government & agency securities16,128(42)7416,160â€”16,160Equity securities10,000(1,600)â€”8,400â€”8,40031,162(1,642)7429,5945,03424,560Level 2:Corporate bonds30,5777927330,929â€”30,929Totals164,721\$(1,563)\$347\$163,505\$108,016\$55,489December 31, 2023CostUnrealized GainsAccrued InterestEstimated FairValueCash & CashEquivalentsInvestmentSecuritiesCash and cash equivalents, excluding money market accounts\$88,778\$â€”\$â€”\$88,778\$88,778\$â€”Level 1:Money market accounts5,662â€”â€”5,6625,662â€”Government & agency securities15,2821264015,448â€”15,448Equity Securities10,000150â€”10,150â€”10,15030,9442764031,2605,66225,598Level 2:Corporate bonds29,44029327030,003â€”30,003Totals149,162\$569\$310\$150,041\$94,405\$55,601The Company had \$65 thousand and \$0 realized gains for the three months ended June 30, 2024 and 2023. The Company had \$74 thousand and \$0 realized gains for the six months ended June 30, 2024 and 2023. During the fourth quarter of 2023, the Company entered into an agreement with LifeMD, Inc (Nasdaq: LFMD), a leading provider of virtual primary care, to purchase shares of common stock of LifeMD for \$10A million. The securities are subject to a registration rights agreement which stipulates that the registration of the securities is to be made as soon as practicable, but not later than 90 days, following written demand by the Company. Written demand was made, and the securities registration remained in process as of June 30, 2024. The registration process was completed, effective July 18, 2024. In addition, the shares were subject to a 180-day lock-up period from the closing date of the agreement, December 11, 2023, which expired as of June 8, 2024. The fair value of the investment is recorded within the investment securities of the consolidated balance sheet. The 13Table of Contentslosses related to the Companyâ€™s LifeMD investment for the three and six months ended June 30, 2024 and 2023 are summarized in the table below (in thousands):Three months ended June 30,20242023Net losses recognized during the period on equity securities\$(4,188)\$â€”A Less: Net losses recognized on equity securities soldâ€”A â€”A Unrealized losses recognized during the reporting period on equity securities still held at the reporting date\$(4,188)\$â€”A Six months ended June 30,20242023Net losses recognized during the period on equity securities\$(1,750)\$â€”A Less: Net losses recognized on equity securities soldâ€”A â€”A Unrealized losses recognized during the reporting period on equity securities still held at the reporting date\$(1,750)\$â€”A The Company concurrently entered into an agreement in which LifeMD would provide services to stand-up the collaboration between LifeMD and the Company. The agreement stipulated an initial milestone payment of \$5A million due upon execution of the agreement for these services. The services under the initial milestone were completed prior to December 31, 2023, and this amount was included in the Companyâ€™s selling, general, and administrative expenses on the consolidated statement of income for the quarter ended December 31, 2023. The Company made a second milestone payment under the agreement of \$2.5A million on March 18, 2024. Of the total \$2.5A million second milestone payment, \$1.3A million was recognized within selling, general, and administrative expenses for services performed by LifeMD for the quarter ended March 31, 2024, with the remaining \$1.2A million recognized in the quarter ended June 30, 2024. The final milestone payment of \$2.5A million was made on June 5, 2024. Of the total \$2.5A million final milestone payment, \$0.8A million was recognized within selling, general, and administrative expenses for services performed by LifeMD for the quarter ended June 30, 2024, with the remaining \$1.7A million to be recognized in the third quarter of 2024.8. DEBTCredit AgreementOn April 13, 2021, the Company and certain of its subsidiaries (collectively, the â€œGuarantorsâ€) entered into a credit agreement (the â€œCredit Agreementâ€) among the Company, the Guarantors, the lenders party thereto and Citibank, N.A., in its capacity as administrative agent. On May 31, 2022, the Credit Agreement was amended to increase the borrowing capacity and convert the interest rate to be based on Secured Overnight Financing Rate (â€œSOFRâ€), from London Inter-Bank Offered Rate (LIBOR) (the â€œAmended Credit Agreementâ€). The Amended Credit Agreement provides for a \$225.0 million senior secured revolving credit facility with a \$20.0 million letter of credit sublimit. The Amended Credit Agreement also provides for an uncommitted incremental facility that permits the Company, subject to certain conditions, to increase the senior secured revolving credit facility by up to \$100.0 million. The Amended Credit Agreement matures on April 13, 2026. The Companyâ€™s obligations under the Amended Credit Agreement are guaranteed by the Guarantors. The obligations of the Company and the Guarantors are secured by first-priority liens on substantially all of the assets of the Company and the Guarantors, subject to certain exceptions.Under the Amended Credit Agreement, the Company will pay to the administrative agent for the account of each revolving lender a commitment fee on a quarterly basis based on amounts committed but unused under the revolving facility from 0.20% to 0.40% per annum depending on the Companyâ€™s Total Net Leverage Ratio (as defined in the Amended Credit Agreement). The Company is also obligated to pay the administrative agent customary fees for credit facilities of this size and type.Revolving borrowings under the Amended Credit Agreement bear interest at a rate per annum equal to (i) the Term SOFR Rate for the interest period plus the Applicable Rate (as defined in the Amended Credit Agreement) based on the Companyâ€™s Total Net Leverage Ratio or (ii) the Alternate Base Rate (as defined in the Amended Credit Agreement) as in effect from time to time 14Table of Contentsplus the Applicable Rate based on the Companyâ€™s Total Net Leverage Ratio. As of June 30, 2024, the Applicable Rate for Term SOFR Loans is 1.25% per annum and the Applicable Rate for ABR Loans is 0.25% per annum. SOFR based loans also include a Credit Spread Adjustment based on the duration of the borrowing. The Amended Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants that, among other things, limit or restrict the ability of the Company and its subsidiaries, subject to negotiated exceptions, to incur additional indebtedness and additional liens on their assets, engage in mergers or acquisitions or dispose of assets, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments and change the nature of their businesses. The Amended Credit Agreement also contains customary events of default, subject to thresholds and grace periods, including, among others, payment default, covenant default, cross default to other material indebtedness and judgment default. In addition, the Amended Credit Agreement requires the Company to maintain a Total Net Leverage Ratio of no more than 2.75 to 1.00 and an Interest Coverage Ratio of at least 3.50 to 1.00.The Company had no borrowings outstanding under the Amended Credit Agreement, inclusive of the credit facility and letter of credit sublimit, as of June 30, 2024 and was in compliance with all covenants.9. SUPPLY CHAIN OPTIMIZATIONDuring the three months ended June 30, 2024, the Company completed a supply chain optimization initiative with the goal of aligning the Companyâ€™s distribution footprint with current demand levels. On June 28, 2024, the Company closed its Maryland Distribution Center located in Ridgely, Maryland. The Company is currently assessing options for the disposition of the land and building, but the associated asset group that includes the land and building is not impaired. The assets within the facility are being actively marketed for sale and were written down to fair value less cost to sell, with the impact reflected below as the loss of impairment of equipment held for sale. The Company identified certain other supply chain assets at other locations within its distribution network that will no longer be utilized and are no longer useful to the Companyâ€™s operations, and adjusted their respective useful lives accordingly, with the impact reflected below in the accelerated depreciation charges.For the three months ended June 30, 2024, the components of the Companyâ€™s supply chain optimization charges were as follows:Three Months EndedJune 30, 2024Loss on impairment of equipment held for sale\$2,499A Accelerated depreciation charges9,190A A A A Non-cash charges for supply chain optimization11,689A One-time severance costs813A A A A Total supply chain optimization\$12,502A For the three months ended June 30, 2024, the supply chain optimization charges were recorded in the Companyâ€™s Condensed Consolidated Statements of Operations as follows:Three Months EndedJune 30, 2024Selling, general, and administrative \$12,502A Total supply chain optimization\$12,502A Item 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS15Table of ContentsNote Regarding Forward-Looking StatementsCertain information in this report contains â€œforward-looking statementsâ€ within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œActâ€). Forward-looking statements generally can be identified by use of phrases or terminology such as â€œintend,â€ â€œanticipate,â€ â€œexpect,â€ or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals, or targets contained herein are also considered forward-looking statements. These statements are based on the current expectations of our management of Medifast and are subject to certain events, risks, uncertainties, and other factors. These risks and uncertainties include, but are not limited to, those described in our 2023 Form 10-K and those described from time to time in our future reports filed with the SEC. Although Medifast believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this report. All of the forward-looking statements contained herein speak only as of the date of this report. We undertake no obligation to update any information contained in this report or to publicly release the results of any revisions to forward-looking statements to reflect events or circumstances of which we may become aware after the date of this report.The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and related notes appearing elsewhere herein.OverviewMedifast is the health and wellness company known for its habit-based and Coach-guided lifestyle solution OPTAVIAâ®. As a physician-founded company with more than 40 years of history, OPTAVIA's lifestyle plans deliver clinically proven health benefits, utilizing scientifically developed products and a framework for habit creation reinforced by independent Coaches and community support. The Company has initiated its business transformation to build a set of differentiated capabilities, reflecting its commitment to providing comprehensive health and wellness solutions to customers as both their needs and the industry evolve, that are expected to position Medifast to be a leader in the dynamic and changing health and wellness space. As part of this transformation, the Company entered into a collaboration with LifeMD, Inc. (Nasdaq: LFMD) (â€œLifeMDâ€) in December of 2023, and launched a significant Company-led marketing effort in May of 2024. Medifast has created a well-capitalized business that has a powerful business model, building a network of approximately 33,900 independent active earning Coaches providing consistent and effective support to customers on their weight loss journeys. In a rapidly changing health and wellness landscape, Medifast is committed to innovating and building upon its scientific and clinical heritage to deliver on its mission of offering the world Lifelong Transformation, Making a Healthy Lifestyle Second Natureâ„¢. With the growing interest in medically supported weight loss and GLP-1 medications powering the emergence of an important new market for products and services to support individuals on their health and wellness journey, Medifast is transforming its business to capitalize on this opportunity. Through the Companyâ€™s collaboration with LifeMD, Inc., OPTAVIA customers now have access to all-in-one holistic solutions, whether they are not utilizing medically supported weight loss, are currently using medical weight loss options, transitioning off medications, or looking for further support after stopping taking medications. This collaboration brings together OPTAVIAâ€™s personalized habit-based, coach-guided approach with medical expertise from board-certified affiliated LifeMD clinicians, allowing access to weight loss medications, including GLP-1 medications, when clinically appropriate. With this collaboration, the Company and LifeMD are developing an integrated offering with the goal of creating a comprehensive and seamless solution for customers who desire to use medications and OPTAVIAâ€™s lifestyle enhancement program, outlined in further detail below. In addition to lifestyle support and a simple roadmap for habit creation, the integrated offering includes scientifically developed nutritional support solutions including a GLP-1 Nutrition Support product kit designed to help mitigate GLP-1 medication side effects, such as muscle loss. Through LifeMD, customers also have access to a medical provider and blood work, as well as prescription and insurance support.As the medications for weight loss continue to evolve and grow, Medifast is dedicated to maintaining a relentless focus on the development of additional support products and supplements designed to meet customer needs and to make living a healthy lifestyle second nature.OPTAVIAâ€™s holistic lifestyle solution is built around four key components:â€¢Independent OPTAVIA Coaches: Independent OPTAVIA Coaches provide individualized support and guidance to customers on the path to optimal health and wellbeing. The Coaches have impacted more than 3 million lives to date.16Table of Contentsâ€¢OPTAVIA Community: A Community of like-minded people provide real-time connection and support.â€¢The Habits of Healthâ® Transformational System: A proprietary system that offers easy steps to a sustainable healthy lifestyle.â€¢Products & Plans: Lifestyle plans with clinically proven health benefits and scientifically developed products, backed by dietitians, scientists, and physicians.OPTAVIA's collaboration with LifeMD offers access to an additional resource for eligible customers:â€¢Clinicians as Partners: Through the collaboration with LifeMD, OPTAVIA customers have access to LifeMDâ€™s board-certified affiliated clinicians and medication, such as GLP-1 medications when clinically appropriate, that support treatment plans for obesity and other health conditions.Across these offerings, customers are aided in achieving their health goals through a network of OPTAVIA Coaches, about 90% of whom were customers first. OPTAVIA Coaches introduce customers to a set of healthy habits, in most cases starting with the habit of healthy eating, and offer exclusive OPTAVIA-branded products, including Fuelings as well as OPTAVIA ACTIVEâ®, a line of essential amino acid supplements and protein powders. Fuelings are nutrient-dense, portion-controlled, nutritionally interchangeable, and simple to use. They are formulated with high-quality ingredients and contain BC30A,â„¢ probiotic cultures, which help support digestive health as part of a balanced diet and healthy lifestyle, vitamins and minerals, as well as other nutrients essential for good health. Our products are used as tools and support the process of integrating healthy habits into our customers' daily lives.The OPTAVIA coaching model is customer-centric and boasts an energized health and wellness community. It promotes holistic health and wellness and positions healthy weight as a catalyst to greater lifestyle changes. OPTAVIA Coaches provide personalized support to customers and motivate them by sharing their passion for healthy living and lifestyle transformation.The entrepreneurial spirit of our OPTAVIA Coaches is another key to our success, as they activate new customers, many of whom go on to become OPTAVIA Coaches. We offer economic incentives designed to support each OPTAVIA Coachâ€™s long-term success, which we believe plays an important role in their financial wellness, providing the opportunity to improve their finances while changing the health trajectory of families, communities, and generations.1OPTAVIA Coaches are independent contractors, not employees, who support customers and market our products and services primarily through word of mouth, email, and social media channels such as Facebook, Instagram, X (formerly known as Twitter), and video conferencing platforms. As entrepreneurs, OPTAVIA Coaches market our products to friends, family, and other acquaintances. OPTAVIA products are shipped directly to customers who are working with an OPTAVIA Coach. OPTAVIA Coaches do not handle inventory or deliver merchandise to customers. This arrangement frees our OPTAVIA Coaches from having to manage inventory and allows them to maintain an arms-length transactional relationship while focusing their attention on support and encouragement.With the expansion of our business to include GLP-1 support tools, we are leveraging multiple channels to enhance customer acquisition and spur meaningful growth. OPTAVIA Coaches remain a fundamental component of our business, and their outreach around our integrated wellness offering is one channel to drive customer acquisition. Additionally, we are collaborating with LifeMD to activate their patient base as another channel for us to acquire customers. Further, in May 2024, we launched a national marketing campaign designed to drive customer acquisition and elevate brand awareness. Additional information surrounding the marketing campaign can be found in the section below titled, â€œRecent Initiatives.â€ These new acquisition channels and investments are intended to evolve the Companyâ€™s current single-channel Coach-focused business model to be one that pairs company advertising with relationship-based Coaching and the ability to access weight

loss medications through our collaboration with LifeMD. Collectively, we believe these initiatives will significantly broaden OPTAVIA’s reach, advancing its mission to empower individuals on their own health journeys, and fuel positive outcomes and revenue streams. We anticipate this momentum will lay the foundation for improved performance in 2025 and beyond.1 OPTAVIA makes no guarantee of financial success. Success with OPTAVIA results from successful sales efforts, which require hard work, diligence, skill, persistence, competence, and leadership. Please see the OPTAVIA Income Disclosure Statement (<http://bit.ly/jidsOPTAVIA>) for statistics on actual earnings of Coaches.17Table of ContentsOur operations are conducted through our wholly owned subsidiaries, Jason Pharmaceuticals, Inc., OPTAVIA, LLC, Jason Enterprises, Inc., Jason Properties, LLC, Seven Crondall Associates, LLC, Corporate Events, Inc., OPTAVIA (Hong Kong) Limited, OPTAVIA (Singapore) PTE. LTD, and OPTAVIA Health Consultation (Shanghai) Co., Ltd.Macroeconomic Conditions and CompetitionCertain economic challenges including the impact of inflation have caused macroeconomic uncertainty and volatility in markets where we, our suppliers and our OPTAVIA Coaches operate.We are exposed to market risks from changes in commodity or other raw material prices. Rising inflation could impact our cost structure and has put pressure on consumer spending. Increases in commodity prices or food costs, including as a result of inflation, could affect the global and U.S. economies and could also adversely impact our business, financial condition, or results of operations. Our variable cost structure can be utilized to adapt to changing market conditions with potential actions including adjustments to our manufacturing, distribution, and customer support infrastructure. In response to changing macroeconomic conditions, the Company may take further actions that alter its business operations that are determined to be in the best interests of its employees, OPTAVIA Coaches and customers, such as evaluating our operational footprint or taking incremental pricing actions to offset supply chain costs and inflationary pressures. The supply chain optimization completed in the quarter ended June 30, 2024, as discussed in Item 1. Notes to Condensed Consolidated Financial Statements are examples of such actions.The weight loss industry is very competitive and encompasses a diverse array of weight loss products and programs. These include a wide variety of commercial weight loss programs, pharmaceutical products, surgical interventions, books, self-help diets, dietary meal replacements, and appetite suppressants as well as digital tools, app-based health and wellness monitoring solutions, and wearable trackers. Potential customers seeking to manage their weight have many options and can turn to online diet-oriented sites, self-directed dieting, traditional center-based competitors, and self-administered products such as prescription medications, over-the-counter medications, and supplements as well as medically supervised programs. Beginning in Q3 2022, we began to see a downward trend in the number of active earning Coaches, driven by a decline in customers and attributable to changing social media algorithms and inflationary pressures on consumer spending. Additionally, the downward trend’s decline became sharper beginning in Q2 2023 due to the increase prevalence and adoption of GLP-1 medications and increased pressures on customer acquisition. We believe that, with continued pressures on customer acquisition, this downward trend in the number of active earning Coaches will continue in the short-term. Medical weight loss solutions, such as GLP-1 medications, have become an increasingly key component of the overall health and wellness ecosystem, and the recent surging awareness and popularity of these weight loss medications serves as another major competing factor, as these products have prompted a huge change in the way that consumers think about weight loss and lifestyle modification solutions in general. We recognize that these weight loss medications have attracted significant attention from the market and pose a threat to our interactions with our customer base. Importantly, the efficacy claims of GLP-1 medications for weight loss are based specifically on their incorporation with lifestyle changes, such as through a structured program like OPTAVIA, that include a reduced calorie diet and increased physical activity. As a result, under Medifast’s offering, access to weight loss medications becomes one important element in an overall tailored lifestyle plan that also includes Coaching, community support, nutritionally balanced meals, and exercise.Our research shows that most of those who are interested in weight loss medications are also looking for support beyond a prescription, including clarity on how to incorporate healthy eating and exercise into their lifestyles while using these medical solutions. While medically supported weight loss can be effective, long-term success is dependent on nutrition and lifestyle changes.We believe our scientific and clinical heritage combined with our commitment to evaluating programs, plans and products through clinical research are primary differentiators that allow us to compete in these markets. Our scientifically designed products were originally developed by a physician, and we have continued the development of nutrition and weight-management products since our founding.These macroeconomic uncertainties make it challenging for our management to estimate our future business performance. However, we intend to continue to actively monitor the impact of these developments on our business and will update our practices accordingly. Medifast has perfected our model over the last 40 plus years, with habits, Coaches, and community at the core, and we will continue to innovate as the industry evolves.18Table of ContentsRecent InitiativesIn response to the current competitive landscape, in which acquiring customers has become more difficult due to competitive pressures from GLP-1 medications being sought after by our potential customers, the Company is focusing on a number of initiatives to aid in increasing revenue and profit growth in the years ahead. At the core of the Company’s transformation is its desire to grow its business by broadening its customer base through increased brand visibility and recognition, and by significantly expanding its total addressable market.Areas of investment include executing our new marketing campaign as well as cultivating new customers through the Company’s collaboration with LifeMD.Through an expected investment of approximately \$25 million in Company-led marketing efforts in 2024, we are committed to driving growth and enhancing brand visibility while highlighting our holistic offer. This high-profile national campaign aims to elevate OPTAVIA brand awareness, foster engagement and drive customer conversion. With a multi-phase, omnichannel approach, the campaign will introduce new consumer and Coach-facing branding and visuals, and elevate the website, social and digital experience. We plan to ramp up our investment in the second half of 2024 and form the foundation of the Company’s strategy to return to growth, broadening and deepening our acquisition channels. This aligns with our three strategic growth pillars’ robust marketing initiatives, coaching network expansion and strategic collaboration with LifeMD’ to empower individuals on their journey to optimal health and wellbeing.We believe by significantly broadening our customer acquisition activities, through launching our new marketing campaign, upgrading customers’ digital experience, and leaning into the medically supported weight loss market through our collaboration with LifeMD, we will be positioned for future success.Critical Accounting Policies and EstimatesThe preparation of our financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Management develops, and changes periodically, these estimates and assumptions based on historical experience and on various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. There were no significant changes in our critical estimates during the first six months of 2024.Our unaudited condensed consolidated financial statements are prepared in accordance with GAAP. Our significant accounting policies are described in Note 2 to the audited consolidated financial statements included in the 2023 Form 10-K. We consider all of our significant accounting policies and estimates to be critical.Overview of Results of OperationsOur product sales accounted for approximately 97% of our revenues for each of the three months ended June 30, 2024 and 2023.19Table of ContentsThe following tables reflect our income statements (in thousands, except percentages):Three months ended June 30, 20242023\$ Change% ChangeRevenue\$168,558\$296,188(127,630)(43.1)%Cost of sales45,120\$85,473(40,353)(47.2)%Gross profit123,438\$210,715(87,277)(41.4)%Selling, general, and administrative131,314\$172,009(40,695)(23.7)%Income (loss) from operations(7,876)\$38,706(46,582)(120.3)%Other income (expense)Interest income1,296\$462\$344 180.5%Other expense(4,070)(51)(4,019)(7880.4)%(2,774)4111(3,185)(774.9)%Income (loss) from operations before income taxes(10,650)\$39,117(49,767)(127.2)%Provision (benefit) for income taxes(2,496)\$8,837(11,333)(128.2)%Net income (loss)\$8,154\$30,280\$38,434(126.9)% of revenueGross profit73.2%71.1%Selling, general, and administrative costs77.9%58.1%Income (loss) from operations(4.7)%13.1%20Table of ContentsSix months ended June 30, 20242023\$ Change% ChangeRevenue\$343,297\$645,170(301,873)(46.8)%Cost of sales92,567\$188,065(95,498)(50.8)%Gross profit250,730\$457,105(206,375)(45.1)%Selling, general, and administrative250,666\$364,887(114,221)(31.3)%Income from operations6492,218(92,154)(99.0)%Other incomeInterest income2,519\$21,238\$796.4%Other expense(1,647)(53)(1,594)(3007.5)%872228644 282.5%Income from operations before income taxes93692,446(91,510)(99.0)%Provision for income taxes77322,198(21,425)(96.5)%Net income\$163\$70,248\$(70,085)(99.8)% of revenueGross profit73.0%70.9%Selling, general, and administrative costs73.0%56.6%Income from operations’ 14.3%Revenue: Revenue decreased \$127.6 million, or 43.1%, to \$168.6 million for the three months ended June 30, 2024 from \$296.2 million for the three months ended June 30, 2023. The decline in revenue for the three months ended June 30, 2024 was primarily driven by a decrease in the number of active earning OPTAVIA Coaches to 33,900 as of June 30, 2024, a 36.2% decrease from 53,100 as of June 30, 2023 and the decline in the productivity per active earning OPTAVIA Coach. The average revenue per active earning OPTAVIA Coach was \$4,972 for the three months ended June 30, 2024, a 10.9% decrease compared to \$5,578 for the three months ended June 30, 2023. Revenue decreased \$301.9 million, or 46.8%, to \$343.3 million for the six months ended June 30, 2024 from \$645.2 million for the six months ended June 30, 2023. The decline in revenue for the six months ended June 30, 2024 was driven by a decrease in the number of active earning OPTAVIA Coaches, the decline in productivity per active earnings OPTAVIA Coach, and a \$9.1 million impact from a timing difference related to changes in the Company’s sales order terms and conditions with its customers realized in the first quarter of 2023. The average revenue per active earning OPTAVIA Coach was \$4,788 for the six months ended June 30, 2024, a 17.0% decrease compared to \$5,771 for the six months ended June 30, 2023. The decrease in productivity per active earning OPTAVIA Coach for the three months ended June 30, 2024 and six months ended June 30, 2024 was driven by continued pressure on customer acquisition.Cost of sales: Cost of sales decreased \$40.4 million, or 47.2%, to \$45.1 million from \$85.5 million for the three months ended June 30, 2024 from the corresponding period in 2023. Cost of sales decreased \$95.5 million, or 50.8%, to \$92.6 million from \$188.1 million for the six months ended June 30, 2024. The decrease in cost of sales for the three months ended June 30, 2024 and the six months ended June 30, 2024 was primarily driven by decreased volumes, cost savings from our Fuel for the Future initiatives, and efficiencies in inventory management.Non-GAAP adjusted cost of sales were \$42.5 million for the three months ended June 30, 2024, a decrease of \$42.9 million, or 50.2%, as compared to \$85.5 million from the corresponding period in 2023. Non-GAAP adjusted cost of sales were \$90.0 million for the six months ended June 30, 2024, a decrease of \$98.1 million, or 52.2%, as compared to \$188.1 million for the corresponding period in 2023. Non-GAAP adjusted cost of sales excludes expenses in connection with the Company’s 21Table of Contentsrestructuring of external manufacturing agreements. Refer to the’ Non-GAAP Financial Measures’ section below for a reconciliation of each of non-GAAP financial measure to its most comparable GAAP financial measure.Gross profit: Gross profit decreased \$87.3 million, or 41.4%, to \$123.4 million from \$210.7 million for the three months ended June 30, 2024 from the corresponding period in 2023. The decrease in gross profit for the three months ended June 30, 2024 was due to lower revenue. As a percentage of revenue, gross profit increased 210 basis points to 73.2% for the three months ended June 30, 2024 from 71.1% for the corresponding period in 2023. Gross profit as a percentage of revenue was positively impacted by cost savings from our Fuel for the Future initiatives and efficiencies in inventory management. For the six months ended June 30, 2024, gross profit decreased \$206.4 million, or 45.1%, to \$250.7 million from \$457.1 million for the six months ended June 30, 2023. The decrease in gross profit for the six months ended June 30, 2024 was due to lower revenue. As a percentage of revenue, gross profit increased 210 basis points to 73.0% for the six months ended June 30, 2024 from 70.9% for the corresponding period in 2023. Gross profit as a percentage of revenue was positively impacted by cost savings from our Fuel for the Future initiatives and efficiencies in inventory management.Non-GAAP adjusted gross profit was \$126.0 million for the three months ended June 30, 2024, a decrease of \$84.7 million, or 40.2%, as compared to \$210.7 million from the corresponding period in 2023. Non-GAAP adjusted gross profit margin increased 370 basis points to 74.8% from 71.1% for the corresponding period in 2023. Non-GAAP adjusted gross profit was \$253.3 million for the six months ended June 30, 2024, a decrease of \$203.8 million, or 44.6%, as compared to \$457.1 million for the corresponding period in 2023. Non-GAAP adjusted gross profit margin increased 290 basis points to 73.8% for the six months ended June 30, 2024 from 70.9% for the corresponding period in 2023. Refer to the’ Non-GAAP Financial Measures’ section below for a reconciliation of each non-GAAP financial measure to its most comparable GAAP financial measure.Selling, general, and administrative: SG&A expenses were \$131.3 million for the three months ended June 30, 2024, a decrease of \$40.7 million, or 23.7%, as compared to \$172.0 million from the corresponding period in 2023. SG&A expenses decreased for the three months ended June 30, 2024 primarily due to decreased Coach compensation on fewer active earning Coaches and lower sales volumes, partially offset by the loss of leverage on fixed costs due to lower sales volumes and supply chain optimization costs. The Company also incurred market research and investment costs related to medically supported weight loss, costs to exit hotel commitments for our annual OPTAVIA convention in future years, reflecting a change in strategy, and costs for our Company-led customer acquisition initiatives. As a percentage of revenue, SG&A expenses were 77.9% for the three months ended June 30, 2024 as compared to 58.1% for the corresponding period in 2023. SG&A expenses as a percentage of revenue increased for the three months ended June 30, 2024 primarily reflecting the loss of leverage on fixed costs due to lower sales volumes and supply chain optimization costs. SG&A expenses included research and development costs of \$1.1 million and \$1.1 million for the three months ended June 30, 2024 and 2023, respectively, in connection with the development of new products and plans, and clinical research activities. SG&A expenses were \$250.7 million for the six months ended June 30, 2024, a decrease of \$114.2 million, or 31.3%, as compared to \$364.9 million from the corresponding period in 2023. SG&A expenses decreased for the six months ended June 30, 2024 primarily due to decreased Coach compensation on fewer active earning Coaches and lower sales volumes, partially offset by the loss of leverage on fixed costs due to lower sales volumes and supply chain optimization costs. The Company also incurred costs for our Company-led customer acquisition initiatives, and market research and investment costs related to medically supported weight loss. As a percentage of revenue, SG&A expenses were 73.0% for the six months ended June 30, 2024 as compared to 56.6% for the corresponding period in 2023 primarily reflecting the loss of leverage on fixed costs due to lower sales volumes and supply chain optimization costs. SG&A expenses included research and development costs of \$2.1 million and \$2.1 million for the six months ended June 30, 2024 and 2023, respectively, in connection with the development of new products and plans, and clinical research activities. Non-GAAP adjusted SG&A expenses were \$113.8 million for the three months ended June 30, 2024, a decrease of \$58.2 million, or 33.8%, as compared to \$172.0 million from the corresponding period in 2023. Non-GAAP adjusted SG&A expenses were \$231.8 million for the six months ended June 30, 2024, a decrease of \$133.1 million, or 36.5%, as compared to \$364.9 million from the corresponding period in 2023. Non-GAAP adjusted SG&A excludes expenses related to the Company’s supply chain optimization costs, costs to exit hotel commitments for our annual OPTAVIA convention in future years, reflecting a change in strategy, and costs for its collaboration with LifeMD. Refer to’ Non-GAAP Financial Measures’ section below for a reconciliation of each non-GAAP financial measure to its most comparable GAAP financial measure.Income (loss) from operations: For the three months ended June 30, 2024, the Company’s loss from operations was \$7.9 million, a \$46.6 million decrease from the \$38.7 million income from operations for the corresponding period in 2023 primarily as a result of decreased gross profit partially offset by decreased SG&A expenses. For the three months ended June 30, 2024 the Company’s loss from operations as a percentage of revenue was 4.7% as compared to the Company’s income from operations as a percentage of revenue of 13.1% for the corresponding period in 2023, due to the factors described above impacting SG&A 22Table of Contentsexpenses, partially offset by the factors impacting gross profit. For the six months ended June 30, 2024, income from operations decreased \$92.2 million to less than \$0.1 million from \$92.2 million for the corresponding period in 2023 primarily as a result of the factors described above impacting SG&A expenses, partially offset by the factors impacting gross profit. Income from operations as a percentage of revenue decreased to less than 0.1% for the six months ended June 30, 2024 from 14.3% for the corresponding period in 2023 due to the factors above impacting SG&A expenses, partially offset by the factors impacting gross profit.Non-GAAP adjusted income from operations was \$12.2 million for the three months ended June 30, 2024, a decrease of \$26.5 million, or 68.4%, as compared to \$38.7 million from the corresponding period in 2023. Non-GAAP adjusted income from operations as a percentage of revenue was 7.3% for the three months ended June 30, 2024, a decrease of 580 basis points from 13.1% for the corresponding period in the prior year Non-GAAP adjusted income from operations was \$21.5 million for the six months ended June 30, 2024, a decrease of \$70.7 million, or 76.7%, as compared to \$92.2 million from the corresponding period in 2023. Non-GAAP adjusted income from operations as a percentage of revenue was 6.3% for the six months ended June 30, 2024, a decrease of 800 basis points from 14.3% for the corresponding period in the prior year. Refer to’ Non-GAAP Financial Measures’ section below for a reconciliation of each non-GAAP financial measure to its most comparable GAAP financial measure.Provision (benefit) for income taxes: For the three months ended June 30, 2024, the Company recorded \$2.5 million in income tax benefit, an effective

tax rate of 23.4%, as compared to \$8.8 million in income tax expense, an effective tax rate of 22.6%, for the three months ended June 30, 2023. The change in the effective tax rate for the three months ended June 30, 2024 was primarily driven by the net loss position in 2024 and the corresponding rate impact from the tax benefit for research and development tax credits, partially offset by the rate impact from the limitation for executive compensation. For the six months ended June 30, 2024, the Company recorded \$0.8 million in income tax expense, an effective tax rate of 82.6%, as compared to \$22.2 million in income tax expense, an effective tax rate of 24.0%, for the six months ended June 30, 2023. The increase in the effective tax rate for the six months ended June 30, 2024 was primarily driven by the impact of the tax shortfall for stock compensation, which was magnified by the near break-even pre-tax income position. Non-GAAP adjusted income tax provision was \$3.6 million for the three months ended June 30, 2024, an effective tax rate of 26.2% as compared to 22.6% for the corresponding period in 2023. Non-GAAP adjusted income tax provision was \$6.6 million for the six months ended June 30, 2024, an effective tax rate of 27.2%, as compared to 24.0% for the corresponding period in 2023. Refer to “Non-GAAP Financial Measures” section below for a reconciliation of each non-GAAP financial measure to its most comparable GAAP financial measure. Net income (loss): Net loss was \$8.2 million, or \$0.75 per diluted share for the three months ended June 30, 2024 as compared to net income of \$30.3 million, or \$2.77 per diluted share, for the three months ended June 30, 2023. Net income was \$0.2 million, or \$0.01 per diluted share for the six months ended June 30, 2024, as compared to \$70.2 million, or \$6.43 per diluted share for the six months ended June 30, 2023. The period-over-period changes were driven by the factors described above. Non-GAAP adjusted net income was \$10.1 million or \$0.92 per diluted share for the three months ended June 30, 2024 as compared to \$2.77 per diluted share for the corresponding period in 2023. Non-GAAP adjusted net income was \$17.5 million or \$1.60 per diluted share for the six months ended June 30, 2024 as compared to \$6.43 per diluted share for the corresponding period in 2023. Refer to “Non-GAAP Financial Measures” section below for a reconciliation of each non-GAAP financial measure to its most comparable GAAP financial measure. Non-GAAP Financial Measures In an effort to provide investors with additional information regarding our results as determined by GAAP, we disclose various non-GAAP financial measures in this quarterly report, our quarterly earnings press release, and other public disclosures. The following GAAP financial measures have been presented on an as-adjusted basis: Cost of sales, Gross profit, SG&A expenses, income (loss) from operations, other income (expense), provision (benefit) for income taxes, net income (loss), and diluted earnings (loss) per share. Each of these as-adjusted financial measures excludes the impact of certain amounts related to supply chain optimization and restructuring of external manufacturing agreements, costs to exit hotel commitments for our OPTAVIA convention in future years, unrealized gains or losses on our investment in LifeMD common stock, and the LifeMD collaboration as further identified below and have not been calculated in accordance with GAAP. A reconciliation of each of these non-GAAP financial measures to its most comparable GAAP financial measure is included below. These non-GAAP financial measures are not intended to replace GAAP financial measures. 23 Table of Contents We use these non-GAAP financial measures internally to evaluate and manage the Company’s operations because we believe they provide useful supplemental information regarding the Company’s on-going economic performance. We have chosen to provide this information to investors to enable them to perform more meaningful comparisons of operating results and as a means to emphasize the results of on-going operations. The following tables reconcile the non-GAAP financial measures included in this report (in thousands, except per share amounts): Three Months Ended June 30, 2024 GAAP (1) Supply Chain Optimization and Restructuring of External Manufacturing Agreements (2) OPTAVIA Convention Cancellation (2) Unrealized Loss on Investment in LifeMD Common Stock LifeMD Prepaid Services Amortization (2) Non-GAAP (2) Cost of sales \$45,120.4 (\$2,579.9) \$42,541.5 Gross profit \$123,438.2 \$2,579.9 \$126,018.1 Selling, general, and administrative \$131,314.4 (12,502.3) (3,000.4) \$2,021.1 \$113,791.9 Income (loss) from operations (7,876.1) 15,081.4 3,000.4 \$2,021.1 \$22,266.0 Other income (expense) (2,774.4) \$4,188.4 \$1,414.4 Provision (benefit) for income taxes (2,496.3) 770.4 750.4 1,047.4 505.4 3,576.4 Net income (loss) (8,154.1) 31,114.2 2,550.3 3,141.4 1,516.4 10,064.4 Diluted earnings (loss) per share (0.75) 1.03 0.21 0.29 0.14 0.92 (1) The weighted-average diluted shares outstanding used in the calculation of these non-GAAP financial measures are the same as the weighted-average shares outstanding used in the calculation of the reported per share amounts. (2) The weighted-average diluted shares outstanding used in the calculation of these non-GAAP financial measures uses 10,962 thousand shares under the treasury stock method. Three Months Ended June 30, 2023 GAAP Supply Chain Optimization and Restructuring of External Manufacturing Agreements OPTAVIA Convention Cancellation Unrealized Loss on Investment in LifeMD Common Stock LifeMD Prepaid Services Amortization Non-GAAP Cost of sales \$85,473.4 \$42,541.5 \$126,018.1 Selling, general, and administrative \$172,009.4 \$172,009.4 Income from operations \$38,706.4 \$38,706.4 Other income \$411.4 \$411.4 Provision for income taxes \$8,837.4 \$8,837.4 Net income \$30,280.4 \$30,280.4 Diluted earnings per share (1) 2.77 \$4,188.4 \$1,414.4 (1) The weighted-average diluted shares outstanding used in the calculation of these non-GAAP financial measures are the same as the weighted-average shares outstanding used in the calculation of the reported per share amounts. 24 Table of Contents Six Months Ended June 30, 2024 GAAP Supply Chain Optimization and Restructuring of External Manufacturing Agreements OPTAVIA Convention Cancellation Unrealized Loss on Investment in LifeMD Common Stock LifeMD Prepaid Services Amortization Non-GAAP Cost of sales \$92,567.4 (\$2,579.9) \$89,987.5 Gross profit \$250,730.4 \$2,579.9 \$253,309.4 Selling, general, and administrative \$250,666.4 (12,502.3) (3,000.4) (3,488.2) 31,114.2 2,550.3 3,141.4 1,516.4 Net income \$163.1 11,311.4 2,250.4 1,313.4 2,511.4 17,548.4 Diluted earnings per share (1) 0.01 1.03 0.21 0.12 0.23 1.60 (1) The weighted-average diluted shares outstanding used in the calculation of these non-GAAP financial measures are the same as the weighted-average shares outstanding used in the calculation of the reported per share amounts. Six Months Ended June 30, 2023 GAAP Supply Chain Optimization and Restructuring of External Manufacturing Agreements OPTAVIA Convention Cancellation Unrealized Loss on Investment in LifeMD Common Stock LifeMD Prepaid Services Amortization Non-GAAP Cost of sales \$188,065.4 \$188,065.4 Gross profit \$457,105.4 \$457,105.4 Selling, general, and administrative \$364,887.4 \$364,887.4 Income from operations \$92,218.4 \$92,218.4 Other income \$228.4 \$228.4 Provision for income taxes \$22,198.4 \$22,198.4 Net income \$70,248.4 \$70,248.4 Diluted earnings per share (1) 6.43 \$4,188.4 \$1,414.4 (1) The weighted-average diluted shares outstanding used in the calculation of these non-GAAP financial measures are the same as the weighted-average shares outstanding used in the calculation of the reported per share amounts. Liquidity and Capital Resources The Company has stockholders’ equity of \$205.34 million and working capital of \$149.14 million at June 30, 2024 as compared with \$201.54 million and \$131.74 million at December 31, 2023, respectively. The \$3.84 million net increase in stockholders’ equity was primarily driven by a \$4.64 million increase in share-based compensation partially offset by \$0.84 million in net shares repurchased for employee taxes. The Company’s cash, cash equivalents and investment securities increased from \$150.04 million at December 31, 2023 to \$163.54 million at June 30, 2024. Net cash provided by operating activities decreased by \$86.94 million to \$20.44 million for the six months ended June 30, 2024 from \$107.24 million for the six months ended June 30, 2023. This was primarily driven by a \$57.24 million decrease in net income excluding non-cash charges, a \$35.04 million decrease related to a smaller inventory reduction in the period ending June 30, 2024 to align with sales demand, and a \$5.54 million decrease resulting from higher prepaid expenses and other current assets, partially offset by a \$12.44 million increase resulting from a smaller reduction in accounts payable and accrued expenses during the period. 25 Table of Contents Net cash used in investing activities was \$5.3 million for the six months ended June 30, 2024 as compared to \$3.9 million for the six months ended June 30, 2023. The increase was primarily driven by a \$1.54 million increase of net purchases of investment securities during the six months ended June 30, 2024. Net cash used in financing activities decreased by \$42.24 million to \$1.5 million for the six months ended June 30, 2024 from \$43.7 million for the six months ended June 30, 2023. This decrease was primarily due to a \$36.3 million decrease in cash dividends paid to stockholders, a \$3.6 million decrease in stock repurchases, and a \$2.4 million decrease in net shares repurchased for employee taxes. In pursuing its business strategy, the Company may require additional cash for operating and investing activities. The Company expects future cash requirements in both the short term and the long term, if any, to be funded from operating cash flow and financing activities. From time to time, the Company evaluates potential acquisitions that complement our business. If consummated, any such transactions may use a portion of our working capital or require the issuance of equity or debt. We have no present understandings, commitments or agreements with respect to any material acquisitions. On April 13, 2021, the Company and certain of its subsidiaries (collectively, the “Guarantors”) entered into a credit agreement among the Company, the Guarantors, the lenders party thereto and Citibank, N.A., in its capacity as administrative agent. On May 31, 2022, the Credit Agreement was amended to increase the borrowing capacity and convert the interest rate to be based on SOFR, from LIBOR (the “Amended Credit Agreement”). The Amended Credit Agreement provides for a \$225.04 million senior secured revolving credit facility with a \$20.04 million letter of credit sublimit. The Amended Credit Agreement also provides for an uncommitted incremental facility that permits the Company, subject to certain conditions, to increase the senior secured revolving credit facility by up to \$100.04 million. The Amended Credit Agreement contains affirmative and negative covenants customarily applicable to credit facilities. As of June 30, 2024, the Company had no borrowings under the credit facility and was in compliance with all of its debt covenants. Item 3. Quantitative and Qualitative Disclosures about Market Risk Market risk is the potential loss arising from adverse changes in market rates and prices, such as interest rates and a decline in the stock market. The Company does not enter into derivatives, foreign exchange transactions or other financial instruments for trading or speculative purposes. The Company is exposed to market risk related to changes in interest rates and market pricing impacting our credit facility and investment in money market securities, government and agency securities, and corporate bonds. Other than for strategic investments, its current investment policy is to maintain an investment portfolio consisting of corporate bonds and U.S. money market securities directly or through managed funds. Its cash is deposited in and invested through highly rated financial institutions in North America. Its marketable securities, purchased during 2023, are subject to interest rate risk and market pricing risk and will fall in value if market interest rates increase or if market pricing decreases. If market interest rates were to increase and market pricing were to decrease immediately and uniformly by 10% from levels at June 30, 2024, the Company estimates that the fair value of its investment portfolio would decline by an immaterial amount and therefore it would not expect its operating results or cash flows to be affected to any significant degree by the effect of a change in market conditions on our investments. Additionally, the Company is exposed to market risk related to price fluctuations in equity markets related to its investment in LifeMD common stock, purchased in December of 2023. If equity prices were to decrease immediately and uniformly by 10% from levels at June 30, 2024, the Company estimates that the fair value of the Company investment would decline by an immaterial amount and therefore it would not expect its operating results or cash flows to be affected by any significant degree by the effect of a change in market conditions on our investment. There have been no material changes to our market risk exposure since December 31, 2023. Item 4. Controls and Procedures Management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Act, as amended, as of June 30, 2024. Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Act is recorded, processed, summarized and reported accurately and on a timely basis. Based on this evaluation performed in accordance with the criteria established in the 2013 Internal Control “Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission, 26 Table of Contents our management concluded that the Company’s disclosure controls and procedures are effective at the reasonable assurance level as of the end of the period covered by this report. Changes in Internal Control over Financial Reporting There have been no material changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Act) during the fiscal quarter ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 27 Table of Contents Part II Other Information Item 1. Legal Proceedings The Company is, from time to time, subject to a variety of litigation and similar proceedings that arise out of the ordinary course of its business. Based upon the Company’s experience, current information and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its results of operations, financial position or liquidity. However, the results of legal actions cannot be predicted with certainty. Therefore, it is possible that the Company’s results of operations, financial condition or cash flows could be materially adversely affected in any particular period by the unfavorable resolution of one or more legal actions. Item 1A. Risk Factors There have been no material changes to the risk factors set forth in Part I, Item 1A of the 2023 Form 10-K. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Issuer Purchases of Equity Securities 2024 Total Number of Shares Purchased (1) Average Price Paid per Share Total Number of Shares Purchased as Part of a Publicly Announced Plan or Program Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs (2) April 1 - April 30 \$4,188.4 \$1,414.4 1,323,568 May 1 - May 31 \$4,188.4 \$1,414.4 1,323,568 June 1 - June 30 \$4,188.4 \$1,414.4 1,323,568 (1) All of the shares of the Company’s common stock reflected in this column were surrendered by employees and directors to the Company to cover minimum tax liability withholding obligations upon the exercise of stock options or the vesting of shares of restricted stock and performance-based share awards previously granted to such employees and directors. (2) At the outset of the quarter ended June 30, 2024, there were 1,323,568 shares of the Company’s common stock eligible for repurchase under the stock repurchase authorization dated September 16, 2014 (the “Stock Repurchase Plan”). As of June 30, 2024, there were 1,323,568 shares of the Company’s common stock eligible for repurchase under the Stock Repurchase Plan. There can be no assurances as to the amount, timing or prices of repurchases, which may vary based on market conditions and other factors. The Stock Repurchase Plan does not have an expiration date and can be modified or terminated by the Board of Directors at any time. 28 Table of Contents Item 6. Exhibits Exhibit Number Description of Exhibit 3.1 Restated and Amended Certificate of Incorporation of Medifast, Inc. (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K (File No. 001-31573) filed February 27, 2015). 3.2 Amended and Restated Bylaws of Medifast, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Amendment No. 1 Current Report on Form 8-K (File No. 001-31573) filed on December 4, 2019). 10.1 Medifast, Inc. Amended and Restated 2012 Share Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-31573) filed on June 21, 2024). 31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith). 31.2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith). 32.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith). 101 The following financial statements from Medifast, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed August 5, 2024, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Operations, (ii) Condensed Consolidated Statements of Comprehensive Income (Loss), (iii) Condensed Consolidated Balance Sheets, (iv) Condensed Consolidated Statements of Cash Flows, (v) Condensed Consolidated Statements of Changes in Stockholders’ Equity, and (vi) Notes to the Condensed Consolidated Financial Statements (filed herewith). 104 Cover Page Interactive Data File - The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. In accordance with SEC Release No. 33-8238, Exhibit 32.1 is being furnished and not filed. 29 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized. Medifast, Inc. By: /s/ DANIEL R. CHARD Daniel R. Chard Chief Executive Officer (Principal Executive Officer) Dated: August 5, 2024 /s/ JAMES P. MALONEY James P. Maloney Chief Financial Officer (Principal Financial Officer) Dated: August 5, 2024 30 EX-31.2 med-20240630xexx311.htm EX-31.1 Document Exhibit 31.1 RULE 13a-14(a) CERTIFICATION I, Daniel R. Chard, certify that: I have reviewed this quarterly report on Form 10-Q of Medifast, Inc. (the “Registrant”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report; 4. The Registrant and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have: (a) Designed

such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and5. The Registrant’s other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.Date:August 5, 2024/s/Á Daniel R. ChardDaniel R. ChardChief Executive Officer EX-31.2 3 med-20240630xexx312.htm EX-31.2 DocumentExhibitÁ 31.2RULE 13a-14(a) CERTIFICATIONI, James P. Maloney, certify that:1.I have reviewed this quarterly report on Form 10-Q of Medifast, Inc. (the Registrant);2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.Date:August 5, 2024/s/Á James P. MaloneyJames P. MaloneyChief Financial Officer EX-32.1 4 med-20240630xexx321.htm EX-32.1 DocumentExhibitÁ 32.1MEDIFAST, INC.CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the Quarterly Report on Form 10-Q (the Report) for the quarter ended June 30, 2024 of Medifast, Inc. (the Company), as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Daniel R. Chard, Chief Executive Officer and I, James P. Maloney, Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of the operations of the Company.By:/s/ DANIEL R. CHARDDaniel R. ChardChief Executive OfficerAugust 5, 2024/s/ JAMES P. MALONEYJames P. MaloneyChief Financial OfficerAugust 5, 2024 EX-101.SCH 5 med-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - SHARE-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - SUPPLY CHAIN OPTIMIZATION link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - SHARE-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - SUPPLY CHAIN OPTIMIZATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - EARNINGS PER SHARE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - SHARE-BASED COMPENSATION - Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - SHARE-BASED COMPENSATION - Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - LEASES - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - LEASES - Future Minimum Lease Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - INVESTMENTS - Cash and Financial Assets Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - INVESTMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - INVESTMENTS - Investment Losses (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - INVESTMENTS - Collaborate Arrangement (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - SUPPLY CHAIN OPTIMIZATION - Summary of Components of Supply Chain Optimization Charges (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - SUPPLY CHAIN OPTIMIZATION - Summary of Condensed Consolidated Statement of Operation (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 med-20240630 cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 med-20240630 def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 med-20240630 lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Credit Agreement Amended Credit Agreement [Member] Government & agency securities US Government Corporations and Agencies Securities [Member] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Minimum Minimum [Member] Cash and cash equivalents, excluding money market accounts Cash And Cash Equivalents Excluding Money Market Funds [Member] Cash And Cash Equivalents Excluding Money Market Funds Adjustments to reconcile net income to cash provided by operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income taxes, prepaid Prepaid Taxes Range [Domain] Statistical Measurement [Domain] Schedule of Supplemental Cash Flow Information Lease, Cost [Table Text Block] Schedule of Cash and Financial Assets Measured at Fair Value on a Recurring Basis Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Maximum total net leverage ratio Maximum Total Net Leverage Ratio Maximum ratio as of any date, of (a) Total Net Funded Indebtedness on such date to (b) Consolidated EBITDA for the Reference Period ended on such date under credit facility. Cover [Abstract] Cover [Abstract] Outstanding at beginning of period (in usd per share) Outstanding at beginning of period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Right-of-use assets Operating Lease, Right-of-Use Asset Outstanding at beginning of period (in shares) Outstanding at end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Schedule of Maturity of Company's Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Share-based Compensation Expense Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Trading Symbol Trading Symbol Less: Net losses recognized on equity securities sold Equity Securities, FV-NI, Realized Gain (Loss) Borrowings outstanding Long-Term Debt, Gross Operating Lease Arrangement for Equipment Operating Lease Arrangement For Equipment [Member] Represents the operating lease arrangement for equipment. Schedule of the Computation of Basic and Diluted EPS Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Total income tax benefit recognized related to restricted stock awards Share-Based Payment Arrangement, Expense, Tax Benefit Award vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period EARNINGS PER SHARE Earnings Per Share [Text Block] Cash dividends declared per share (in usd per share) Common Stock, Dividends, Per Share, Declared Options and restricted stock Options And Restricted Stock [Member] Options And Restricted Stock Options exercised by directors Stock Issued During Period, Value, Stock Options Exercised Dividends included in accounts payable and accrued expenses Dividends, Cash Stockholders' Equity Equity, Attributable to Parent [Abstract] Granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Market and Performance-based Share Awards Market and performance-based share awards Market And Performance-based Share [Member] Market And Performance-based Share Net losses recognized during the period on equity securities Equity Securities, FV-NI, Gain (Loss) Options exercised by directors Proceeds from Stock Options Exercised Restructuring and Related Activities [Abstract] Granted In 2020 Granted In 2020 [Member] Granted In 2020 Investment, Name [Domain] Investment, Name [Domain] Schedule of Restricted Stock Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Variable Rate [Axis] Variable Rate [Axis] LEASES Lessee, Operating Leases [Text Block] Common stock, outstanding (in shares) Common Stock, Shares, Outstanding Other expense Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Lease obligations, net of current lease obligations Operating Lease, Liability, Noncurrent Investments, All Other Investments [Abstract] Investments, All Other Investments [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Second Milestone Payment Collaborative Arrangement, Transaction With Party To Collaborative Arrangement, Second Milestone Payment [Member] Collaborative Arrangement, Transaction With Party To Collaborative Arrangement, Second Milestone Payment Unrecognized compensation costs Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Effect of dilutive common stock equivalents (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Amortization of discount on investment securities Investment Income, Net, Amortization of Discount and Premium Cash And Cash Equivalents And Marketable securities [Line Items] Cash And Cash Equivalents And Marketable securities [Line Items] N/A Money market accounts Money Market Funds [Member] Net cash flow provided by operating activities Net Cash Provided by (Used in) Operating Activities Treasury Stock Treasury Stock, Common [Member] Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Schedule of Accumulated Other Comprehensive Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Estimated Fair Value, Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Equity Components [Axis] Equity Components [Axis] Local Phone Number Local Phone Number Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Use of Estimates Use of Estimates, Policy [Policy Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Recognition and Exercise Packaging Retail Related Inventory, Packaging and Other Supplies Aggregate intrinsic value of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Other assets Increase (Decrease) in Other Operating Assets Change in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Entity Small Business Entity Small Business Cost, Equity securities Equity Securities, FV-NI, Cost Summary of Components Optimization Charges Restructuring and Related Costs [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Award Date [Axis] Award Date [Axis] Proceeds from sale and maturities of investment securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock Common Stock [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Uncommitted Incremental Facility Uncommitted Incremental Facility [Member] Uncommitted Incremental Facility Anti-dilutive awards (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Loss on impairment of equipment held for sale Impairment of Long-Lived Assets to be Disposed of Operating lease expense Operating Lease, Expense Granted In 2024 Granted In 2024 [Member] Granted In 2024 Entity Emerging Growth Company Entity Emerging Growth Company Credit Facility [Domain] Credit Facility [Domain] Cash and cash equivalents - beginning of the period Cash and cash equivalents - end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Initial Milestone Payment Collaborative Arrangement, Transaction With Party To Collaborative Arrangement, Initial Milestone Payment

[Member] Collaborative Arrangement, Transaction With Party To Collaborative Arrangement, Initial Milestone Payment Estimated Fair Value, Equity securities Equity Securities, FV-NI, Current Net shares repurchased for employee taxes (in shares) Shares withheld for employee taxes Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Entity Central Index Key Entity Central Index Key Numerator: Numerator [Abstract] Numerator [Abstract] Scenario [Axis] Scenario [Axis] Non-cash lease expense Operating Lease, Expense, Non-Cash Operating Lease, Expense, Non-Cash Employee service share based compensation nonvested awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Current Assets Assets, Current [Abstract] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] INVENTORIES Inventory Disclosure [Text Block] Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Equity Component [Domain] Equity Component [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Net shares repurchased for employee taxes Payments for Repurchase of Other Equity Stock Options Share-Based Payment Arrangement, Option [Member] Vested (in usds per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Text Block [Abstract] 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Operating Lease Arrangement for Real Estate Operating Lease Arrangement For Real Estate [Member] Represents the operating lease arrangement for real estate. Restricted Stock Restricted Stock [Member] Entity Shell Company Entity Shell Company Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Corporate bonds Municipal Bonds [Member] Security Exchange Name Security Exchange Name Basis spread on variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Statement [Table] Statement [Table] Award Type [Axis] Award Type [Axis] Counterparty Name [Axis] Counterparty Name [Axis] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price City Area Code City Area Code Current Liabilities Liabilities, Current [Abstract] Minimum interest coverage ratio Minimum Interest Coverage Ratio Minimum Interest Coverage Ratio Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property, plant and equipment - net of accumulated depreciation Property, Plant and Equipment, Net Total liabilities Liabilities Exercisable at end of the period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Total current assets Assets, Current Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Revolving Credit Facility Revolving Credit Facility [Member] Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Stock repurchases Payments for Repurchase of Common Stock Exercisable at end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Current lease obligations Operating Lease, Liability, Current Common stock, issued (in shares) Balance (in shares) Balance (in shares) Common Stock, Shares, Issued Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Income taxes payable Increase (Decrease) in Income Taxes Payable Accrued Interest, Debt securities Debt Securities, Available-For-Sale, Accrued Interest Debt Securities, Available-For-Sale, Accrued Interest Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Total supply chain optimization Total supply chain optimization Restructuring Costs and Asset Impairment Charges Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Earnings (loss) per share Earnings Per Share [Abstract] Earnings Per Share [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Options exercised by directors (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Inventories Increase (Decrease) in Inventories Debt Instrument [Line Items] Debt Instrument [Line Items] Treasury stock retired from stock repurchases (in shares) Treasury Stock, Shares, Retired Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Common stock, authorized (in shares) Common Stock, Shares Authorized Unrealized Gains (Losses), Equity securities Unrealized losses recognized during the reporting period on equity securities still held at the reporting date Equity Securities, FV-NI, Unrealized Gain (Loss) Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted average discount rate (as a percent) Operating Lease, Weighted Average Discount Rate, Percent Unrealized losses on investment securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Diluted (in shares) Weighted average shares of common stock outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Total Operating Lease, Liability Net cash flow used in financing activities Net Cash Provided by (Used in) Financing Activities Performance-based Shares Performance-based share awards Performance Shares [Member] Credit Facility [Axis] Credit Facility [Axis] Total stockholders' equity Balance Balance Equity, Attributable to Parent Cash dividends declared to stockholders Dividends, Common Stock, Cash Accelerated depreciation charges Restructuring and Related Cost, Accelerated Depreciation Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Loss on sale or disposal of property, plant and equipment Gain (Loss) on Disposition of Property Plant Equipment Foreign currency translation Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax INVESTMENTS Financial Instruments Disclosure [Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Gross profit Gross Profit Deferred income taxes Deferred Income Tax Expense (Benefit) Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Selling, general, and administrative Selling, General and Administrative Expense Level 2 Fair Value, Inputs, Level 2 [Member] DEBT Debt Disclosure [Text Block] Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Other comprehensive income (loss), net of tax Other comprehensive income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Awards granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Granted In March 2022 Granted In March 2022 [Member] Granted In March 2022 Entity Address, Postal Zip Code Entity Address, Postal Zip Code Unrealized Gains (Losses), Total Short-Term Investments, Unrealized Gain (Loss) Short-Term Investments, Unrealized Gain (Loss) Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Unrealized loss on equity investment securities Equity Securities, FV-NI, Unrealized Loss Document Fiscal Period Focus Document Fiscal Period Focus Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Common stock, par value \$0.001 per share: 20,000 shares authorized; 10,937 and 10,896 issued outstanding at June 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Weighted-average remaining contractual life of options outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term ASSETS Assets [Abstract] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Document Type Document Type Commitment fee (as a percent) Line of Credit Facility, Commitment Fee Percentage Cash and cash equivalents Cost, Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Additional shares earned (as a percent) Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Additional Shares Earned, Percentage Schedule of Investments [Table] Schedule of Investments [Table] Granted In 2023 Granted In 2023 [Member] Granted In 2023 Weighted-average remaining contractual life of options exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Raw materials Inventory, Raw Materials, Gross Final Milestone Payment Collaborative Arrangement, Transaction With Party To Collaborative Arrangement, Final Milestone Payment [Member] Collaborative Arrangement, Transaction With Party To Collaborative Arrangement, Final Milestone Payment Cost, Debt securities Debt Securities, Available-for-Sale, Amortized Cost Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] SOFR Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Forfeiture of dividends on unvested awards Dividends, Forfeited Dividends, Forfeited Maximum Maximum [Member] Finished goods Inventory, Finished Goods, Gross Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Basic (in usd per share) Earnings per share - basic (in usd per share) Earnings Per Share, Basic Antidilutive Securities [Axis] Antidilutive Securities [Axis] Thereafter Lessee Operating Lease Liability Payments Due After Year Four Lessee Operating Lease Liability Payments Due After Year Four Accounting Policies [Abstract] Accounting Policies [Abstract] Operating cash flow used in operating leases Operating Lease, Payments Award expiration period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Non-food finished goods Inventory Non Food Finished Goods Amount before last-in first-out (LIFO) and valuation reserves of (Non-food) merchandise or goods held by the entity that are readily available for sale. Current Fiscal Year End Date Current Fiscal Year End Date Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Investments Investment Securities Short-Term Investments Statistical Measurement [Axis] Statistical Measurement [Axis] Granted In October 2021 Granted In October 2021 [Member] Granted In October 2021 Income (loss) from operations before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Share-based compensation (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Total current liabilities Liabilities, Current Granted In 2022 Granted In 2022 [Member] Granted In 2022 Equity Award [Domain] Award Type [Domain] Weighted average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] TOTAL ASSETS Assets Shares Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Non-cash charges for supply chain optimization Non-cash charges for supply chain optimization Noncash Charges For Supply Chain Optimization Noncash Charges For Supply Chain Optimization Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Deferred tax assets Deferred Income Tax Assets, Net Additional Paid-In Capital Additional Paid-in Capital [Member] Milestone payments Collaborative Arrangement, Rights And Obligations, Milestone Payments Collaborative Arrangement, Rights And Obligations, Milestone Payments Nonoperating Income (Expense) Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Base Rate Base Rate [Member] Total lease payments Lessee, Operating Lease, Liability, to be Paid Unvested awards (in shares) Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Net cash flow used in investing activities Net Cash Provided by (Used in) Investing Activities Income (loss) from operations Operating Income (Loss) Variable Rate [Domain] Variable Rate [Domain] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity Treasury stock retired from stock repurchases Treasury Stock, Retired, Cost Method, Amount Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Additional paid-in capital Additional Paid in Capital Cost of sales Cost of Revenue Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Cash dividends paid to stockholders Payments of Dividends Interest income Interest Income (Expense), Nonoperating Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Presentation of Financial Statements Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Right-of-use assets obtained in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Scenario [Domain] Scenario [Domain] Accumulated other comprehensive income Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Schedule of Investment Losses Gain (Loss) on Securities [Table Text Block] Retained Earnings Retained Earnings [Member] Net shares repurchased for employee taxes Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Unrealized Gains (Losses), Debt securities Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax Forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Share-based compensation, shares authorized under stock option plans, exercise price range,

upper range limit (in usd per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Inventories Total Inventory, Net Basic (in shares) Weighted average shares of common stock outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic LifeMD LifeMD [Member] LifeMD Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Performance period (in years) Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Additional Shares Earned, Performance Period Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Additional Shares Earned, Performance Period Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Investments made Payments to Acquire Investments Financial Instruments [Domain] Financial Instruments [Domain] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Outstanding at beginning of period (in usd per share) Outstanding at beginning of period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Entity Filer Category Entity Filer Category Purchase of investment securities Payments to Acquire Debt Securities, Available-for-Sale Letter of Credit Letter of Credit [Member] EX-101.PRE 9 med-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover - shares 6 Months Ended Jun. 30, 2024 Jul. 29, 2024 Cover [Abstract] Å Document Type 10-Q Å Document Quarterly Report true Å Document Period End Date Jun. 30, 2024 Å Document Transition Report false Å Entity File Number 001-31573 Å Entity Registrant Name Medifast, Inc. Å Entity Incorporation, State or Country Code DE Å Entity Tax Identification Number 13-3714405 Å Entity Address, Address Line One 100 International Drive Å Entity Address, City or Town Baltimore Å Entity Address, State or Province MD Å Entity Address, Postal Zip Code 21202 Å City Area Code 410 Å Local Phone Number 581-8042 Å Title of 12(b) Security Common Stock, par value \$0.001 per share Å Trading Symbol MED Å Security Exchange Name NYSE Å Entity Current Reporting Status Yes Å Entity Interactive Data Current Yes Å Entity Filer Category Large Accelerated Filer Å Entity Small Business false Å Entity Emerging Growth Company false Å Entity Shell Company false Å Entity Common Stock, Shares Outstanding Å 10,937,418 Entity Central Index Key 0000910329 Å Current Fiscal Year End Date --12-31 Å Document Fiscal Year Focus 2024 Å Document Fiscal Period Focus Q2 Å Amendment Flag false Å X - Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItem Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItem Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItem Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItem Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItem Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItem Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItem Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItem Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItem Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItem Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItem Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItem Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD (\$ shares in Thousands, \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2023 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Income Statement [Abstract] Å Å Å Revenue 168,558 \$ 296,188 \$ 343,297 \$ 645,170 Cost of sales 45,120 85,473 92,567 188,065 Gross profit 123,438 210,715 250,730 457,105 Selling, general, and administrative 131,314 172,009 250,666 364,887 Income (loss) from operations (7,876) 38,706 64,9218 Other income (expense) Å Å Å Interest income 1,296 462 2,519 281 Other expense (4,070) (51) (1,647) (53) Total other income (expense) (2,774) 411 872 228 Income (loss) from operations before income taxes (10,650) 39,117 936 92,446 Provision (benefit) for income taxes (2,496) 8,837 773 22,198 Net income (loss) \$ (8,154) \$ 30,280 \$ 163 \$ 70,248 Earnings (loss) per share Å Å Å Basic (in usd per share) \$ (0.75) \$ 2.78 \$ 0.01 \$ 6.46 Diluted (in usd per share) \$ (0.75) \$ 2.77 \$ 0.01 \$ 6.43 Weighted average shares outstanding Å Å Å Basic (in shares) 10,937 10,888 10,923 10,876 Diluted (in shares) 10,937 10,917 10,967 10,923 Cash dividends declared per share (in usd per share) \$ 0 \$ 1.65 \$ 0 \$ 3.30 X - DefinitionAggregate dividends declared during the period for each share of common stock outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_CommonStockDividendsPerShareDeclared Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Balance Type: na Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -

2Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 59 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 59 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 59 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/214748524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 59 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/214748524/942-220-S99-1)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Name Accounting Standards Codification -Section 59 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Name Accounting Standards Codification -Section 59 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 59 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 59 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/214748524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/214748524/942-220-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap EarningsPerShareBasic Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)

Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-10>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph \(a\) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(h\)\) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 3: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48> + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-20-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-20-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31> + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)

Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1:

Paragraph 14A - Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4): [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5): [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6): [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7): [http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: <a href=): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.6-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3): [http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: <a href=): <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4](http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4): [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5): [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6): <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8): [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9): [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10): [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16): [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12)

Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 - SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-1Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference> 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference> 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-1Reference> 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference> 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference> 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference> 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference> 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15.R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - \$ / shares Jun. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Å Å Common stock, par value (in usd per share) \$ 0.001 \$ 0.001 Common stock, authorized (in shares) 20,000,000 20,000,000 Common stock, issued (in shares) 10,937,000 10,896,000 Common stock, outstanding (in shares) 10,937,000 10,896,000 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference> 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference> 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOffFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16.R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD (\$) \$ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Operating Activities Å Å Net income \$ 163 \$ 70,248 Adjustments to reconcile net income to cash provided by operating activities Å Å Depreciation and amortization 6,328 6,342 Non-cash lease expense 2,225 2,514 Share-based compensation 4,625 3,120 Loss on sale or disposal of property, plant and equipment 51 619 Realized gain on sale of investment securities (74) 0 Amortization of discount on investment securities (372) 0 Deferred income taxes 9 800 Unrealized loss on equity investment securities 1,752 0 Non-cash charges for supply chain optimization 11,689 0 Change in operating assets and liabilities: Å Å Inventories 14,988 49,960 Prepaid expenses and other current assets (1,809) 3,721 Other assets 206 (2,142) Accounts payable and accrued expenses (19,430) (31,851) Income taxes payable (1) 3,874 Net cash flow provided by operating activities 20,351 107,205 Investing Activities Å Å Purchase of investment securities (17,646) 0 Proceeds from sale and maturities of investment securities 16,118 0 Purchase of property and equipment (3,779) (3,859) Net cash flow used in investing activities (5,307) (3,859) Financing Activities Å Å Options exercised by directors 36 105 Net shares repurchased for employee taxes (833) (3,238) Cash dividends paid to stockholders (714) (36,996) Stock repurchases 0 (3,602) Net cash flow used in financing activities (1,511) (43,731) Foreign currency impact 43 99 Increase in cash and cash equivalents 13,576 59,714 Cash and cash equivalents - beginning of the period 94,440 87,691 Cash and cash equivalents - end of period 108,016 147,405 Supplemental disclosure of cash flow information: Å Å Income taxes paid 504 17,520 Dividends included in accounts payable and accrued expenses \$ 659 \$ 18,987 X - DefinitionNoncash Charges For Supply Chain Optimization + ReferencesNo definition available. + Details Name: med_NoncashChargesForSupplyChainOptimization Namespace Prefix: med Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionOperating Lease, Expense, Non-Cash + ReferencesNo definition available. + Details Name: med_OperatingLeaseExpenseNonCash Namespace Prefix: med_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading). + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference> 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1> + Details Name: us-gaap_DebtSecuritiesRealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference> 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-9> + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference> 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference> 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_DividendsCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accretion (amortization) of purchase discount (premium) on nonoperating securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Cod

[illegible]

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(1)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_TreasuryStockRetiredCostMethodAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionNumber of shares of common and preferred stock retired from treasury during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_TreasuryStockValueAcquiredCostMethod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] A SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESBasis of Presentation - The accompanying unaudited condensed consolidated financial statements of Medifast, Inc. and its wholly-owned subsidiaries (â€œMedifast,â€ the â€œCompany,â€ â€œwe,â€ â€œus,â€ or â€œourâ€) included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (â€œGAAPâ€) for interim reporting and pursuant to the rules and regulations of the Securities and Exchange Commission (the â€œSECâ€). Accordingly, certain information and notes that are normally required by GAAP have been condensed or omitted. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included and management believes the disclosures that are made are adequate to make the information presented not misleading. The condensed consolidated balance sheet at December 31, 2023 has been derived from the 2023 audited consolidated financial statements at that date included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (â€œ2023 Form 10-Kâ€). The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of results that may be expected for the fiscal year ending December 31, 2024. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in the 2023 Form 10-K.Presentation of Financial Statements - The unaudited condensed consolidated financial statements included herein include the accounts of the Company. All significant intercompany accounts and transactions have been eliminated.Use of Estimates - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.The Company is, from time to time, subject to a variety of litigation and similar proceedings that arise out of the ordinary course of its business. Based upon the Company's experience, current information and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its results of operations, financial position or liquidity. However, the results of legal actions cannot be predicted with certainty. Therefore, it is possible that the Company's results of operations, financial condition or cash flows could be materially adversely affected in any particular period by the unfavorable resolution of one or more legal actions.Accounting Pronouncements - Adopted in 2024In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-03â€Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (â€œASU 2023-03â€) to (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. For public business entities, the amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company adopted the standard during the quarter ended March 31, 2024. The adoption of the standard had no material impact on the Company's financial statements.The Company has not adopted any new accounting standards during the three months ended June 30, 2024. Recently Issued Accounting Pronouncements - Pending AdoptionIn December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2023-09â€Income Taxes (Topic 740): Improvements to Income Tax Disclosures (â€œASU 2023-09â€) to enhance the transparency and decision usefulness of income tax disclosures, including jurisdictional information, by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disclosures. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024. Prospective application is required, though retrospective application is permitted. Entities are permitted to early adopt the standard. The Company did not early adopt for the 2024 reporting period. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INVENTORIES 6 Months Ended Jun. 30, 2024 Inventory Disclosure [Abstract] A INVENTORIES INVENTORIESInventories consist principally of raw materials, non-food finished goods and packaged meal replacements, protein, and supplements held in the Company's warehouses and outsourced distribution centers. Inventories are stated at the lower of cost or net realizable value, utilizing the first-in, first-out method. The cost of finished goods includes the cost of

raw materials, packaging supplies, direct and indirect labor and other indirect manufacturing costs. On a quarterly basis, management reviews inventories for unsalable or obsolete inventories. Inventories consisted of the following (in thousands): June 30, 2024 December 31, 2023 Raw materials \$5,507 \$7,944 Packaging \$1,219,962 Non-food finished goods \$2,423,703 Finished goods \$1,721,43,248 Reserve for obsolete inventory (1,286) (2,266) Total \$39,603 \$54,591 X - References No definition available. + Details Name: us-gaap_InventoriesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap_InventoriesDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 EARNINGS PER SHARE 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] A EARNINGS PER SHARE EARNINGS PER SHARE Basic earnings per share (â€œEPSâ€) computations are calculated utilizing the weighted average number of shares of the Companyâ€™s common stock outstanding during the periods presented. Diluted EPS is calculated utilizing the weighted average number of shares of the Companyâ€™s common stock outstanding adjusted for the effect of dilutive common stock equivalents. The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data): Three months ended June 30, 2024 2023 2024 2023 Numerator: Net income (loss) $(8,154) $30,280 $163 $70,248 Denominator: Weighted average shares of common stock outstanding 10,937,108,881 9,231,087,6 Effect of dilutive common stock equivalents â€” 294,447 Weighted average shares of common stock outstanding 10,937,109,171 9,231,087,6 Earnings per share - basic $(0.75) $2.78 $0.01 $6.46 Earnings per share - diluted $(0.75) $2.77 $0.01 $6.43 The calculation of diluted EPS excluded 326 thousand and 45 thousand antidilutive restricted stock awards for the three months ended June 30, 2024 and 2023, respectively, and 142 thousand and 22 thousand antidilutive restricted stock awards for the six months ended June 30, 2024 and 2023, respectively. EPS is computed independently for each of the periods presented above, and accordingly, the sum of the quarterly earnings per common share may not equal the year-to-date total computed. X - References No definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for earnings per share. + References Reference 1: <a href=) Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2> Reference 4: [http://www.xbrl.org/2003/role/exampleRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SHARE-BASED COMPENSATION 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] A SHARE-BASED COMPENSATION SHARE-BASED COMPENSATION Stock Options The Company has issued non-qualified and incentive stock options to employees and non-employee directors. The fair values of these options were estimated on the grant dates using the Black-Scholes option pricing model, which required estimates of the expected term of the option, the risk-free interest rate, the expected volatility of the price of the Companyâ€™s common stock, and dividend yield. Options outstanding as of June 30, 2024 generally vested over a period of 3 years and expire 10 years from the date of grant. The exercise price of these options is $66.68. Due to the Companyâ€™s lack of option exercise history on the date of grant, the expected term was calculated using the simplified method defined as the midpoint between the vesting period and the contractual term of each option. The risk-free interest rate was based on the U.S. Treasury yield curve in effect on the date of grant that most closely corresponded to the expected term of the option. The expected volatility was based on the historical volatility of the Companyâ€™s common stock over the period of time equivalent to the expected term for each award. The dividend yield was computed as the annualized dividend rate at the grant date divided by the strike price of the stock option. For the six months ended June 30, 2024 and 2023, the Company did not grant stock options. The following table is a summary of our stock option activity (in thousands, except per share data): Six months ended June 30, 2024 2023 Awards Weighted-Average Exercise Price Awards Weighted-Average Exercise Price Outstanding at beginning of period 26A 62.20A 33A $54.98A Exercised (1) 27.68A (4) 27.18A Forfeited (2) 26.52A â€” A â€” A Outstanding at end of the period 23A $66.68A 29A $58.65A As of June 30, 2024, the weighted-average remaining contractual life for both the outstanding stock options and exercisable stock options was 3.6 years with an aggregate intrinsic value of $0. There was no unrecognized compensation on the awards for the period ended June 30, 2024. For the six months ended June 30, 2024 and 2023, the Company received $36 thousand and $105 thousand in cash proceeds from the exercise of stock options, respectively. The total intrinsic value for stock options exercised during the six months ended June 30, 2024 and 2023 was $15 thousand and $328 thousand, respectively. Restricted Stock The Company has issued restricted stock to employees and non-employee directors generally with vesting terms up to 3 years after the date of grant. The fair value of the restricted stock is equal to the market price of the Companyâ€™s common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period. The following table summarizes our restricted stock activity (in thousands, except per share data): Six months ended June 30, 2024 2023 Shares Weighted-Average Grant Date Fair Value Shares Weighted-Average Grant Date Fair Value Outstanding at beginning of period 114A $127.87A 60A $188.11A Granted 210A 32.23A 85A 98.17A Vested (34) 138.80A (24) 169.42A Forfeited (4) 52.06A (3) 156.26A Outstanding at end of the period 286A $57.21A 118A $127.93A The Company withheld approximately 11 thousand shares and 9 thousand shares of the Companyâ€™s common stock to cover minimum tax liability withholding obligations upon the vesting of shares of restricted stock for the six months ended June 30, 2024 and 2023, respectively. The total fair value of restricted stock awards vested during the six months ended June 30, 2024 and 2023 was $1.3 million and $2.5 million, respectively. Market and Performance-based Share Awards The Company has issued market and performance-based share awards in 2022 and 2023 and performance-based share awards in 2020, 2021, and 2024 to certain key executives who were granted deferred shares and may earn between 0% and 250% of the target number depending upon both the Companyâ€™s total stockholder return (â€œTSRâ€), for those with market conditions, and the Companyâ€™s performance against predetermined performance goals over a three-year performance period after the date of grant. Market and performance-based share awards that are tied to the Companyâ€™s TSR are valued using the Monte Carlo method and are recognized ratably as expense over the awardâ€™s performance period. The fair value of the performance-based share awards is equal to the market price of the Companyâ€™s common stock on the date of grant adjusted by expected level of achievement over the performance period. Expense for performance-based share awards is amortized ratably over the performance period. In the event that management determines that the Company will not reach the lower threshold of the predetermined performance goals established in the grant agreement, any previously recognized expense is reversed in the period in which such a determination is made. Management determined that the market and performance-based share awards granted in March of 2022 and performance-based share awards granted in October of 2021 would not reach the lower threshold of the predetermined performance goals resulting in a $1.4A million and $0.1A million decrease in the Companyâ€™s share-based compensation expense during the three months ended March 31, 2023 and June 30, 2024 respectively. The Company withheld 8 thousand shares and 21 thousand shares of the Companyâ€™s common stock to cover minimum tax liability withholding obligations upon the vesting of shares of performance-based share awards for the six months ended June 30, 2024 and 2023, respectively. The total fair value of performance-based share awards issued during the six months ended June 30, 2024 and 2023 was $1.3 million and $5.3 million, respectively. Share-based compensation expense for all types of awards granted is recorded in selling, general, and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The total expense during the three months ended June 30, 2024 and 2023 was as follows (in thousands): Three months ended June 30, 2024 2023 Shares Share-Based Compensation Expense Shares Share-Based Compensation Expense Options and restricted stock 309A $1,717A 147A $1,642A Performance-based share awards granted in 2024 117A 371A â€” A â€” A Market and performance-based share awards granted in 2023 47A 482A 47A 482A Market and performance-based share awards granted in 2022 24A â€” A â€” A 24A â€” A Performance-based share awards granted in 2021 11A (116) 14A 340A Performance-based share awards granted in 2020 â€” A â€” A 28A 50A Total share-based compensation 498A $2,454A 260A $2,514A The total expense during the six months ended June 30, 2024 and 2023 was as follows (in thousands): Six months ended June 30, 2024 2023 Shares Share-Based Compensation Expense Shares Share-Based Compensation Expense Options and restricted stock 309A $3,317A 147A $2,869A Performance-based share awards granted in 2024 117A 448A â€” A â€” A Market and performance-based share awards granted in 2023 47A 964A 47A 561A Market and performance-based share awards granted in 2022 24A â€” A â€” A 24A (1,388) Performance-based share awards granted in 2021 11A (104) 14A 980A Performance-based share awards granted in 2020 â€” A â€” A 28A 98A Total share-based compensation 498A $4,625A 260A $3,120A The total income tax benefit recognized in the accompanying Condensed Consolidated Statements of Operations for stock awards was $0.1A million and $0.0A million for the three months ended June 30, 2024 and 2023, respectively, and the income tax expense of $0.4A million and income tax benefit of $0.1A million for the six months ended June 30, 2024 and 2023, respectively. There was $10.7 million of total unrecognized compensation cost related to restricted stock awards as of June 30, 2024, which is expected to be recognized over a weighted-average period of 2.00 years. There was $6.6 million of unrecognized compensation costs related to the 71 thousand market and performance-based shares and 118 thousand performance-based shares presented in the table above as of June 30, 2024, which is expected to be recognized over a weighted-average period of 1.88 years. X - Definition The entire disclosure for share-based payment arrangement. + References Reference 1: <a href=) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 LEASES 6 Months Ended Jun. 30, 2024 Leases [Abstract] A LEASES LEASES Operating Leases The Company has operating leases for office and warehouse space and certain equipment. In certain of the Companyâ€™s lease agreements, the rental payments are adjusted periodically based on defined terms within the lease. The Company did not have any finance leases for the six-month periods ended June 30, 2024 and 2023. Our leases relating to office and warehouse space have lease terms of 65 months to 102 months. Our leases relating to equipment have lease terms of 36 months, with certain of them having automatic renewal clauses. The Companyâ€™s warehouse agreements also contain non-lease components, in the form of payments towards variable logistics services and labor charges, which the Company is obligated to pay based on the services consumed by it. Such amounts are not included in the measurement of the lease liability but are recognized as expenses when they are incurred. The operating lease expense was \$1.2A million and \$1.3A million for the three months ended June 30, 2024 and 2023, respectively, and \$2.5A million and \$2.8A million for the six months ended June 30, 2024 and 2023, respectively. Supplemental cash flow information related to the Companyâ€™s operating leases was as follows (in thousands): Six months ended June 30, 2024 2023 Cash paid for amounts included in the measurements of lease liabilities Operating cash flow used in operating leases \$3,141A \$3,387A Right-of-use assets obtained in exchange for lease obligations Operating leases \$â€” A \$753A As of June 30, 2024, the weighted average remaining lease term was 3 years, 5 months and the weighted average discount rate was 2.30%. The following table presents the maturity of the Companyâ€™s operating lease liabilities as of June 30, 2024 (in thousands): 2024 (excluding the six months ended June 30, 2024) \$3,171A 2025 462A 2026 478A 2027 553A 2028 618A Thereafter 240A Total lease payments \$19,827A Less: imputed interest (727) Total \$19,100A X - References No definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 ACCUMULATED OTHER COMPREHENSIVE INCOME 6 Months Ended Jun. 30, 2024 Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] A ACCUMULATED OTHER COMPREHENSIVE INCOME ACCUMULATED OTHER COMPREHENSIVE INCOME The following table sets forth the components of accumulated other comprehensive income, net of tax where applicable (in thousands): June 30, 2024 December 31, 2023 Foreign currency translation (5) $(48) Unrealized net gains on investment securities 31A 296A Accumulated other comprehensive income $26A $248A X - References No definition available. + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. + References Reference 1: <a href=) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) Reference 4:

perspective of a market participant.The following tables present the Company's cash and financial assets that are measured at fair value on a recurring basis as of each of the hierarchy levels (in thousands):June 30, 2024CostUnrealized Gains (Losses)Accrued InterestEstimated FairValueCash & CashEquivalentsInvestmentSecuritiesCash and cash equivalents, excluding money market accounts\$102,982\$â€\$â€™â€\$â€™â€\$â€™â€Level 1:Money market accounts5,034\$â€â€™â€â€™â€â€™â€Government & agency securities16,128(42)7416,160Equity Securities10,000(1,600)\$â€8,400\$â€8,40031,162(1,642)7429,5945,03424,560Level 2:Corporate bonds30,5777927330,929Total\$164,721\$(1,563)\$347\$163,505\$108,016\$55,489December 31, 2023CostUnrealized GainsAccrued InterestEstimated FairValueCash & CashEquivalentsInvestmentSecuritiesCash and cash equivalents, excluding money market accounts\$88,778\$â€\$â€™â€\$â€™â€\$â€™â€Level 1:Money market accounts5,662\$â€â€™â€â€™â€â€™â€Government & agency securities15,2821264015,448\$â€™â€\$â€™â€\$â€™â€\$â€™â€Equity Securities10,00150â€™â€\$â€™â€10,150\$â€™â€10,15030,944764031,2605,66225,598Level 2:Corporate bonds29,44029327030,003â€™â€\$â€™â€30,003Total\$149,162\$569\$310\$150,041\$94,440\$55,601The Company had \$65 thousand and \$0 realized gains for the three months ended June 30, 2024 and 2023. The Company had \$74 thousand and \$0 realized gains for the six months ended June 30, 2024 and 2023. During the fourth quarter of 2023, the Company entered into an agreement with LifeMD, Inc (Nasdaq: LFMD), a leading provider of virtual primary care, to purchase shares of common stock of LifeMD for \$10A million. The securities are subject to a registration rights agreement which stipulates that the registration of the securities is to be made as soon as practicable, but not later than 90 days, following written demand by the Company. Written demand was made, and the securities registration remained in process as of June 30, 2024. The registration process was completed, effective July 18, 2024. In addition, the shares were subject to a 180-day lock-up period from the closing date of the agreement, December 11, 2023, which expired as of June 8, 2024. The fair value of the investment is recorded within the investment securities of the consolidated balance sheet. The losses related to the Company's LifeMD investment for the three and six months ended June 30, 2024 and 2023 are summarized in the table below (in thousands):Three months ended June 30, 20242023Net losses recognized during the period on equity securities\$(4,188)\$â€\$â€™â€A Less: Net losses recognized on equity securities sold\$â€\$â€™â€A â€™â€A Unrealized losses recognized during the reporting period on equity securities still held at the reporting dates\$(4,188)\$â€\$â€™â€A Six months ended June 30, 20242023Net losses recognized during the period on equity securities\$(1,750)\$â€\$â€™â€A Less: Net losses recognized on equity securities sold\$â€\$â€™â€A â€™â€A Unrealized losses recognized during the reporting period on equity securities still held at the reporting dates\$(1,750)\$â€\$â€™â€A The Company concurrently entered into an agreement in which LifeMD would provide services to stand-up the collaboration between LifeMD and the Company. The agreement stipulated an initial milestone payment of \$5A million due upon execution of the agreement for these services. The services under the initial milestone were completed prior to December 31, 2023, and this amount was included in the Company's selling, general, and administrative expenses on the consolidated statement of income for the quarter ended December 31, 2023. The Company made a second milestone payment under the agreement of \$2.5A million on March 18, 2024. Of the total \$2.5A million second milestone payment, \$1.3A million was recognized within selling, general, and administrative expenses for services performed by LifeMD for the quarter ended March 31, 2024, with the remaining \$1.2A million recognized in the quarter ended June 30, 2024. The final milestone payment of \$2.5A million was made on June 5, 2024. Of the total \$2.5A million final milestone payment, \$0.8A million was recognized within selling, general, and administrative expenses for services performed by LifeMD for the quarter ended June 30, 2024, with the remaining \$1.7A million to be recognized in the third quarter of 2024. X - DefinitionThe entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + ReferencesNo definition available. + Details Name: us-gaap FinancialInstrumentsDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap InvestmentsAllOtherInvestmentsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DEBT 6 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] A DEBT DEBT-CREDIT AgreementOn April 13, 2021, the Company and certain of its subsidiaries (collectively, the "Guarantors") entered into a credit agreement (the "Credit Agreement") among the Company, the Guarantors, the lenders party thereto and Citibank, N.A., in its capacity as administrative agent. On May 31, 2022, the Credit Agreement was amended to increase the borrowing capacity and convert the interest rate to be based on Secured Overnight Financing Rate ("SOFR"), from London Inter-Bank Offered Rate (LIBOR) (the "Amended Credit Agreement"). The Amended Credit Agreement provides for a \$225.0 million senior secured revolving credit facility with a \$20.0 million letter of credit submit. The Amended Credit Agreement also provides for an uncommitted incremental facility that permits the Company, subject to certain conditions, to increase the senior secured revolving credit facility by up to \$100.0 million. The Amended Credit Agreement matures on April 13, 2026. The Company's obligations under the Amended Credit Agreement are guaranteed by the Guarantors. The obligations of the Company and the Guarantors are secured by first-priority liens on substantially all of the assets of the Company and the Guarantors, subject to certain exceptions.Under the Amended Credit Agreement, the Company will pay to the administrative agent for the account of each revolving lender a commitment fee on a quarterly basis based on amounts committed but unused under the revolving facility from 0.20% to 0.40% per annum depending on the Company's Total Net Leverage Ratio (as defined in the Amended Credit Agreement). The Company is also obligated to pay the administrative agent customary fees for credit facilities of this size and type.Revolving borrowings under the Amended Credit Agreement bear interest at a rate per annum equal to (i) the Term SOFR Rate for the interest period plus the Applicable Rate (as defined in the Amended Credit Agreement) based on the Company's Total Net Leverage Ratio or (ii) the Alternate Base Rate (as defined in the Amended Credit Agreement) as in effect from time to time plus the Applicable Rate based on the Company's Total Net Leverage Ratio. As of June 30, 2024, the Applicable Rate for Term SOFR Loans is 1.25% per annum and the Applicable Rate for ABR Loans is 0.25% per annum. SOFR based loans also include a Credit Spread Adjustment based on the duration of the borrowing. The Amended Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants that, among other things, limit or restrict the ability of the Company and its subsidiaries, subject to negotiated exceptions, to incur additional indebtedness and additional liens on their assets, engage in mergers or acquisitions or dispose of assets, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments and change the nature of their businesses. The Amended Credit Agreement also contains customary events of default, subject to thresholds and grace periods, including, among others, payment default, covenant default, cross default to other material indebtedness and judgment default. In addition, the Amended Credit Agreement requires the Company to maintain a Total Net Leverage Ratio of no more than 2.75 to 1.00 and an Interest Coverage Ratio of at least 3.50 to 1.00. The Company had no borrowings outstanding under the Amended Credit Agreement, inclusive of the credit facility and letter of credit submit, as of June 30, 2024 and was in compliance with all covenants. X - ReferencesNo definition available. + Details Name: us-gaap DebtDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 - SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 - SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 - SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 - SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/194

statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates. The Company is, from time to time, subject to a variety of litigation and similar proceedings that arise out of the ordinary course of its business. Based upon the Company’s experience, current information and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its results of operations, financial position or liquidity. However, the results of legal actions cannot be predicted with certainty. Therefore, it is possible that the Company’s results of operations, financial condition or cash flows could be materially adversely affected in any particular period by the unfavorable resolution of one or more legal actions. Accounting Pronouncements and Recently Issued Accounting Pronouncements Accounting Pronouncements - Adopted in 2024 In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-03 “Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (ASC ASU 2023-03)” to (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. For public business entities, the amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company adopted the standard during the quarter ended March 31, 2024. The adoption of the standard had no material impact on the Company’s financial statements. The Company has not adopted any new accounting standards during the three months ended June 30, 2024. Recently Issued Accounting Pronouncements - Pending Adoption In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASC ASU 2023-09)” to enhance the transparency and decision usefulness of income tax disclosures, including jurisdictional information, by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disclosures. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024. Prospective application is required, though retrospective application is permitted. Entities are permitted to early adopt the standard. The Company did not early adopt for the 2024 reporting period. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements. X - References No definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + References No definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity’s financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + References No definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles. + References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference> 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent> + Details Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference> 3: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference) 4: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference> 6: <http://www.xbrl.org/1943274/2147482861/275-10-50-12Reference> 7: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8> + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INVENTORIES (Tables) 6 Months Ended Jun. 30, 2024 Inventory Disclosure [Abstract] A Schedule of Inventories Inventories consisted of the following (in thousands): June 30, 2024 December 31, 2023 Raw materials \$5,507 \$7,944 Packaging 1,219,962 Non-food finished goods 2,442,703 Finished goods 31,721 43,248 Reserve for obsolete inventory (1,286) (2,266) Totals \$39,603 \$54,591 X - References No definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1> + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 EARNINGS PER SHARE (Tables) 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] A Schedule of the Computation of Basic and Diluted EPS The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data): Three months ended June 30, Six months ended June 30, 2024 2023 2022 2021 Numerator: Net income (loss) \$(8,154) \$30,280 \$163 \$70,248 Denominator: Weighted average shares of common stock outstanding 10,937,108 888,109 923,107 876 Effect of dilutive common stock equivalents \$294,447 Weighted average shares of common stock outstanding 10,937,108 917,107 967,109 923 Earnings per share - basic \$(0.75) \$2.78 \$0.01 \$6.46 Earnings per share - diluted \$(0.75) \$2.77 \$0.01 \$6.43 X - References No definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of an entity’s basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SHARE-BASED COMPENSATION (Tables) 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] A Schedule of Stock Option Activity The following table is a summary of our stock option activity (in thousands, except per share data): Six months ended June 30, 2024 2023 Awards Weighted-Average Exercise Price Awards Weighted-Average Exercise Price Outstanding at beginning of period 26A \$66.20A 33A \$54.98A Exercised (1) 27.68A (4) 27.18A Forfeited (2) 26.52A A A A Outstanding at end of the period 23A \$66.68A 29A \$58.65A Exercisable at end of the period 23A \$66.68A 29A \$58.65A Schedule of Restricted Stock Activity The following table summarizes our restricted stock activity (in thousands, except per share data): Six months ended June 30, 2024 2023 Shares Weighted-Average Grant Date Fair Value Shares Weighted-Average Grant Date Fair Value Outstanding at beginning of period 114A \$127.87A 60A \$188.11A Granted 210A 32.23A 85A 98.17A Vested (34) 138.80A (24) 169.42A Forfeited (4) 52.06A (3) 156.26A Outstanding at end of the period 286A \$57.21A 118A \$127.93A Schedule of Share-based Compensation Expense The total expense during the three months ended June 30, 2024 and 2023 was as follows (in thousands): Three months ended June 30, 2024 2023 Shares Share-Based Compensation Expense Shares Share-Based Compensation Expense Options and restricted stock 309A \$1,717A 147A \$1,642A Performance-based share awards granted in 2024 117A 371A A A A Market and performance-based share awards granted in 2023 47A 482A A A A Market and performance-based share awards granted in 2022 44A A A A A Performance-based share awards granted in 2021 11A (116) 14A 340A Performance-based share awards granted in 2020 A A A A A Total share-based compensation 498A \$2,454A 260A \$2,514A The total expense during the six months ended June 30, 2024 and 2023 was as follows (in thousands): Six months ended June 30, 2024 2023 Shares Share-Based Compensation Expense Shares Share-Based Compensation Expense Options and restricted stock 309A \$3,317A 147A \$2,869A Performance-based share awards granted in 2024 117A 448A A A A Market and performance-based share awards granted in 2023 47A 561A A A A Market and performance-based share awards granted in 2022 44A A A A A Performance-based share awards granted in 2021 11A (104) 14A 980A Performance-based share awards granted in 2020 A A A A A Total share-based compensation 498A \$4,625A 260A \$3,120A X - References No definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of share-based payment arrangement. + References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of the changes in outstanding nonvested restricted stock units. + References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference) 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference) 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 LEASES (Tables) 6 Months Ended Jun. 30, 2024 Leases [Abstract] A Schedule of Supplemental Cash Flow Information Supplemental cash flow information related to the Company’s operating leases was as follows (in thousands): Six months ended June 30, 2024 2023 Cash paid for amounts included in the measurements of lease liabilities Operating cash flow used in operating leases \$3,141A \$3,387A Right-of-use assets obtained in exchange for lease obligations Operating leases \$A A \$753A Schedule of Maturity of Company’s Operating Lease Liabilities The following table presents the maturity of the Company’s operating lease liabilities as of June 30, 2024 (in thousands): 2024 (excluding the six months ended June) A 30, 2024) \$3,171A 2025 \$462A 2026 \$478A 2027 \$553A 2028 \$618A Thereafter \$240A Total lease payments \$19,827A Less: imputed interest (727) Total \$19,100A X - Definition Tabular disclosure of lessee’s lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4> + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - References No definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of undiscounted cash flows of lessee’s operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) 6 Months Ended Jun. 30, 2024 Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] A Schedule of Accumulated Other Comprehensive Income The following table sets forth the components of accumulated other comprehensive income, net of tax where applicable (in thousands): June 30, 2024 December 31, 2023 Foreign currency translation \$(5) \$(48) Unrealized net gains on investment securities 31A 296A Accumulated other comprehensive income \$26A \$248A X - References No definition available. + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of the components of accumulated other comprehensive income (loss). + References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14Reference> 2: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference> 3: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20> + Details Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INVESTMENTS (Tables) 6 Months Ended Jun. 30, 2024 Investments, All Other Investments [Abstract] Â Schedule of Cash and Financial Assets Measured at Fair Value on a Recurring Basis The following tables present the Company's cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands): June 30, 2024 Cost/Unrealized Gains (Losses)/Accrued Interest Estimated Fair Value Cash & Cash Equivalents Investment Securities Cash and cash equivalents, excluding money market accounts \$102,982 \$â€" \$â€" \$102,982 \$102,982 \$â€" Level 1: Money market accounts \$,034 \$â€" \$â€" \$,034 \$,034 \$ Government & agency securities \$16,128 (42) 7416,160 \$â€" \$16,160 Equity Securities \$10,000 (1,600) \$â€" \$8,400 \$â€" \$8,400 \$1,162 (1,642) 7429,594 \$,034 24,560 Level 2: Corporate bonds \$30,577 792 7330,929 \$â€" \$30,929 Total \$164,721 \$ (1,563) \$347 \$163,505 \$108,016 \$55,489 December 31, 2023 Cost/Unrealized Gains/Accrued Interest Estimated Fair Value Cash & Cash Equivalents Investment Securities Cash and cash equivalents, excluding money market accounts \$88,778 \$â€" \$â€" \$88,778 \$â€" \$â€" Level 1: Money market accounts \$,662 \$â€" \$â€" \$,662 \$,662 \$ Government & agency securities \$15,281 264 015,448 \$â€" \$15,448 Equity Securities \$10,000 150 \$â€" \$10,150 \$â€" \$10,150 30,944 764 031,260 \$,662 25,598 Level 2: Corporate bonds \$29,440 293 270 30,003 \$â€" \$30,003 Total \$149,162 \$569 \$31 \$150,041 \$94,440 \$55,601 Schedule of Investment Losses The losses related to the Company's LifeMD investment for the three and six months ended June 30, 2024 and 2023 are summarized in the table below (in thousands): Three months ended June 30, 2024 2023 Net losses recognized during the period on equity securities \$ (4,188) \$â€" Â Less: Net losses recognized on equity securities sold \$â€" Â Â Â Unrealized losses recognized during the reporting period on equity securities still held at the reporting date \$ (4,188) \$â€" Â Six months ended June 30, 2024 2023 Net losses recognized during the period on equity securities \$ (1,750) \$â€" Â Less: Net losses recognized on equity securities sold \$â€" Â Â Â Unrealized losses recognized during the reporting period on equity securities still held at the reporting date \$ (1,750) \$â€" Â X - Definition Tabular disclosure of realized and unrealized gain (loss) on investment in security. + References Reference 1:

Section S99 - Paragraph 1 - Subparagraph (SX 210.9-04(27)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef - Topic 944 - SubTopic 220 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.7-04(23)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef - Topic 260 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 7 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 6 - Publisher FASB - URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 9 - Publisher FASB - URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef - Topic 805 - SubTopic 60 - Name Accounting Standards Codification - Section 65 - Paragraph 1 - Subparagraph (g) - Publisher FASB - URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef - Topic 740 - SubTopic 323 - Name Accounting Standards Codification - Section 65 - Paragraph 2 - Subparagraph (g)(3) - Publisher FASB - URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef - Topic 220 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 2 - Subparagraph (SX 210.5-03(20)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef - Topic 235 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.4-08(g)(1)(iii)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef - Topic 323 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 3 - Subparagraph (c) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef - Topic 825 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 28 - Subparagraph (f) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef - Topic 220 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 6 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 3 - Publisher FASB - URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Subparagraph (b)(2) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef - Topic 815 - SubTopic 40 - Name Accounting Standards Codification - Section 65 - Paragraph 1 - Subparagraph (f) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 8 - Publisher FASB - URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 11 - Subparagraph (a) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 11 - Subparagraph (b) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 4 - Publisher FASB - URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef - Topic 946 - SubTopic 830 - Name Accounting Standards Codification - Section 55 - Paragraph 10 - Publisher FASB - URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 - SubTopic 220 - Name Accounting Standards Codification - Section 45 - Paragraph 7 - Publisher FASB - URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef - Topic 944 - SubTopic 220 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.7-04(18)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 - SubTopic 220 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.6-07(9)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 - SubTopic 220 - Name Accounting Standards Codification - Section S99 - Paragraph 3 - Subparagraph (SX 210.6-09(1)(d)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(4)(ii)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(4)(ii)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(4)(iii)(A)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(4)(iv)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(5)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(4)(i)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(4)(iii)(A)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(4)(iii)(B)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(4)(iv)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(5)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef - Topic 260 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 60B - Subparagraph (a) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef - Topic 205 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 7 - Publisher FASB - URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef - Topic 230 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 28 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef - Topic 220 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 1A - Subparagraph (a) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef - Topic 220 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 1B - Subparagraph

xbrl:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of tax benefit for recognition of expense of award under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph \(a\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details) Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemBalance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) \(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) (2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: <a href=) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details> Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemBalance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemBalance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details> Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemBalance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph \(e\)\(1\) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemBalance Type: na Period Type: duration X - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=med_MarketAndPerformanceBasedShareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=med_GrantedInMarch2022Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=med_GrantedInOctober2021Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SHARE-BASED COMPENSATION - Stock Options Activity (Details) - \$ / shares shares in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Awards A Outstanding at beginning of period (in shares) 26 33 Exercised (in shares) (1) (4) Forfeited (in shares) (2) 0 Outstanding at end of the period (in shares) 23 29 Exercisable at end of the period (in shares) 23 29 Weighted-Average Exercise Price A Outstanding at beginning of period (in usd per share) 66.68 58.65 Exercisable at end of the period (in usd per share) 66.68 58.65 X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-

types:perShareItem**Type** Balance **Type**: na **Period** **Type**: instant X - **Definition**The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + **References**Reference 1: [Type Balance **Type**: na **Period** **Type**: instant X - **Definition**A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + **References**No definition available. + **Details** Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_Data Type: xbrli:stringItem**Type** Balance **Type**: na **Period** **Type**: duration X - **Definition**Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + **References**Reference 1: \[Type Balance **Type**: na **Period** **Type**: duration X - **Definition**Number of share options \\(or share units\\) exercised during the current period. + **References**Reference 1: \\[Type Balance **Type**: na **Period** **Type**: duration X - **Definition**Weighted average fair value as of the grant date of equity-based award plans other than stock \\\(unit\\\) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + **References**Reference 1: \\\[Type Balance **Type**: na **Period** **Type**: duration X - **Definition**The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock \\\\(or unit\\\\) option plans \\\\(for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan\\\\). + **References**Reference 1: \\\\[Type Balance **Type**: na **Period** **Type**: instant X - **References**No definition available. + **Details** Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_Data Type: xbrli:stringItem**Type** Balance **Type**: na **Period** **Type**: duration X - **Definition**The number of equity-based payment instruments, excluding stock \\\\\(or unit\\\\\) options, that vested during the reporting period. + **References**Reference 1: \\\\\[Type Balance **Type**: na **Period** **Type**: duration X - **Details** Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data **Type**: na **Balance** **Type**: Period **Type**: XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards \\\\\\(Details\\\\\\) - USD \\\\\\(\\\\\\\$\\\\\\) shares in Thousands, \\\\\\\$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award \\\\\\[Line Items\\\\\\] A A A Shares 498 260 498 260 Share-Based Compensation Expense \\\\\\\$ 2,454 \\\\\\\$ 2,514 \\\\\\\$ 4,625 \\\\\\\$ 3,120 Options and restricted stock A A A Share-based Compensation Arrangement by Share-based Payment Award \\\\\\[Line Items\\\\\\] A A A Shares 309 147 309 147 Share-Based Compensation Expense \\\\\\\$ 1,717 \\\\\\\$ 1,642 \\\\\\\$ 3,317 \\\\\\\$ 2,869 Market and performance-based share awards | Granted In 2024 A A A Share-based Compensation Arrangement by Share-based Payment Award \\\\\\[Line Items\\\\\\] A A A Shares 47 47 47 47 Share-Based Compensation Expense \\\\\\\$ 482 \\\\\\\$ 482 \\\\\\\$ 561 Market and performance-based share awards | Granted In 2022 A A A Share-based Compensation Arrangement by Share-based Payment Award \\\\\\[Line Items\\\\\\] A A A Shares 24 24 24 24 Share-Based Compensation Expense \\\\\\\$ 0 \\\\\\\$ 0 \\\\\\\$ 0 \\\\\\(1,388\\\\\\) Performance-based share awards | Granted In 2024 A A A Share-based Compensation Arrangement by Share-based Payment Award \\\\\\[Line Items\\\\\\] A A A Shares 117 0 117 0 Share-Based Compensation Expense \\\\\\\$ 371 \\\\\\\$ 0 \\\\\\\$ 448 \\\\\\\$ 0 Performance-based share awards | Granted In 2021 A A A Share-based Compensation Arrangement by Share-based Payment Award \\\\\\[Line Items\\\\\\] A A A Shares 114 1 14 14 Share-Based Compensation Expense \\\\\\\$ \\\\\\(116\\\\\\) \\\\\\\$ 340 \\\\\\\$ \\\\\\(104\\\\\\) \\\\\\\$ 980 Performance-based share awards | Granted In 2020 A A A Share-based Compensation Arrangement by Share-based Payment Award \\\\\\[Line Items\\\\\\] A A A Shares 0 28 0 28 Share-Based Compensation Expense \\\\\\\$ 0 \\\\\\\$ 50 \\\\\\\$ 0 \\\\\\\$ 98 X - **Definition**Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. + **References**Reference 1:\\\\\]\\\\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\\(c\\\\\)\\\\\(2\\\\\)\\\\\(iii\\\\\)\\\\\(02\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 +Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock \\\\\(or unit\\\\\) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: <a href=\\\\\)\\\\]\\\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\\(c\\\\)\\\\(2\\\\)\\\\(iii\\\\)\\\\(01\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 +Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: <a href=\\\\)\\\]\\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\\(c\\\)\\\(2\\\)\\\(iii\\\)\\\(03\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 +Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock \\\(or unit\\\) option plans \\\(for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan\\\). + ReferencesReference 1: <a href=\\\)\\]\\(http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(28\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(29\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \\(c\\)\\(1\\)\\(iv\\)\\(02\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.3-04\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 +Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SHARE-BASED COMPENSATION - Restricted Stock Activity \\(Details\\) - Restricted Stock - \\$ / shares shares in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Shares A - Outstanding at beginning of period \\(in shares\\) 114.60 Granted \\(in shares\\) 210.85 Vested \\(in shares\\) \\(34\\) \\(24\\) Forfeited \\(in shares\\) \\(4\\) \\(3\\) Outstanding at end of period \\(in shares\\) 286.118 Weighted-Average Grant Date Fair Value A - Outstanding at beginning of period \\(in usd per share\\) \\$ 127.87 \\$ 188.11 Granted \\(in usd per share\\) 32.23 98.17 Vested \\(in usds per share\\) 138.80 169.42 Forfeited \\(in usd per share\\) 52.06 156.26 Outstanding at beginning of period \\(in usd per share\\) \\$ 57.21 \\$ 127.93 X - DefinitionThe number of equity-based payment instruments, excluding stock \\(or unit\\) options, that were forfeited during the reporting period. + ReferencesReference 1: <a href=\\)\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 +Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: <a href=\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 +Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: <a href=)

2-Reference 17: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18>: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19>: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20>: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21>: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22>: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23>: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24>: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25>: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26>: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27>: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28>: <http://www.xbrl.org/2003/role/disclosureRef>-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI

Accounting Standards Codification -Section 45 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-5AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INVESTMENTS - Cash and Financial Assets Measured at Fair Value on a Recurring Basis (Details) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended 12 Months Ended Jun. 30, 2024 Jun. 30, 2024 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Cash And Cash Equivalents And Marketable securities [Line Items] Å Å Å Å Cost, Cash and cash equivalents \$ 108,016 Å \$ 108,016 Å \$ 94,440 Cost, Total 164,721 Å 164,721 Å 149,162 Unrealized Gains (Losses), Equity securities (4,188) \$ 0 (1,750) \$ 0 Å Unrealized Gains (Losses), Total (1,563) Å (1,563) Å 569 Accrued Interest, Debt securities 347 Å 347 Å 310 Estimated Fair Value, Total 163,505 Å 163,505 Å 150,041 Investment Securities 55,489 Å 55,489 Å 55,601 Level 1 Å Å Å Å Cash And Cash Equivalents And Marketable securities [Line Items] Å Å Å Å Cost, Equity securities 10,000 Å 10,000 Å 10,000 Cost, Total 31,162 Å 31,162 Å 30,944 Unrealized Gains (Losses), Equity securities Å Å (1,600) Å 150 Unrealized Gains (Losses), Total (1,642) Å (1,642) Å 276 Accrued Interest, Debt securities 74 Å 74 Å 40 Estimated Fair Value, Equity securities 8,400 Å 8,400 Å 10,150 Estimated Fair Value, Total 29,594 Å 29,594 Å 31,260 Investment Securities 24,560 Å 24,560 Å 25,598 Government & agency securities | Level 1 Å Å Å Å Cash And Cash Equivalents And Marketable securities [Line Items] Å Å Å Å Cost, Debt securities 16,128 Å 16,128 Å 15,282 Unrealized Gains (Losses), Debt securities (42) Å (42) Å 126 Accrued Interest, Debt securities 74 Å 74 Å 40 Estimated Fair Value, Debt securities 16,160 Å 16,160 Å 15,448 Corporate bonds | Level 2 Å Å Å Å Cash And Cash Equivalents And Marketable securities [Line Items] Å Å Å Å Cost, Debt securities 30,577 Å 30,577 Å 29,440 Unrealized Gains (Losses), Debt securities 79 Å 79 Å 293 Accrued Interest, Debt securities 273 Å 273 Å 270 Estimated Fair Value, Debt securities 30,929 Å 30,929 Å 30,003 Cash and cash equivalents, excluding money market accounts Å Å Å Å Cash And Cash Equivalents And Marketable securities [Line Items] Å Å Å Å Cost, Cash and cash equivalents 102,982 Å 102,982 Å 88,778 Estimated Fair Value, Cash and cash equivalents 102,982 Å 102,982 Å 88,778 Money market accounts | Level 1 Å Å Å Å Cash And Cash Equivalents And Marketable securities [Line Items] Å Å Å Å Cost, Cash and cash equivalents 5,034 Å 5,034 Å 5,662 Estimated Fair Value, Cash and cash equivalents \$ 5,034 Å \$ 5,034 Å 5,662 X - DefinitionN/A + ReferencesNo definition available. + Details Name: med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems Namespace Prefix: med_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionCash, Cash Equivalents, And Short-Term Investments, Fair Value Disclosure + ReferencesNo definition available. + Details Name: med_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure Namespace Prefix: med_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionDebt Securities, Available-For-Sale, Accrued Interest + ReferencesNo definition available. + Details Name: med_DebtSecuritiesAvailableForSaleAccruedInterest Namespace Prefix: med_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionShort-Term Investments, Unrealized Gain (Loss) + ReferencesNo definition available. + Details Name: med_ShortTermInvestmentsUnrealizedGainLoss Namespace Prefix: med_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionCash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CashCashEquivalentsAndShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionCost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_EquitySecuritiesFvNiCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=med_CashAndCashEquivalentsExcludingMoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INVESTMENTS - Narrative (Details) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Dec. 31, 2023 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Schedule of Investments [Line Items] Å Å Å Å Realized gains \$ 65 Å \$ 0 \$ 74 \$ 0 LifeMD Å Å Å Å Schedule of Investments [Line Items] Å Å Å Å Investments made Å \$ 10,000 Å Å Å X - DefinitionAmount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_DebtSecuritiesRealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the purchase of all investments (debt, security, other) during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with

domain members defined in one or many axes to the table. - ReferencesReference 1:

Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1:

[illegible]

```

XGK?2C8?EU,0 MZ(&TXRC5 C1B=8 3S?>DU1(A5%<@V+FR1T-Y-H31=F5E%15:V4M2>YU341CQ4C^NWAU5YS;
MKM)9@U/M79GE1N)D[10N:870A31^V7+R083EL5^P9>SVCRYNNDN2=-V,#+M-CMB90Q_!J,6(0BSF)Q%3B5C2IXJ8$;1/B"EG"8CAOLD2?J1XGWO1/<F<
M"WM)R(J)21EFN$M#>GOUR(G)S(P)M@JWXSHXJ.BJ2+17M0?M2EO_ U1+ P04 "16A@59 M0M%Y1JT# #0!P <^'AL+W=O,RF$,J[VJ>3U5CI9=XJ($T5<7T[AR%VLZ"?
G:86/U,M="U"-),6;UW:/^L$V7H0/XZEX15?P4Y$M9<-8/<^<G%Q(X0"LRM0V1L^>E"X^N&B,W/6;0A72,Q^,<^B>OG;OLF<+>?J[B MA2UGP3B-E L7$;AMJ]QKV?
@/(EC/,"MK5-PDQROEA590<5E^V+JGDG MX?S[VX>+>9:75+Y5/LM;=<:&[17IO(L^>E.Y0J[V7F7D?=>7]I MNJYJ1JXOKJ;118 W7?41YV6?>D]I,K-B<@U?W1 ZY(K%$O
IF/3KU%=1. M4JY(M@J9=1@+Q+V/784"ILF&@R,1&F&R[5W6G%M]=>OIT1Y)G2U7TX)JY M6Z5SK^F@%(F(IKVR:75+;1\TQ:3$1$?9=,Z61")FIES^+QU:YJZX+^29E/E-
*4(8-D0_ G^1NQ-FV/6J5N9%2Z1+L62 M="*1JOY+^XC(O\18&X2+V/743(K;KLT)^<D/Z^O9C S0OW, FS+($T,4I M?J1Z1%<21^>R-SRR,2S;J032?U.[@Q,^=
AZ^AY,D3G;TOU>6]01?2?AD^M" M918;JOWGBGZG(Z5K25_2US^&FG;AMNM=L_56=N6W;M^X+TZ3<@, 5N<+! MT2 W,X?1<2JV0L21^>T OAA24(N=F=> ^YOB>YBX-
X(00)4SL#1!0 ( M %<15G<+&PO=VJRW-H965TQ>3>B[6Z^8RXJ3X4?]>ELPX6M7P7$;AS=90<-05(2) M6613<(+&L+PM:8#G7JBO81%>#&0063D=^>F=?>
8S(AFU)?"NIO(N, L)[CCDY1&V;H+J1>01OJ9&4.24N3-X M^E3#;7,##>?IG^VYIF, TP$ "89@LG1=WS_ NCI^FWJL?0 MOI,C Q2#WV K,@>1JTA/66,G_!@DT=5T-
O>S^>J49;HH^CB+&4)RM:4GXL&5 M12<^S$H,1,R18;6PCJN<4/!/-!<4N@/X' MIB,B8B7TDK!<8FDAG)Q(87$Y%:(G2CQSB<1ME V, DLML09ZAGPA@5EPEM<= MVN/M&9U
%JYA^<@-OJ/Y1"BK^N1^>X"6#*TNUY,ZK @>WHM+EDJ B+M I18M1Q;>T1^X&=<#>00>4HS MI$B&$4B@<^> URF0W8;2F9J@<^> T17UQWIMQJG/1&I P'1]!"DG1:MIG MT^>W
/,3JY8I2<^>N' M^MIG&9(10J)WV,2V7JW+!&T1 B14Z^H$KPV1Y[?C]2,3(2)OZ1AC(P MZR2Z;>?7PF89 F5+ E1;CTX&S(E=90R@ C" T,M2XJR[2AH^E]P'6]2: M^FX<+&
(OJ)+=-6'D7>WS+&E B4HUQV10Z/>G/2#%,8I;-P, C=&S=NZ, J5^JOSIF KM,ZW,J1&P=O=VJRW-H965T.7))@9H J8V+VJEFH87;WPJ5J4&PET6%;&4DFY^[]=>LQR8O!(ZY
M^P*R+&+>B7Z]>ENQ6<+>1> 3 C+O.L,]>JF;75J?J)FJGJ[M/S44;R9Y$J" MHYX^FID6$15>78<@OJH.>RZV+V[V$E:G/> M7CWQ54YG%B>+.[F?^KNA/UC?
JOAZ;BADLI<^%$J@FDQ.>]=N^O!KB>%OPI MQ<^*TQ@PE&2MUCP^?T_>CPR)3"06*7#XJR"N198A(6#<C>T6SUQR)&JOCFOHO
M)@O,(N9&7^0L+YG:V7D0J[43^B9V;J]9BNHY;DBO41EAOZRA5L[B^H1X2U M>;49,AEX?1SQTH/KOVQV5#6&T(B6J)W^YD5M^<+;5@FE<+>=1P0^+2;F1.
M^#B4.ZOAK81J]N+NM[NOGXZN+>N^?637-UJN_!U_> GM/[WO9<6L^>XZ2B M=-.4HA5LH@<?>=B989^<+>S_>X D^>R^<CQJ]UGHAH,^>M)MU(CH1=M5G7$MCJ]I
A"FYI4O+>LNM>+>5-X^Y=C8S6G3R3W">JH&S;3QM;Y M;^8$>=<J B TCJ[?S4S&R/^S@?>1P/MA% 45<+>ATE=F=5R8F$)UZZD3I8] [BBADBH^H"5C&1SS.U
M^%,+00M,Q$14:@A!8U)TVXU.R196L51-F9Z-M^>M^>.&,$1L B $ZV0(G W M, IFLRR^<+>C(XLIS5YE+>D_ NDMF^D-21(^M4QPO.Y2D?798B3C<+>#)Q8^ M2IO^J3V,MS?
W11(8LH U0(!1<@JGY0&@;ALI!"I2;4#&XG D^>)"#TC4,(&@[DV^>V>=>(1Q.^8X^82Z<_ O#G9 M[COE25]&8P^K"<-3$PF(-Y&^&6&6W!>@QOD^E^&A$3C<-1!>=<6J]M[ANK4%
MUUSXO4EG^ FZW>#S$ S6>J1Y>N-K$QP, O#>A#>B[S9.H;1P2N4+KE^M1] MG;74I^N1,B, K^H'WZ5+>1^W1J;1/4^9>E.T6464R4NK/ MU2YHAD).1E^E@9-^ 28B+E%>
3,3V0VEY>.>L1O=;"/+1$;=>A75+>1( 2K M^K=A&M41^OMJG?93=6M,+OFLJBP <OIW^<0,0^V^CTOIQ!$SOR^ ^T;NBD M[8^XQ[3P JV,1$!$=>D^BTOJ!FIMYPY"1(X4?
FOJ(CDBWJ^&W.AA/(V1B MX2D>^N8C77PVE)>%>VR17=>=>9?U%KB%<T@+>48N2J2C2(38?J)SL$5HB_JN M^G4(O6^S^Q9C(O)&%7(O))&CX^K3J193="H
(RVA>DY<+>D6V^WQRO.VPJ5^L M+>3JVE!480!N4V)Y>KT(I Q34I)(W.-5_&3/ AH R^T C:Q<+>C&#> MUOSX^+>
^&#&#&74^>DK8559!LZ.H.D.%3^9TL7@>599L,53#&471V+QO4 M4JRSX^>DHX^N53<+>(P;F>LO95[!01,KJ]^>LAIE?K^+][UENMZH^>I3&P%YQMJ@>57)5@?>+DL
N(YI4V^>0!N1J]D[ET;>Z)7]>7^>1 L1UREIGE.WPS^M15H80R$47COA1R Q-28;(/97RA? M47Y74-1 DKY?MGH/7?>T ;>G(1^C^XJH+ 40260R0/(!#MB,5#>=<JO M3MB7KK8C
"IO(RC8VA &L<C4QOMF$;H@>AXY)@>P>P>CCO[ ^C=HRY8GCB MA&P%U?L64=>=>$/G^FQ?> I]HJ4QH.Y?>FX(SX3C^>UW;W4^PW83!UO MF90>^/P1ORJ^Q65
9!>+&F9QRIOQE?7?>2L2DYM0UIYJ%>KF5 5HW+>=>= MUX%YU1B&M&^>219528(**WK">=>K,%Q?T N.O6;+1#>@H[QR16KHNF^>_YF@/85^YG>5Z^H(593X&JTH%HIJY$;E.
M4ZL=4YG9K(F^>U+AA(EG^2(2T+>P1>K$O^>KSK5WX^>M^>^>TJ74(VDLLJ, M=9_SJ)R6WJ^>M^>I81&Z3^>LP4USRU5TP2STS=>=H9=>5$)F$Z,>K^<EM6^>^*W MH:D9PFV)E$[
M2SXOQXK(TI&9%17)] M>^(73Z)>K^<I?>1RM71L_>GJ< @&6[<17.V$567H/VH?E94;Y5<[AF^&4W=SB>T85DH$;TUSK<6C<4#51)TNIC:
M,JU<1_ C4579.15^07^6. @>K18:KB2Z$Y/UQBX0015 <3L^U?>^>HLP,BJ3^>7^>M^>Q$%> >D>M^>0^5Y2) MGV/O4ITW5>1CNJ,T]^>S?GB4[IEK:O2^F^XK^>Y>_NB/PF^E15_
<+>MJT^#8(^C/C@>)>^>V M^>PW _6Y6(IE&26P=I5E3ZU)>_UGY+V1O90R5NU=>2JFG;.>X[&M4$;EFP MQM+KJ3XJ]OD@+>V3ABP6162^12?>
[!871N0^I&VW&QM^>^>U_96F1^>V+LE,&T14)$GK0KQ^>?<K- O]>B36; MMJZD>Q^J^V^>7^>O1;QQ@>D 8%:"KPXKK2TZ=>XJ;W^KG04 HB\O?7LK^NLY5F MMOGHY)]JZD:[KX8
AR;2HBL3$Q@>[C3L>+>T^>PK^F5@>UJRIE=E-PJ]1 MTK@&
```

```

AN5C1^#LMLM8K^#84I45^#74,KJ)?[L^F^5W1P M^M@ ODEA^T+D+6V%N3L8Y=>+WCRC^ MV^O2^&XB^+Z U^B^3N^G01 M,B6XV&I8HH)UP13)?[...
GXFWAXO-PMF^#N43CJ3P^?WJ];SCT A M(A)@6S=-8S6^$7 MYXV^LJ,6D^94G-28I^8TH+&H^E0F<(Y3D)=;SKV9MNCN,^%&6CZ4+?+ZF M6INH^
Y3FCU4WDJ@J=(4/5+I.A.TSP2HRB^O.O)[J58MM^ VCVWV^H2HF%J M^T(OT+@&F@A1+3ZC^C^I57(3WL9V1P15M^F/31LR0Q3N IA:1!:@&N^4BE MC^R^%,+?8L[V1(DB9.
6&6 UCD.4T: M^?Y21/YG^=-/R%ED2HSY^L^%&878;H#N(8XN^%ODK+VV4P^?J^OU; 7I8 M^Y^2%2&6MS9+46^8T1+U^@T^602>G#<+U/S4=^ABVC W^OVC(465V1K1^FD
IAV7G6GW;2?M4/N3;WJ57QC:LN%AA$S,K4T1^%M^&T%&(VLWC;2T IUVX+^ M6^BL MWG4IJ^8IUT_I^#I+U1+ P04 _I!6A@59.:)(KH$ %W#&@ &0 M^'AL+W=O7>D;[ MB?
D+>J@&:CAOLA+&6&MM%Z=>=CHJ66^I1E.66%+3./B;^WJ4Y:2N212K M^G/J=P/KP&P-^_#=6 [[87SK,2Q1+4J^BX^?SC 7ZT+;VU7?T?SA380/L^
33LJLQJ@OKWY5C242=62;,"2Y6$B3.JIY1=WH6F?VP+>.,UVJGX:221^?WYN%+M.FBYQB^,^%&=&=M/L#LQXSTON^?71K-53VD,=;[M;[AV=HIERA6+ B_QENK%
4I6W,497^7Z6JP_XR:;>T^@E(FE^?VNMJ;]^%QDI&87,7E09&5U_>]=>Q MB-UG-#&C=&%F JXFLQE^YYL^,^%&N09C21F88-U5J^3D^C MZXN3LJ^D^XB.<7UV,^Y.IY.1C=?
6&6 UCD.4T: M^?Y21/YG^=-/R%ED2HSY^L^%&878;H#N(8XN^%ODK+VV4P^?J^OU; 7I8 M^Y^2%2&6MS9+46^8T1+U^@T^602>G#<+U/S4=^ABVC W^OVC(465V1K1^FD
IAV7G6GW;2?M4/N3;WJ57QC:LN%AA$S,K4T1^%M^&T%&(VLWC;2T IUVX+^ M6^BL MWG4IJ^8IUT_I^#I+U1+ P04 _I!6A@59.:)(KH$ %W#&@ &0 M^'AL+W=O7>D;[ MB?
D+>J@&:CAOLA+&6&MM%Z=>=CHJ66^I1E.66%+3./B;^WJ4Y:2N212K M^G/J=P/KP&P-^_#=6 [[87SK,2Q1+4J^BX^?SC 7ZT+;VU7?T?SA380/L^
33LJLQJ@OKWY5C242=62;,"2Y6$B3.JIY1=WH6F?VP+>.,UVJGX:221^?WYN%+M.FBYQB^,^%&=&=M/L#LQXSTON^?71K-53VD,=;[M;[AV=HIERA6+ B_QENK%
4I6W,497^7Z6JP_XR:;>T^@E(FE^?VNMJ;]^%QDI&87,7E09&5U_>]=>Q MB-UG-#&C=&%F JXFLQE^YYL^,^%&N09C21F88-U5J^3D^C MZXN3LJ^D^XB.<7UV,^Y.IY.1C=?
6&6 UCD.4T: M^?Y21/YG^=-/R%ED2HSY^L^%&878;H#N(8XN^%ODK+VV4P^?J^OU; 7I8 M^Y^2%2&6MS9+46^8T1+U^@T^602>G#<+U/S4=^ABVC W^OVC(465V1K1^FD
IAV7G6GW;2?M4/N3;WJ57QC:LN%AA$S,K4T1^%M^&T%&(VLWC;2T IUVX+^ M6^BL MWG4IJ^8IUT_I^#I+U1+ P04 _I!6A@59.:)(KH$ %W#&@ &0 M^'AL+W=O7>D;[ MB?
D+>J@&:CAOLA+&6&MM%Z=>=CHJ66^I1E.66%+3./B;^WJ4Y:2N212K M^G/J=P/KP&P-^_#=6 [[87SK,2Q1+4J^BX^?SC 7ZT+;VU7?T?SA380/L^
33LJLQJ@OKWY5C242=62;,"2Y6$B3.JIY1=WH6F?VP+>.,UVJGX:221^?WYN%+M.FBYQB^,^%&=&=M/L#LQXSTON^?71K-53VD,=;[M;[AV=HIERA6+ B_QENK%
4I6W,497^7Z6JP_XR:;>T^@E(FE^?VNMJ;]^%QDI&87,7E09&5U_>]=>Q MB-UG-#&C=&%F JXFLQE^YYL^,^%&N09C21F88-U5J^3D^C MZXN3LJ^D^XB.<7UV,^Y.IY.1C=?
6&6 UCD.4T: M^?Y21/YG^=-/R%ED2HSY^L^%&878;H#N(8XN^%ODK+VV4P^?J^OU; 7I8 M^Y^2%2&6MS9+46^8T1+U^@T^602>G#<+U/S4=^ABVC W^OVC(465V1K1^FD
IAV7G6GW;2?M4/N3;WJ57QC:LN%AA$S,K4T1^%M^&T%&(VLWC;2T IUVX+^ M6^BL MWG4IJ^8IUT_I^#I+U1+ P04 _I!6A@59.:)(KH$ %W#&@ &0 M^'AL+W=O7>D;[ MB?
D+>J@&:CAOLA+&6&MM%Z=>=CHJ66^I1E.66%+3./B;^WJ4Y:2N212K M^G/J=P/KP&P-^_#=6 [[87SK,2Q1+4J^BX^?SC 7ZT+;VU7?T?SA380/L^
33LJLQJ@OKWY5C242=62;,"2Y6$B3.JIY1=WH6F?VP+>.,UVJGX:221^?WYN%+M.FBYQB^,^%&=&=M/L#LQXSTON^?71K-53VD,=;[M;[AV=HIERA6+ B_QENK%
4I6W,497^7Z6JP_XR:;>T^@E(FE^?VNMJ;]^%QDI&87,7E09&5U_>]=>Q MB-UG-#&C=&%F JXFLQE^YYL^,^%&N09C21F88-U5J^3D^C MZXN3LJ^D^XB.<7UV,^Y.IY.1C=?
6&6 UCD.4T: M^?Y21/YG^=-/R%ED2HSY^L^%&878;H#N(8XN^%ODK+VV4P^?J^OU; 7I8 M^Y^2%2&6MS9+46^8T1+U^@T^602>G#<+U/S4=^ABVC W^OVC(465V1K1^FD
IAV7G6GW;2?M4/N3;WJ57QC:LN%AA$S,K4T1^%M^&T%&(VLWC;2T IUVX+^ M6^BL MWG4IJ^8IUT_I^#I+U1+ P04 _I!6A@59.:)(KH$ %W#&@ &0 M^'AL+W=O7>D;[ MB?
D+>J@&:CAOLA+&6&MM%Z=>=CHJ66^I1E.66%+3./B;^WJ4Y:2N212K M^G/J=P/KP&P-^_#=6 [[87SK,2Q1+4J^BX^?SC 7ZT+;VU7?T?SA380/L^
33LJLQJ@OKWY5C242=62;,"2Y6$B3.JIY1=WH6F?VP+>.,UVJGX:221^?WYN%+M.FBYQB^,^%&=&=M/L#LQXSTON^?71K-53VD,=;[M;[AV=HIERA6+ B_QENK%
4I6W,497^7Z6JP_XR:;>T^@E(FE^?VNMJ;]^%QDI&87,7E09&5U_>]=>Q MB-UG-#&C=&%F JXFLQE^YYL^,^%&N09C21F88-U5J^3D^C MZXN3LJ^D^XB.<7UV,^Y.IY.1C=?
6&6 UCD.4T: M^?Y21/YG^=-/R%ED2HSY^L^%&878;H#N(8XN^%ODK+VV4P^?J^OU; 7I8 M^Y^2%2&6MS9+46^8T1+U^@T^602>G#<+U/S4=^ABVC W^OVC(465V1K1^FD
IAV7G6GW;2?M4/N3;WJ57QC:LN%AA$S,K4T1^%M^&T%&(VLWC;2T IUVX+^ M6^BL MWG4IJ^8IUT_I^#I+U1+ P04 _I!6A@59.:)(KH$ %W#&@ &0 M^'AL+W=O7>D;[ MB?
D+>J@&:CAOLA+&6&MM%Z=>=CHJ66^I1E.66%+3./B;^WJ4Y:2N212K M^G/J=P/KP&P-^_#=6 [[87SK,2Q1+4J^BX^?SC 7ZT+;VU7?T?SA380/L^
33LJLQJ@OKWY5C242=62;,"2Y6$B3.JIY1=WH6F?VP+>.,UVJGX:221^?WYN%+M.FBYQB^,^%&=&=M/L#LQXSTON^?71K-53VD,=;[M;[AV=HIERA6+ B_QENK%
4I6W,497^7Z6JP_XR:;>T^@E(FE^?VNMJ;]^%QDI&87,7E09&5U_>]=>Q MB-UG-#&C=&%F JXFLQE^YYL^,^%&N09C21F88-U5J^3D^C MZXN3LJ^D^XB.<7UV,^Y.IY.1C=?
6&6 UCD.4T: M^?Y21/YG^=-/R%ED2HSY^L^%&878;H#N(8XN^%ODK+VV4P^?J^OU; 7I8 M^Y^2%2&6MS9+46^8T1+U^@T^602>G#<+U/S4=^ABVC W^OVC(465V1K1^FD
IAV7G6GW;2?M4/N3;WJ57QC:LN%AA$S,K4T1^%M^&T%&(VLWC;2T IUVX+^ M6^BL MWG4IJ^8IUT_I^#I+U1+ P04 _I!6A@59.:)(KH$ %W#&@ &0 M^'AL+W=O7>D;[ MB?
D+>J@&:CAOLA+&6&MM%Z=>=CHJ66^I1E.66%+3./B;^WJ4Y:2N212K M^G/J=P/KP&P-^_#=6 [[87SK,2Q1+4J^BX^?SC 7ZT+;VU7?T?SA380/L^
33LJL
```

[illegible]

Calendars...*/.report.rc { background-color: #f0f0f0; }/* Even rows...*/.report.re, .report.reu { background-color: #def; } .report.reu td { border-bottom: 1px solid black; } /* Odd rows...*/.report.ro, .report.rou { background-color: white; } .report.rou td { border-bottom: 1px solid black; } .report.rou table td, .report.rou table td { border-bottom: 0px solid black; } /* styles for footnote marker */.report.fn { white-space: nowrap; } /* styles for numeric types */.report.num, .report.nump { text-align: right; white-space: nowrap; } .report.nump { padding-left: 2em; } .report.nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */.report.text { text-align: left; white-space: normal; } .report.text.big { margin-bottom: 1em; width: 17em; } .report.text.more { display: none; } .report.text.note { font-style: italic; font-weight: bold; } .report.text.small { width: 10em; } .report.supp { font-style: italic; } .report.outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1.html 135 221 1 false 40 0 false 4 false false R1.htm 0000001 - Document - Cover Sheet http://www.medfast1.com/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 2 false false R3.htm 9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) Sheet http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) Statements 3 false false R4.htm 9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 4 false false R5.htm 9952154 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 5 false false R6.htm 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 6 false false R7.htm 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) Sheet http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) Statements 7 false false R8.htm 9952157 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.medfast1.com/role/SUMMARYOF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 9952158 - Disclosure - INVENTORIES Sheet http://www.medfast1.com/role/INVENTORIES INVENTORIES Notes 9 false false R10.htm 9952159 - Disclosure - EARNINGS PER SHARE Sheet http://www.medfast1.com/role/EARNINGSPERSHARE EARNINGS PER SHARE Notes 10 false false R11.htm 9952160 - Disclosure - SHARE-BASED COMPENSATION Sheet http://www.medfast1.com/role/SHAREBASEDCOMPENSATION SHARE-BASED COMPENSATION Notes 11 false false R12.htm 9952161 - Disclosure - LEASES Sheet http://www.medfast1.com/role/LEASES LEASES Notes 12 false false R13.htm 9952162 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME Sheet http://www.medfast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME ACCUMULATED OTHER COMPREHENSIVE INCOME Notes 13 false false R14.htm 9952163 - Disclosure - INVESTMENTS Sheet http://www.medfast1.com/role/INVESTMENTS INVESTMENTS Notes 14 false false R15.htm 9952164 - Disclosure - DEBT Sheet http://www.medfast1.com/role/DEBT DEBT Notes 15 false false R16.htm 9952165 - Disclosure - SUPPLY CHAIN OPTIMIZATION Sheet http://www.medfast1.com/role/SUPPLYCHAINOPTIMIZATION SUPPLY CHAIN OPTIMIZATION Notes 16 false false R17.htm 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.medfast1.com/role/SUMMARYOF SIGNIFICANT ACCOUNTING POLICIES Policies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 9954472 - Disclosure - INVENTORIES (Tables) Sheet http://www.medfast1.com/role/INVENTORIESTables INVENTORIES (Tables) Tables http://www.medfast1.com/role/INVENTORIES 18 false false R19.htm 9954473 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://www.medfast1.com/role/EARNINGSPERSHARETables EARNINGS PER SHARE (Tables) Tables http://www.medfast1.com/role/EARNINGSPERSHARE 19 false false R20.htm 9954474 - Disclosure - SHARE-BASED COMPENSATION (Tables) Sheet http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONTables SHARE-BASED COMPENSATION (Tables) Tables http://www.medfast1.com/role/SHAREBASEDCOMPENSATION 20 false false R21.htm 9954475 - Disclosure - LEASES (Tables) Sheet http://www.medfast1.com/role/LEASESTables LEASES (Tables) Tables http://www.medfast1.com/role/LEASES 21 false false R22.htm 9954476 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) Sheet http://www.medfast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) Tables http://www.medfast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME 22 false false R23.htm 9954477 - Disclosure - INVESTMENTS (Tables) Sheet http://www.medfast1.com/role/INVESTMENTSTables INVESTMENTS (Tables) Tables http://www.medfast1.com/role/INVESTMENTS 23 false false R24.htm 9954478 - Disclosure - SUPPLY CHAIN OPTIMIZATION (Tables) Sheet http://www.medfast1.com/role/SUPPLYCHAINOPTIMIZATIONTables SUPPLY CHAIN OPTIMIZATION (Tables) Tables http://www.medfast1.com/role/SUPPLYCHAINOPTIMIZATION 24 false false R25.htm 9954479 - Disclosure - INVENTORIES (Details) Sheet http://www.medfast1.com/role/INVENTORIESDetails INVENTORIES (Details) Details http://www.medfast1.com/role/INVENTORIESTables 25 false false R26.htm 9954480 - Disclosure - EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details) Sheet http://www.medfast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details) Details 26 false false R27.htm 9954481 - Disclosure - EARNINGS PER SHARE - Narrative (Details) Sheet http://www.medfast1.com/role/EARNINGSPERSHARENarrativeDetails EARNINGS PER SHARE - Narrative (Details) Details 27 false false R28.htm 9954482 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details) Sheet http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails SHARE-BASED COMPENSATION - Narrative (Details) Details 28 false false R29.htm 9954483 - Disclosure - SHARE-BASED COMPENSATION - Stock Options Activity (Details) Sheet http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails SHARE-BASED COMPENSATION - Stock Options Activity (Details) Details 29 false false R30.htm 9954484 - Disclosure - SHARE-BASED COMPENSATION - Restricted Stock Activity (Details) Sheet http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails SHARE-BASED COMPENSATION - Restricted Stock Activity (Details) Details 30 false false R31.htm 9954485 - Disclosure - SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details) Sheet http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details) Details 31 false false R32.htm 9954486 - Disclosure - LEASES - Narrative (Details) Sheet http://www.medfast1.com/role/LEASESNarrativeDetails LEASES - Narrative (Details) Details 32 false false R33.htm 9954487 - Disclosure - LEASES - Supplemental Cash Flow Information (Details) Sheet http://www.medfast1.com/role/LEASESSupplementalCashFlowInformationDetails LEASES - Supplemental Cash Flow Information (Details) Details 33 false false R34.htm 9954488 - Disclosure - LEASES - Future Minimum Lease Commitments (Details) Sheet http://www.medfast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails LEASES - Future Minimum Lease Commitments (Details) Details 34 false false R35.htm 9954489 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) Sheet http://www.medfast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) Details 35 false false R36.htm 9954490 - Disclosure - INVESTMENTS - Cash and Financial Assets Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.medfast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonRecurringBasisDetails INVESTMENTS - Cash and Financial Assets Measured at Fair Value on a Recurring Basis (Details) Details 36 false false R37.htm 9954491 - Disclosure - INVESTMENTS - Narrative (Details) Sheet http://www.medfast1.com/role/INVESTMENTSNarrativeDetails INVESTMENTS - Narrative (Details) Details 37 false false R38.htm 9954492 - Disclosure - INVESTMENTS - Investment Losses (Details) Sheet http://www.medfast1.com/role/INVESTMENTSInvestmentLossesDetails INVESTMENTS - Investment Losses (Details) Details 38 false false R39.htm 9954493 - Disclosure - INVESTMENTS - Collaborate Arrangement (Details) Sheet http://www.medfast1.com/role/INVESTMENTSCollaborateArrangementDetails INVESTMENTS - Collaborate Arrangement (Details) Details 39 false false R40.htm 9954494 - Disclosure - DEBT (Details) Sheet http://www.medfast1.com/role/DEBTDDetails DEBT (Details) Details http://www.medfast1.com/role/DEBT 40 false false R41.htm 9954495 - Disclosure - SUPPLY CHAIN OPTIMIZATION - Summary of Components of Supply Chain Optimization Charges (Details) Sheet http://www.medfast1.com/role/SUPPLYCHAINOPTIMIZATIONSummaryofComponentsofSupplyChainOptimizationChargesDetails SUPPLY CHAIN OPTIMIZATION - Summary of Components of Supply Chain Optimization Charges (Details) Details 41 false false R42.htm 9954496 - Disclosure - SUPPLY CHAIN OPTIMIZATION - Summary of Condensed Consolidated Statement of Operation (Details) Sheet http://www.medfast1.com/role/SUPPLYCHAINOPTIMIZATIONSummaryofCondensedConsolidatedStatementofOperationDetails SUPPLY CHAIN OPTIMIZATION - Summary of Condensed Consolidated Statement of Operation (Details) Details 42 false false All Reports Book All Reports med-20240630.htm med-20240630.xsd med-20240630-cal.xml med-20240630-def.xml med-20240630-lab.xml med-20240630_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "med-20240630.htm", { "nsprefix": "med", "nsuri": "http://www.medfast1.com/20240630", "dts": { "inline": { "local": { "med-20240630.htm", }, "schema": { "local": { "med-20240630.xsd", }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/irr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/irr/role/net-2009-12-16.xsd", "http://www.xbrl.org/irr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fash.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fash.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fash.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fash.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fash.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" } } }, "calculationLink": { "local": { "med-20240630-cal.xml" } }, "definitionLink": { "local": { "med-20240630-def.xml" } }, "labelLink": { "local": { "med-20240630-lab.xml" } }, "presentationLink": { "local": { "med-20240630_pre.xml" } } }, "keyStandard": 208, "keyCustom": 13, "axisStandard": 15, "axisCustom": 0, "memberStandard": 20, "memberCustom": 18, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2024.5 }, "contextCount": 135, "entityCount": 1, "segmentCount": 40, "elementCount": 341, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024.592; "http://xbrl.sec.gov/dei/2024.29 }, "report": { "R1": { "role": "http://www.medfast1.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "med-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "med-20240630.htm", "unique": true } }, "R4": { "role": "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef":

```

"us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:PrepaidTaxes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "unique": true } }, "R5": { "role": "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParentetical", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parentetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parentetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parentetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "div", "td": "tr", "table": "div", "body": "html" }, "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "div", "td": "tr", "table": "div", "body": "html" }, "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "R6": { "role": "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSONUNAUDITED", "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": " ", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "R7": { "role": "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSONUNAUDITED", "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": " ", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-34", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-39", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "unique": true }, "R8": { "role": "http://www.medfast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "9952157 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": " ", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "R9": { "role": "http://www.medfast1.com/role/INVENTORIES", "longName": "9952158 - Disclosure - INVENTORIES", "shortName": "INVENTORIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": " ", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "R10": { "role": "http://www.medfast1.com/role/EARNINGS PER SHARE", "longName": "9952159 - Disclosure - EARNINGS PER SHARE", "shortName": "EARNINGS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": " ", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "R11": { "role": "http://www.medfast1.com/role/SHAREBASEDCOMPENSATION", "longName": "9952160 - Disclosure - SHARE-BASED COMPENSATION", "shortName": "SHARE-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": " ", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "R12": { "role": "http://www.medfast1.com/role/LEASES", "longName": "9952161 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": " ", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "R13": { "role": "http://www.medfast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME", "longName": "9952162 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "disclosure", "subGroupType": " ", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "R14": { "role": "http://www.medfast1.com/role/INVESTMENTS", "longName": "9952163 - Disclosure - INVESTMENTS", "shortName": "INVESTMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": " ", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "R15": { "role": "http://www.medfast1.com/role/DEBT", "longName": "9952164 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": " ", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "R16": { "role": "http://www.medfast1.com/role/SUPPLYCHAINOPTIMIZATION", "longName": "9952165 - Disclosure - SUPPLY CHAIN OPTIMIZATION", "shortName": "SUPPLY CHAIN OPTIMIZATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": " ", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "uniqueAnchor
```

```

"ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.medfast1.com/role/SUPPLYCHAINOPTIMIZATIONTables", "longName": "9954478 - Disclosure - SUPPLY CHAIN OPTIMIZATION (Tables)", "shortName": "SUPPLY CHAIN OPTIMIZATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.medfast1.com/role/INVENTORIESDetails", "longName": "9954479 - Disclosure - INVENTORIES (Details)", "shortName": "INVENTORIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.medfast1.com/role/EARNINGSPEERSHAREComputationOfBasicandDilutedEPSDetails", "longName": "9954480 - Disclosure - EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details)", "shortName": "EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "body", "html", "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.medfast1.com/role/EARNINGSPEERSHARENarrativeDetails", "longName": "9954481 - Disclosure - EARNINGS PER SHARE - Narrative (Details)", "shortName": "EARNINGS PER SHARE - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c-60", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "div", "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "longName": "9954482 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)", "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": { "span", "div", "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails", "longName": "9954483 - Disclosure - SHARE-BASED COMPENSATION - Stock Options Activity (Details)", "shortName": "SHARE-BASED COMPENSATION - Stock Options Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails", "longName": "9954484 - Disclosure - SHARE-BASED COMPENSATION - Restricted Stock Activity (Details)", "shortName": "SHARE-BASED COMPENSATION - Restricted Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-66", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONSummaryOfPerformancebasedShareAwardsDetails", "longName": "9954485 - Disclosure - SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details)", "shortName": "SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.medfast1.com/role/LEASESNarrativeDetails", "longName": "9954486 - Disclosure - LEASES - Narrative (Details)", "shortName": "LEASES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span", "div", "ix:continuation", "body", "html", "1, "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.medfast1.com/role/LEASESSupplementalCashFlowInformationDetails", "longName": "9954487 - Disclosure - LEASES - Supplemental Cash Flow Information (Details)", "shortName": "LEASES - Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.medfast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails", "longName": "9954488 - Disclosure - LEASES - Future Minimum Lease Commitments (Details)", "shortName": "LEASES - Future Minimum Lease Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.medfast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails", "longName": "9954489 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Details)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html", "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.medfast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonARecurringBasisDetails", "longName": "9954490 - Disclosure - INVESTMENTS - Cash and Financial Assets Measured at Fair Value on a Recurring Basis (Details)", "shortName": "INVESTMENTS - Cash and Financial Assets Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.medfast1.com/role/INVESTMENTSNarrativeDetails", "longName": "9954491 - Disclosure - INVESTMENTS - Narrative (Details)", "shortName": "INVESTMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesRealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span", "div", "ix:continuation", "body", "html", "1, "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.medfast1.com/role/INVESTMENTSInvestmentLossesDetails", "longName": "9954492 - Disclosure - INVESTMENTS - Investment Losses (Details)", "shortName": "INVESTMENTS - Investment Losses (Details)", "isDefault": "false", "groupType": "disc
```

"6", "ancestors": { "span": "div", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "unique": true }, "R40": { "role": "http://www.medfast1.com/role/DEBTDetails", "longName": "9954494 - Disclosure - DEBT (Details)", "shortName": "DEBT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-134", "name": "med:MaximumTotalNetLeverageRatio", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "div", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "R41": { "role": "http://www.medfast1.com/role/SUPPLYCHAINOPTIMIZATIONSummaryOfComponentsOfSupplyChainOptimizationChargesDetails", "longName": "9954495 - Disclosure - SUPPLY CHAIN OPTIMIZATION - Summary of Components of Supply Chain Optimization Charges (Details)", "shortName": "SUPPLY CHAIN OPTIMIZATION - Summary of Components of Supply Chain Optimization Charges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "unique": true }, "R42": { "role": "http://www.medfast1.com/role/SUPPLYCHAINOPTIMIZATIONSummaryOfCondensedConsolidatedStatementOfOperationDetails", "longName": "9954496 - Disclosure - SUPPLY CHAIN OPTIMIZATION - Summary of Condensed Consolidated Statement of Operation (Details)", "shortName": "SUPPLY CHAIN OPTIMIZATION - Summary of Condensed Consolidated Statement of Operation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RestructuringCostsAndAssetImpairmentCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "med-20240630.htm", "first": true, "uniqueAnchor": null }, "tag": { "role": "us-gaap:AccountingPoliciesAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": "en-us", "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]", "auth_ref": { "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.medfast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails", "parentTag": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medfast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails", "lang": "en-us", "role": { "terseLabel": "Unrealized net gains on investment securities", "label": "AOI, Debt Securities, Available for Sale, Adjustment, after Tax", "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)", "auth_ref": { "r670" } }, "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.medfast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails", "parentTag": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.medfast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails", "lang": "en-us", "role": { "terseLabel": "Foreign currency translation", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses", "auth_ref": { "r117", "r120", "r121", "r122", "r379" } }, "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.medfast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails", "parentTag": "us-gaap:StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.medfast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails", "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.medfast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails", "lang": "en-us", "role": { "terseLabel": "Accumulated other comprehensive income", "totalLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source", "auth_ref": { "r16", "r17", "r54", "r114", "r448", "r469", "r470" } }, "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "lang": "en-us", "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "auth_ref": { "us-gaap:AccumulatedOtherComprehensiveIncomeMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED", "lang": "en-us", "role": { "terseLabel": "Accumulated Other Comprehensive Income", "label": "AOI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners", "auth_ref": { "r1", "r9", "r17", "r360", "r363", "r403", "r465", "r466", "r671", "r672", "r673", "r681", "r682", "r683", "r685" } }, "us-gaap:AdditionalPaidInCapital", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "parentTag": "us-gaap:StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "lang": "en-us", "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock", "auth_ref": { "r45", "r633", "r774" } }, "us-gaap:AdditionalPaidInCapitalMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED", "lang": "en-us", "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders", "auth_ref": { "r474", "r681", "r682", "r683", "r685", "r746", "r775" } }, "us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED", "lang": "en-us", "role": { "negatedLabel": "Net shares repurchased for employee taxes", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement", "auth_ref": { "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions", "crdr": "credit", "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED", "lang": "en-us", "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Recognition and Exercise", "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement", "auth_ref": { "us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "lang": "en-us", "role": { "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://www.medfast1.com/role/Cover", "lang": "en-us", "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission", "auth_ref": { "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://www.medfast1.com/role/EARNINGSPEPERSHARENarrativeDetails", "lang": "en-us", "role": { "verboseLabel": "Anti-dilutive awards (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented", "auth_ref": { "r167" } }, "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": { "http://www.medfast1.com/role/EARNINGSPEPERSHARENarrativeDetails", "lang": "en-us", "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security", "auth_ref": { "r22" } }, "us-gaap:AntidilutiveSecuritiesNameDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": { "http://www.medfast1.com/role/EARNINGSPEPERSHARENarrativeDetails", "lang": "en-us", "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented", "auth_ref": { "r22" } }, "us-gaap:ArrangementsAndNonarrangementTransactionsMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": { "http://www.medfast1.com/role/INVESTMENTSCollaborateArrangementDetails", "lang": "en-us", "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than

Collaborative {Domain}"; "label": "Collaborative Arrangement and Arrangement Other than Collaborative {Domain}"; "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } } , "auth_ref": { "r354" } } , "us-gaap-Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } } , "auth_ref": { "r97", "r98", "r112", "r140", "r171", "r173", "r179", "r180", "r221", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r355", "r357", "r380", "r446", "r497", "r603", "r604", "r633", "r645", "r708", "r709", "r764" } } , "us-gaap-AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets Abstract" } } } } , "auth_ref": { } } , "us-gaap-AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } } } , "auth_ref": { "r108", "r116", "r140", "r221", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r355", "r357", "r380", "r633", "r708", "r709", "r764" } } , "us-gaap-AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Current Assets", "label": "Assets, Current Abstract" } } } } } } , "us-gaap-AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap-CashCashEquivalentsAndShortTermInvestments", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cost, Debt securities", "label": "Debt Securities, Available for Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } } } , "auth_ref": { "r188", "r229", "r445" } } , "us-gaap-AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "med_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure", "weight": 1.0, "order": 3.0 } } , "presentation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value, Debt securities", "label": "Debt Securities, Available for Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } } } , "auth_ref": { "r186", "r229" } } , "us-gaap-AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Award Date [Axis]", "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } } } , "auth_ref": { "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737" } } , "us-gaap-AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateDomain", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Award Date {Domain}", "label": "Award Date {Domain}", "documentation": "Date or year award under share-based payment arrangement is granted." } } } } , "auth_ref": { "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737" } } , "us-gaap-AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } } } , "auth_ref": { "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331" } } , "us-gaap-BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BaseRateMember", "presentation": { "http://www.medifast1.com/role/DEBTDetails": { "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } } } , "auth_ref": { } } , "us-gaap-BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": { "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } } } , "auth_ref": { } } , "med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "CashAndCashEquivalentsAndMarketableSecuritiesLineItems", "presentation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash And Cash Equivalents And Marketable securities [Line Items]", "label": "Cash And Cash Equivalents And Marketable securities [Line Items]", "documentation": "N/A" } } } } , "auth_ref": { } } , "med_CashAndCashEquivalentsAndMarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "CashAndCashEquivalentsAndMarketableSecuritiesTable", "presentation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash And Cash Equivalents And Marketable securities [Table]", "label": "Cash And Cash Equivalents And Marketable securities [Table]", "documentation": "N/A" } } } } , "auth_ref": { } } , "us-gaap-CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 2.0 } } , "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap-CashCashEquivalentsAndShortTermInvestments", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cost, Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } } } , "auth_ref": { "r20", "r110", "r593" } } , "us-gaap-CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } } } , "auth_ref": { "r110" } } , "med_CashAndCashEquivalentsExcludingMoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "CashAndCashEquivalentsExcludingMoneyMarketFundsMember", "presentation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents, excluding money market accounts", "label": "Cash And Cash Equivalents Excluding Money Market Funds [Member]", "documentation": "Cash And Cash Equivalents Excluding Money Market Funds" } } } } , "auth_ref": { } } , "us-gaap-CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "med_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value, Cash and cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } } , "auth_ref": { "r748", "r749" } } , "us-gaap-CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "totalLabel": "Cost, Total", "label": "Cash, Cash Equivalents, and Short-Term Investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } } } , "auth_ref": { "r669" } } , "med_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "totalLabel": "Estimated Fair Value, Total", "label": "Cash, Cash Equivalents, And Short-Term Investments, Fair Value Disclosure", "documentation": "Cash, Cash Equivalents, And Short-Term Investments, Fair Value Disclosure" } } } } , "auth_ref": { } } , "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents - beginning of the period", "periodEndLabel": "Cash and cash equivalents - end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest

rates.": {}}, {"auth_ref": {"r20", "r66", "r137"}}, {"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": {"debit", "calculation": {"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASHFLOWSUNAUDITED": {"parentTag": null, "weight": null, "order": null, "root": true }}, "presentation": {"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASHFLOWSUNAUDITED": {"lang": {"en-us": {"role": {"totalLabel": "Increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." }}, "auth_ref": {"r0", "r66"}}, {"dei_CityAreaCode": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": {"http://www.medifast1.com/role/Cover": {"lang": {"en-us": {"role": {"terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" }}, "auth_ref": {}}, {"med_CollaborativeArrangementRightsAndObligationsMilestonePayments": {"xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "CollaborativeArrangementRightsAndObligationsMilestonePayments", "crdr": {"credit", "presentation": {"http://www.medifast1.com/role/INVESTMENTSCollaborateArrangementDetails": {"lang": {"en-us": {"role": {"terseLabel": "Milestone payments", "label": "Collaborative Arrangement, Rights And Obligations, Milestone Payments", "documentation": "Collaborative Arrangement, Rights And Obligations, Milestone Payments" }}, "auth_ref": {}}, {"med_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementFinalMilestonePaymentMember": {"xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementFinalMilestonePaymentMember", "presentation": {"http://www.medifast1.com/role/INVESTMENTSCollaborateArrangementDetails": {"lang": {"en-us": {"role": {"terseLabel": "Final Milestone Payment", "label": "Collaborative Arrangement, Transaction With Party To Collaborative Arrangement, Final Milestone Payment [Member]", "documentation": "Collaborative Arrangement, Transaction With Party To Collaborative Arrangement, Final Milestone Payment" }}, "auth_ref": {}}, {"med_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementInitialMilestonePaymentMember": {"xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementInitialMilestonePaymentMember", "presentation": {"http://www.medifast1.com/role/INVESTMENTSCollaborateArrangementDetails": {"lang": {"en-us": {"role": {"terseLabel": "Initial Milestone Payment", "label": "Collaborative Arrangement, Transaction With Party To Collaborative Arrangement, Initial Milestone Payment [Member]", "documentation": "Collaborative Arrangement, Transaction With Party To Collaborative Arrangement, Initial Milestone Payment" }}, "auth_ref": {}}, {"med_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementSecondMilestonePaymentMember": {"xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementSecondMilestonePaymentMember", "presentation": {"http://www.medifast1.com/role/INVESTMENTSCollaborateArrangementDetails": {"lang": {"en-us": {"role": {"terseLabel": "Second Milestone Payment", "label": "Collaborative Arrangement, Transaction With Party To Collaborative Arrangement, Second Milestone Payment [Member]", "documentation": "Collaborative Arrangement, Transaction With Party To Collaborative Arrangement, Second Milestone Payment" }}, "auth_ref": {}}, {"us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": {"http://www.medifast1.com/role/INVESTMENTSCollaborateArrangementDetails": {"lang": {"en-us": {"role": {"terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." }}, "auth_ref": {"r354"}}, {"us-gaap_CommonStockDividendsPerShareDeclared": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": {"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSUNAUDITED": {"lang": {"en-us": {"role": {"verboseLabel": "Cash dividends declared per share (in usd per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." }}, "auth_ref": {"r81"}}, {"us-gaap_CommonStockMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": {"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CHANGESINSTOCKHOLDERSEQUITYUNAUDITED": {"lang": {"en-us": {"role": {"terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." }}, "auth_ref": {"r636", "r637", "r638", "r640", "r641", "r642", "r643", "r681", "r682", "r685", "r746", "r773", "r775"}}, {"us-gaap_CommonStockParOrStatedValuePerShare": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": {"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParentetical": {"lang": {"en-us": {"role": {"terseLabel": "Common stock, par value (in usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." }}, "auth_ref": {"r44"}}, {"us-gaap_CommonStockSharesAuthorized": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": {"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParentetical": {"lang": {"en-us": {"role": {"terseLabel": "Common stock, issued (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." }}, "auth_ref": {"r44", "r485"}}, {"us-gaap_CommonStockSharesIssued": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": {"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParentetical": {"lang": {"en-us": {"role": {"terseLabel": "Common stock, issued (in shares)", "label": "Common Stock, Shares Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." }}, "auth_ref": {"r44"}}, {"us-gaap_CommonStockSharesOutstanding": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": {"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParentetical": {"lang": {"en-us": {"role": {"terseLabel": "Common stock, outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." }}, "auth_ref": {"r10", "r44", "r485", "r503", "r775", "r776"}}, {"us-gaap_CommonStockValue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": {"credit", "calculation": {"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {"parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 }}, "presentation": {"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {"lang": {"en-us": {"role": {"verboseLabel": "Common stock, par value \$0.001 per share; 20,000 shares authorized; 10,937 and 10,896 issued outstanding at June 30, 2024 and Decemberu00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." }}, "auth_ref": {"r44", "r447", "r633"}}, {"us-gaap_ComprehensiveIncomeNetOfTax": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": {"credit", "calculation": {"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF COMPREHENSIVEINCOMELOSSUNAUDITED": {"parentTag": null, "weight": null, "order": null, "root": true }}, "presentation": {"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF COMPREHENSIVEINCOMELOSSUNAUDITED": {"lang": {"en-us": {"role": {"totalLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." }}, "auth_ref": {"r18", "r125", "r127", "r132", "r440", "r456", "r457"}}, {"us-gaap_ComprehensiveIncomeNoteTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": {"http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME": {"lang": {"en-us": {"role": {"terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." }}, "auth_ref": {"r53", "r131", "r439", "r454"}}, {"us-gaap_CostOfRevenue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": {"debit", "calculation": {"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSUNAUDITED": {"parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 }}, "presentation": {"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONSUNAUDITED": {"lang": {"en-us": {"role": {"verboseLabel": "Cost of sales", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." }}, "auth_ref": {"r57", "r140", "r221", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r380", "r603", "r708"}}, {"srt_CounterpartyNameAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": {"http://www.medifast1.com/role/INVESTMENTSCollaborateArrangementDetails": {"lang": {"en-us": {"role": {"terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" }}, "auth_ref": {"r141", "r142", "r264", "r288", "r404", "r421", "r444", "r597", "r599"}}, {"dei_CoverAbstract": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": {"en-us": {"role": {"terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." }}, "auth_ref": {}}, {"us-gaap_CreditFacilityAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": {"http://www.medifast1.com/role/DEBTDetails": {"lang": {"en-us": {"role": {"terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." }}, "auth_ref": {"r250", "r706"}}, {"us-gaap_CreditFacilityDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": {"http://www.medifast1.com/role/DEBTDetails": {"lang": {"en-us": {"role": {"terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." }}, "auth_ref": {"r250", "r706", "r707"}}, {"dei_CurrentFiscalYearEndDate": {"xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": {"http://www.medifast1.com/role/Cover": {"lang": {"en-us": {"role": {"terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." }}, "auth_ref": {}}, {"us-gaap_DebtDisclosureAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": {"en-us": {"role": {"terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" }}, "auth_ref": {}}, {"us-gaap_DebtDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": {"http://www.medifast1.com/role/DEBT": {"lang": {"en-us": {"role": {"terseLabel": "DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." }}, "auth_ref": {"r78", "r139", "r235", "r236", "r237", "r238", "r239", "r249", "r250", "r260", "r266", "r267", "r268", "r269", "r270", "r271", "r276", "r283", "r284", "r286", "r388"}}, {"us-gaap_DebtInstrumentAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": {"http://www.medifast1.com/role/DEBTDetails": {"lang": {"en-us": {"role": {"terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." }}, "auth_ref": {"r14", "r35", "r36", "r88", "r89", "r143", "r261", "r262", "r263", "r264", "r267", "r272", "r273", "r274", "r275", "r277",

```

"r278","r279","r280","r281","r282","r608","r609","r610","r611","r612","r631","r678","r702","r703","r704","r758","r759"}}, "us-gaap-DebtInstrumentBasisSpreadOnVariableRate": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate", "presentation": {"http://www.medfast1.com/role/DEBTDetailed", "lang": {"en-us": {"role": {"terseLabel": "Basis spread on variable rate (as a percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."}}}, "auth_ref": {}}, "us-gaap-DebtInstrumentCarryingAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": {"http://www.medfast1.com/role/DEBTDetailed", "lang": {"en-us": {"role": {"terseLabel": "Borrowings outstanding", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."}}}, "auth_ref": {"r14", "r89", "r287"}}, "us-gaap-DebtInstrumentLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": {"http://www.medfast1.com/role/DEBTDetailed", "lang": {"en-us": {"role": {"terseLabel": "Debt Instrument Line Items", "label": "Debt Instrument Line Items", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}, "auth_ref": {"r143", "r261", "r262", "r263", "r264", "r265", "r267", "r272", "r274", "r275", "r277", "r278", "r279", "r280", "r281", "r282", "r608", "r609", "r610", "r611", "r612", "r631", "r678", "r702", "r703", "r704", "r758", "r759"}}, "us-gaap-DebtInstrumentNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": {"http://www.medfast1.com/role/DEBTDetailed", "lang": {"en-us": {"role": {"terseLabel": "Debt Instrument, Name Domain", "label": "Debt Instrument, Name Domain", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."}}}, "auth_ref": {"r14", "r143", "r261", "r262", "r263", "r264", "r265", "r267", "r272", "r274", "r275", "r277", "r278", "r279", "r280", "r281", "r282", "r608", "r609", "r610", "r611", "r612", "r631", "r678", "r702", "r703", "r704", "r758", "r759"}}, "us-gaap-DebtInstrumentTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": {"http://www.medfast1.com/role/DEBTDetailed", "lang": {"en-us": {"role": {"terseLabel": "Schedule of Long-term Debt Instruments Table", "label": "Schedule of Long-term Debt Instruments Table", "documentation": "Disclosure of information about long-term debt instrument or arrangement."}}}, "auth_ref": {"r14", "r27", "r28", "r33", "r79", "r80", "r143", "r261", "r262", "r263", "r264", "r265", "r267", "r272", "r274", "r275", "r277", "r278", "r279", "r280", "r281", "r282", "r285", "r608", "r609", "r610", "r611", "r612", "r631", "r678", "r758", "r759"}}, "med-DebtSecuritiesAvailableForSaleAccruedInterest": {"xbrltype": "monetaryItemType", "nsuri": "http://www.medfast1.com/20240630", "localname": "DebtSecuritiesAvailableForSaleAccruedInterest", "crdr": "debit", "presentation": {"http://www.medfast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails", "lang": {"en-us": {"role": {"terseLabel": "Accrued Interest, Debt securities", "label": "Debt Securities, Available For Sale, Accrued Interest", "documentation": "Debt Securities, Available For Sale, Accrued Interest"}}, "auth_ref": {}}, "us-gaap-DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax", "crdr": "credit", "presentation": {"http://www.medfast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails", "lang": {"en-us": {"role": {"terseLabel": "Unrealized Gains (Losses), Debt securities", "label": "Debt Securities, Available for Sale, Accumulated Gross Unrealized Gain (Loss), before Tax", "documentation": "Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)."}}, "auth_ref": {"r693", "r694"}}, "us-gaap-DebtSecuritiesRealizedGainLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesRealizedGainLoss", "crdr": "credit", "calculation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {"parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0}}, "presentation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.medfast1.com/role/INVESTMENTSNarrativeDetails", "lang": {"en-us": {"role": {"negatedTerseLabel": "Realized gain on sale of investment securities", "verboseLabel": "Realized gains", "label": "Debt Securities, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)."}}, "auth_ref": {"r459", "r674", "r675"}}, "us-gaap-DeferredIncomeTaxAssetsNet": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {"parentTag": "us-gaap-Assets", "weight": 1.0, "order": 5.0}}, "presentation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "lang": {"en-us": {"role": {"terseLabel": "Deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."}}}, "auth_ref": {"r339", "r340"}}, "us-gaap-DeferredIncomeTaxExpenseBenefit": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {"parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0}}, "presentation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "lang": {"en-us": {"role": {"terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."}}}, "auth_ref": {"r6", "r104", "r680"}}, "med-DenominatorAbstract": {"xbrltype": "stringItemType", "nsuri": "http://www.medfast1.com/20240630", "localname": "DenominatorAbstract", "presentation": {"http://www.medfast1.com/role/EARNINGSPerShareComputationofBasicandDilutedEPSDetails", "lang": {"en-us": {"role": {"verboseLabel": "Denominator", "label": "Denominator Abstract", "documentation": "Denominator Abstract"}}, "auth_ref": {}}, "us-gaap-DepreciationDepletionAndAmortization": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {"parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0}}, "presentation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "lang": {"en-us": {"role": {"terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."}}}, "auth_ref": {"r6", "r171", "r176", "r180", "r603", "r604"}}, "us-gaap-DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": {"http://www.medfast1.com/role/SHAREBASEDCOMPENSATION", "lang": {"en-us": {"role": {"verboseLabel": "SHARE-BASED COMPENSATION", "label": "Share-Based Payment Arrangement Text Block", "documentation": "The entire disclosure for share-based payment arrangement."}}}, "auth_ref": {"r302", "r305", "r333", "r334", "r336", "r618"}}, "us-gaap-DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract", "lang": {"en-us": {"role": {"terseLabel": "Share-based Payment Arrangement Abstract", "label": "Share-Based Payment Arrangement Abstract", "documentation": "Share-Based Payment Arrangement Abstract"}}, "auth_ref": {}}, "us-gaap-DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": {"http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONTables", "lang": {"en-us": {"role": {"terseLabel": "Schedule of Share-based Compensation Expense", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award Table Text Block", "documentation": "Tabular disclosure of share-based payment arrangement."}}}, "auth_ref": {"r8", "r31"}}, "us-gaap-DividendsCash": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCash", "crdr": "debit", "presentation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "lang": {"en-us": {"role": {"verboseLabel": "Dividends included in accounts payable and accrued expenses", "label": "Dividends, Cash", "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred."}}}, "auth_ref": {"r32", "r81"}}, "us-gaap-DividendsCommonStockCash": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "lang": {"en-us": {"role": {"negatedLabel": "Cash dividends declared to stockholders", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."}}}, "auth_ref": {"r81"}}, "med-DividendsForfeited": {"xbrltype": "monetaryItemType", "nsuri": "http://www.medfast1.com/20240630", "localname": "DividendsForfeited", "crdr": "credit", "presentation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "lang": {"en-us": {"role": {"terseLabel": "Forfeiture of dividends on unvested awards", "label": "Dividends, Forfeited", "documentation": "Dividends, Forfeited"}}, "auth_ref": {}}, "dei-DocumentsFiscalPeriodFocus": {"xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": {"http://www.medfast1.com/role/Cover", "lang": {"en-us": {"role": {"terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 
```

"http://www.medifast1.com/role/EARNINGSPEPERSHARECompuationofBasicandDilutedEPSDetails", "lang": { "en-us": { "role": { "terseLabel": "Diluted (in usd per share)", "verboseLabel": "Earnings per share - diluted (in usd per share)" }, "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r133", "r149", "r150", "r151", "r152", "r153", "r154", "r162", "r164", "r165", "r166", "r170", "r350", "r353", "r367", "r368", "r441", "r458", "r600" } }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://www.medifast1.com/role/EARNINGSPEPERSHARE", "lang": { "en-us": { "role": { "verboseLabel": "EARNINGS PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": { "r159", "r167", "r168", "r169" } } }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "lang": { "en-us": { "role": { "terseLabel": "Foreign currency impact", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r381" } } }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Employee service share based compensation nonvested awards", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": { "r335" } } }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Compensation cost recognition weighted average period (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDnHnMnS' format; for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r335" } } }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation costs", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": { "r738" } } }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Total income tax benefit recognized related to restricted stock awards", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": { "r332" } } }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": { } }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": { } }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": { } }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": { } }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": { } }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "r647" } }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": { } }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { } }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "r647" } }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits; the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": { } }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "r647" } }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": { } }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": { "r651" } }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": { "r647" } }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "r647" } }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": { "r647" } }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN); also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": { "r647" } } }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUNAUDITED", "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": { "r10", "r106", "r128", "r129", "r130", "r144", "r145", "r146", "r148", "r153", "r155", "r157", "r172", "r222", "r223", "r234", "r290", "r343", "r344", "r347", "r348", "r349", "r351", "r352", "r353", "r359", "r360", "r361", "r362", "r363", "r364", "r366", "r382", "r383", "r384", "r385", "r386", "r387", "r389", "r391", "r403", "r454", "r465", "r466", "r467", "r474", "r522" } } }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": { "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]", "auth_ref": { "r218", "r219", "r220", "r346", "r653", "r654", "r655", "r741", "r742", "r743", "r744" } } }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_ShortTermInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails", "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value, Equity securities", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": { "r113", "r378", "r595" } } }, "us-

gaap_EquitySecuritiesFvNiCost", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiCost", "crdr": "debit", "calculation": {"http://www.medfast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": {"parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0, "order": 3.0 }, "presentation": {"http://www.medfast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Cost, Equity securities", "label": "Equity Securities, FV-NI, Cost", "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value." }}, "auth_ref": {"r445"} }}, {"us-gaap_EquitySecuritiesFvNiGainLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "calculation": {"http://www.medfast1.com/role/INVESTMENTSInvestmentLossesDetails": {"parentTag": null, "weight": null, "order": null, "root": true }}, "presentation": {"http://www.medfast1.com/role/INVESTMENTSInvestmentLossesDetails"}, "lang": {"en-us": {"role": {"totalLabel": "Net losses recognized during the period on equity securities", "label": "Equity Securities, FV-NI, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." }}, "auth_ref": {"r461", "r699"} }}, {"us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "calculation": {"http://www.medfast1.com/role/INVESTMENTSInvestmentLossesDetails": {"parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss", "weight": 1.0, "order": 1.0 }, "presentation": {"http://www.medfast1.com/role/INVESTMENTSInvestmentLossesDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Less: Net losses recognized on equity securities sold", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." }}, "auth_ref": {"r459", "r699"} }}, {"us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "debit", "calculation": {"http://www.medfast1.com/role/INVESTMENTSInvestmentLossesDetails": {"parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss", "weight": 1.0, "order": 2.0 }, "presentation": {"http://www.medfast1.com/role/INVESTMENTSInvestmentLossesDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Less: Net losses recognized on equity securities sold", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." }}, "auth_ref": {"r460", "r699"} }}, {"us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiUnrealizedLoss", "crdr": "debit", "calculation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS UNAUDITED": {"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 }, "presentation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS UNAUDITED"}, "lang": {"en-us": {"role": {"terseLabel": "Unrealized loss on equity investment securities", "label": "Equity Securities, FV-NI, Unrealized Loss", "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." }}, "auth_ref": {"r217"} }}, {"us-gaap_FairValueByFairValueHierarchyLevelAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": {"http://www.medfast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." }}, "auth_ref": {"r274", "r294", "r295", "r296", "r297", "r298", "r299", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r408", "r409", "r410", "r609", "r610", "r614", "r615", "r616", "r621", "r624"} }}, {"us-gaap_FairValueInputsLevel1Member": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": {"http://www.medfast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." }}, "auth_ref": {"r274", "r294", "r299", "r370", "r375", "r408", "r614", "r615", "r616", "r621"} }}, {"us-gaap_FairValueInputsLevel2Member": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": {"http://www.medfast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." }}, "auth_ref": {"r274", "r294", "r299", "r370", "r371", "r375", "r409", "r609", "r610", "r614", "r615", "r616", "r621"} }}, {"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": {"http://www.medfast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." }}, "auth_ref": {"r274", "r294", "r295", "r296", "r297", "r298", "r299", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r408", "r409", "r410", "r609", "r610", "r614", "r615", "r616", "r621", "r624"} }}, {"us-gaap_FinancialInstrumentAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": {"http://www.medfast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." }}, "auth_ref": {"r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r224", "r225", "r226", "r227", "r228", "r230", "r231", "r232", "r285", "r289", "r365", "r377", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000"} }}, {"us-gaap_FinancialInstrumentsDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": {"http://www.medfast1.com/role/INVESTMENTS"}, "lang": {"en-us": {"role": {"verboseLabel": "INVESTMENTS", "label": "Financial Instruments Disclosure [Text Block]", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long-term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." }}, "auth_ref": {} }}, {"us-gaap_GainLossOnInvestmentsTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnInvestmentsTextBlock", "presentation": {"http://www.medfast1.com/role/INVESTMENTSTables"}, "lang": {"en-us": {"role": {"terseLabel": "Schedule of Investment Losses", "label": "Gain (Loss) on Securities [Table Text Block]", "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security." }}, "auth_ref": {"r674", "r675"} }}, {"us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS UNAUDITED": {"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 }, "presentation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS UNAUDITED"}, "lang": {"en-us": {"role": {"negatedTerseLabel": "Loss on sale or disposal of property, plant and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." }}, "auth_ref": {"r6"} }}, {"med_GrantedIn2020Member": {"xbrltype": "domainItemType", "nsuri": "http://www.medfast1.com/20240630", "localname": "GrantedIn2020Member", "presentation": {"http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Granted In 2020", "label": "Granted In 2020 [Member]", "documentation": "Granted In 2020"} }}, "auth_ref": {} }}, {"med_GrantedIn2021Member": {"xbrltype": "domainItemType", "nsuri": "http://www.medfast1.com/20240630", "localname": "GrantedIn2021Member", "presentation": {"http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Granted In 2021", "label": "Granted In 2021 [Member]", "documentation": "Granted In 2021"} }}, "auth_ref": {} }}, {"med_GrantedIn2022Member": {"xbrltype": "domainItemType", "nsuri": "http://www.medfast1.com/20240630", "localname": "GrantedIn2022Member", "presentation": {"http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Granted In 2022", "label": "Granted In 2022 [Member]", "documentation": "Granted In 2022"} }}, "auth_ref": {} }}, {"med_GrantedIn2023Member": {"xbrltype": "domainItemType", "nsuri": "http://www.medfast1.com/20240630", "localname": "GrantedIn2023Member", "presentation": {"http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Granted In 2023", "label": "Granted In 2023 [Member]", "documentation": "Granted In 2023"} }}, "auth_ref": {} }}, {"med_GrantedIn2024Member": {"xbrltype": "domainItemType", "nsuri": "http://www.medfast1.com/20240630", "localname": "GrantedIn2024Member", "presentation": {"http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Granted In 2024", "label": "Granted In 2024 [Member]", "documentation": "Granted In 2024"} }}, "auth_ref": {} }}, {"med_GrantedInMarch2022Member": {"xbrltype": "domainItemType", "nsuri": "http://www.medfast1.com/20240630", "localname": "GrantedInMarch2022Member", "presentation": {"http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Granted In March 2022", "label": "Granted In March 2022 [Member]", "documentation": "Granted In March 2022"} }}, "auth_ref": {} }}, {"med_GrantedInOctober2021Member": {"xbrltype": "domainItemType", "nsuri": "http://www.medfast1.com/20240630", "localname": "GrantedInOctober2021Member", "presentation": {"http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Granted In October 2021", "label": "Granted In October 2021 [Member]", "documentation": "Granted In October 2021"} }}, "auth_ref": {} }}, {"us-gaap_GrossProfit": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONS UNAUDITED": {"parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "presentation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONS UNAUDITED"}, "lang": {"en-us": {"role": {"totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." }}, "auth_ref": {"r55", "r57", "r97", "r140", "r221", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r380", "r602", "r603", "r687", "r688", "r689", "r690", "r691", "r708"} }}, {"us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "calculation": {"http://www.medfast1.com/role/SUPPLYCHAINOPTIMIZATIONSummaryofComponentsofSupplyChainOptimizationChargesDetails": {"parentTag": "med_NoncashChargesForSupplyChainOptimization", "weight": 1.0, "order": 1.0 }, "presentation": {"http://www.medfast1.com/role/SUPPLYCHAINOPTIMIZATIONSummaryofComponentsofSupplyChainOptimizationChargesDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Loss on impairment of equipment held for sale", "label": "Impairment of Long-Lived Assets to be Disposed of", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." }}, "auth_ref": {"r6", "r75", "r622"} }}, {"us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONS UNAUDITED": {"parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "presentation": {"http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONS UNAUDITED"}, "lang": {"en-us": {"role": {"totalLabel": "Income (loss) from operations before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense

```

and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": { "r56", "r93", "r97", "r442", "r452", "r602", "r603", "r687", "r688", "r689", "r690", "r691" } }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]" } } }, "Income Statement [Abstract]" } }, "auth_ref": { "r5", "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Provision (benefit) for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": { "r99", "r105", "r156", "r157", "r171", "r177", "r180", "r341", "r342", "r345", "r462", "r620" } }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid", "label": "Income Taxes Paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } } }, "auth_ref": { "r21", "r68", "r677", "r739", "r740" } }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } } }, "auth_ref": { "r5" } }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } } }, "auth_ref": { "r5" } }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } } }, "auth_ref": { "r5" } }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Change in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } } }, "auth_ref": { "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } } }, "auth_ref": { "r5" } }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } } }, "auth_ref": { "r5" } }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } } }, "auth_ref": { "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "lang": { "en-us": { "role": { "verboseLabel": "Interest income", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } } }, "auth_ref": { "r603", "r676", "r688" } }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } } }, "auth_ref": { "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": { "http://www.medfast1.com/role/INVENTORIES": { "lang": { "en-us": { "role": { "verboseLabel": "INVENTORIES", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } } }, "auth_ref": { "r233" } }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.medfast1.com/role/INVENTORIESDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.medfast1.com/role/INVENTORIESDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } } }, "auth_ref": { "r664" } }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "http://www.medfast1.com/role/INVENTORIESDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "http://www.medfast1.com/role/INVENTORIESDetails": { "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Total", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } } }, "auth_ref": { "r115", "r594", "r633" } }, "med_InventoryNonFoodFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medfast1.com/20240630", "localname": "InventoryNonFoodFinishedGoods", "crdr": "debit", "calculation": { "http://www.medfast1.com/role/INVENTORIESDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.medfast1.com/role/INVENTORIESDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Non-food finished goods", "label": "Inventory Non Food Finished Goods", "documentation": "Amount before last-in first-out (LIFO) and valuation reserves of (Non-food) merchandise or goods held by the entity that are readily available for sale." } } } }, "auth_ref": { "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.medfast1.com/role/INVENTORIESDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medfast1.com/role/INVENTORIESDetails": { "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } } }, "auth_ref": { "r665" } }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryValuationReserves", "crdr": "credit", "calculation": { "http://www.medfast1.com/role/INVENTORIESDetails": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 5.0 } }, "presentation": { "http://www.medfast1.com/role/INVENTORIESDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Reserve for obsolete inventory", "label": "Inventory Valuation Reserves", "documentation": "Amount of valuation reserve for inventory." } } } }, "auth_ref": { "r74", "r667" } }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "crdr": "credit", "calculation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": { "http://www.medfast1.com/role/CONDENSEDCONS
```

"http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails", "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": { "r400" } }, "med_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "calculation": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "documentation": "Lessee Operating Lease Liability Payments Due After Year Four" } } }, "auth_ref": { } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": { "r400" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "2020", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": { "r400" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": { "r400" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": { "r400" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "2024 (excluding the six months ended June 30, 2024)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "auth_ref": { "r763" } }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails", "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "auth_ref": { "r400" } }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": { "http://www.medifast1.com/role/LEASESNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Lease term (in months)", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "auth_ref": { "r761" } }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": { "http://www.medifast1.com/role/LEASES", "lang": { "en-us": { "role": { "verboseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "auth_ref": { "r390" } }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": { "http://www.medifast1.com/role/DEBTDetails", "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "auth_ref": { } }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.", "auth_ref": { "r14", "r35", "r36", "r37", "r39", "r40", "r41", "r42", "r140", "r221", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r356", "r357", "r358", "r380", "r484", "r601", "r645", "r708", "r764", "r765" } }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "auth_ref": { "r49", "r90", "r450", "r633", "r679", "r700", "r755" } }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY", "label": "Liabilities and Equity [Abstract]", "auth_ref": { } }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "auth_ref": { "r37", "r109", "r140", "r221", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r356", "r357", "r358", "r380", "r633", "r708", "r764", "r765" } }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "lang": { "en-us": { "role": { "terseLabel": "Current Liabilities", "label": "Liabilities, Current [Abstract]", "auth_ref": { } }, "med_LifeMDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "LifeMDMember", "presentation": { "http://www.medifast1.com/role/INVESTMENTSCollaborateArrangementDetails", "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "LifeMD", "label": "LifeMD [Member]", "documentation": "LifeMD", "auth_ref": { } }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": { "http://www.medifast1.com/role/DEBTDetails", "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "auth_ref": { "r34", "r38" } }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity.", "auth_ref": { } }, "med_MarketAndPerformanceBasedShareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "MarketAndPerformanceBasedShareMember", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryOfPerformanceBasedShareAwardsDetails", "lang": { "en-us": { "role": { "verboseLabel": "Market and Performance-based Share Awards", "terseLabel": "Market and performance-based share awards", "label": "Market And Performance-based Share [Member]", "documentation": "Market And Performance-based Share", "auth_ref": { } }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://www.medifast1.com/role/DEBTDetails", "http://www.medifast1.com/role/LEASESNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "auth_ref": { "r245", "r246", "r247", "r248", "r300", "r338", "r373", "r437", "r463", "r464", "r471", "r476", "r477", "r528", "r547", "r551", "r552", "r581", "r591", "r592", "r605", "r613", "r617", "r624", "r625", "r629", "r630", "r635", "r710", "r766", "r767", "r768", "r769", "r770", "r771" } }, "med_MaximumTotalNetLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "MaximumTotalNetLeverageRatio", "presentation": { "http://www.medifast1.com/role/DEBTDetails", "lang": { "en-us": { "role": { "terseLabel": "Maximum total net leverage ratio", "label": "Maximum Total Net Leverage Ratio", "documentation": "Maximum ratio as of any date, of (a) Total Net Funded Indebtedness on such date to (b) Consolidated EBITDA for the Reference Period ended on such date under credit facility.", "auth_ref": { } }, "med_MinimumInterestCoverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "MinimumInterestCoverageRatio", "presentation": { "http://www.medifast1.com/role/DEBTDetails", "lang": { "en-us": { "role": { "terseLabel": "Minimum interest coverage ratio", "label": "Minimum Interest Coverage Ratio", "documentation": "Minimum Interest Coverage Ratio", "auth_ref": { } }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": { "http://www.medifast1.com/role/DEBTDetails", "http://www.medifast1.com/role/LEASESNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "auth_ref": { "r245", "r246", "r247", "r248", "r300", "r338", "r373", "r437", "r463", "r464", "r471", "r476", "r477", "r528", "r547", "r551", "r552", "r581", "r591", "r592", "r605", "r613", "r617", "r624", "r625", "r629", "r630", "r635", "r710", "r766", "r767", "r768", "r769", "r770", "r771" } }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonRecurringBasisDetails", "lang": { "en-us": { "role": { "terseLabel": "Money market accounts", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to,

commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": { "r711" } }, "us-gaap_MunicipalBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MunicipalBondsMember", "presentation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds", "label": "Municipal Bonds [Member]", "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments." } } }, "auth_ref": { } }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "lang": { "en-us": { "role": { "totalLabel": "Net cash flow used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": { "r136" } }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "lang": { "en-us": { "role": { "verboseLabel": "Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": { } }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "lang": { "en-us": { "role": { "totalLabel": "Net cash flow used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": { "r136" } }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": { } }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "lang": { "en-us": { "role": { "totalLabel": "Net cash flow provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": { "r66", "r67", "r69" } }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": { } }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED", "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "http://www.medifast1.com/role/EARNINGSPerShareComputationofBasicandDilutedEPSDetails": { "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)", "terseLabel": "Net income", "label": "Net Income", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": { "r58", "r69", "r94", "r107", "r123", "r126", "r130", "r140", "r147", "r149", "r150", "r151", "r152", "r153", "r156", "r157", "r163", "r221", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r350", "r353", "r368", "r380", "r453", "r505", "r520", "r521", "r644", "r708" } }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": { "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies": { "lang": { "en-us": { "role": { "verboseLabel": "Accounting Pronouncements and Recently Issued Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": { } }, "med_NoncashChargesForSupplyChainOptimization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "NoncashChargesForSupplyChainOptimization", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/SUPPLYCHAINOPTIMIZATIONSummaryofComponentsofSupplyChainOptimizationChargesDetails": { "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges", "weight": 1.0, "order": 2.0 } }, "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.medifast1.com/role/SUPPLYCHAINOPTIMIZATIONSummaryofComponentsofSupplyChainOptimizationChargesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Non-cash charges for supply chain optimization", "totalLabel": "Non-cash charges for supply chain optimization", "label": "Noncash Charges For Supply Chain Optimization", "documentation": "Noncash Charges For Supply Chain Optimization" } } }, "auth_ref": { } }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": { "r60" } }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": { } }, "med_NumeratorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "NumeratorAbstract", "presentation": { "http://www.medifast1.com/role/EARNINGSPerShareComputationofBasicandDilutedEPSDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Numerator", "label": "Numerator [Abstract]", "documentation": "Numerator [Abstract]" } } }, "auth_ref": { } }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": { "r97", "r602", "r687", "r688", "r689", "r690", "r691" } }, "med_OperatingLeaseArrangementForEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "OperatingLeaseArrangementForEquipmentMember", "presentation": { "http://www.medifast1.com/role/LEASESNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating Lease Arrangement for Equipment", "label": "Operating Lease Arrangement For Equipment [Member]", "documentation": "Represents the operating lease arrangement for equipment." } } }, "auth_ref": { } }, "med_OperatingLeaseArrangementForRealEstateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "OperatingLeaseArrangementForRealEstateMember", "presentation": { "http://www.medifast1.com/role/LEASESNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating Lease Arrangement for Real Estate", "label": "Operating Lease Arrangement For Real Estate [Member]", "documentation": "Represents the operating lease arrangement for real estate." } } }, "auth_ref": { } }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": { "http://www.medifast1.com/role/LEASESNarrativeDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Operating lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": { "r760" } }, "med_OperatingLeaseExpenseNonCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "OperatingLeaseExpenseNonCash", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Non-cash lease expense", "label": "Operating Lease, Expense, Non-Cash", "documentation": "Operating Lease, Expense, Non-Cash" } } }, "auth_ref": { } }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year-Maturity [Abstract]" } } }, "auth_ref": { } }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": { "r393" } }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Current lease obligations", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": { "r393" } }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": {

"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Lease obligations, net of current lease obligations", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": { "r393" } }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": { "http://www.medifast1.com/role/LEASESSupplementalCashFlowInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating cash flow used in operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": { "r394", "r396" } }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "label": "Operating Lease, Right of Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": { "r392" } }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://www.medifast1.com/role/LEASESNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate (as a percent)", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": { "r399", "r632" } }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": { "http://www.medifast1.com/role/LEASESNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYmMnDnHnMnS' format; for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r398", "r632" } }, "med_OptionsAndRestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "OptionsAndRestrictedStockMember", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Options and restricted stock", "label": "Options And Restricted Stock [Member]", "documentation": "Options And Restricted Stock" } } }, "auth_ref": { } }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": { "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies": { "lang": { "en-us": { "role": { "verboseLabel": "Presentation of Financial Statements", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": { "r70", "r71", "r72", "r85" } }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": { "r111" } }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature, attributable to parent entity." } } }, "auth_ref": { "r4", "r9", "r86" } }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Unrealized losses on investment securities", "label": "OCI, Debt Securities, Available for Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": { "r118", "r119", "r120", "r454" } }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED": { "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": { } }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED": { "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss), net of tax", "terseLabel": "Other comprehensive income", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": { "r4", "r9", "r86", "r124", "r127", "r153" } }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSUNAUDITED": { "lang": { "en-us": { "role": { "verboseLabel": "Other expense", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": { "r62" } }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "lang": { "en-us": { "role": { "negatedLabel": "Stock repurchases", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": { "r65" } }, "us-gaap_PaymentsForRepurchaseOfOtherEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfOtherEquity", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "lang": { "en-us": { "role": { "negatedLabel": "Net shares repurchased for employee taxes", "label": "Payments for Repurchase of Other Equity", "documentation": "Amount of cash outflow to reacquire equity classified as other." } } }, "auth_ref": { "r65" } }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "lang": { "en-us": { "role": { "negatedLabel": "Cash dividends paid to stockholders", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": { "r65" } }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of investment securities", "label": "Payments to Acquire Debt Securities, Available for Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r19", "r134", "r185" } }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "presentation": { "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Investments made", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": { "r63" } }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": { "r64" } }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Performance-based Shares", "verboseLabel": "Performance-based share awards", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": { } }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r669" } }, "us-gaap_PrepaidFaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidFaxes" }

"PrepaidTaxes","crdr":"","debit","calculation":{"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED":{"parentTag":"us-gaap_AssetsCurrent","weight":1.0,"order":1.0},"presentation":{"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"},"lang":{"en-us":{"role":{"terseLabel":"Income taxes, prepaid","label":"Prepaid Taxes","documentation":"Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."}}},"auth_ref":{"r596","r607","r701"}}, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities","crdr":"","debit","calculation":{"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED":{"parentTag":"us-gaap_NetCashProvidedByUsedInInvestingActivities","weight":1.0,"order":2.0},"presentation":{"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"},"lang":{"en-us":{"role":{"terseLabel":"Proceeds from sale and maturities of investment securities","label":"Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale","documentation":"Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."}}}},"auth_ref":{"r134","r135","r692"}}, "us-gaap_ProceedsFromStockOptionsExercised":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ProceedsFromStockOptionsExercised","crdr":"","debit","calculation":{"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED":{"parentTag":"us-gaap_NetCashProvidedByUsedInFinancingActivities","weight":1.0,"order":3.0},"presentation":{"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"},"lang":{"en-us":{"role":{"terseLabel":"Options exercised by directors","label":"Proceeds from Stock Options Exercised","documentation":"Amount of cash inflow from exercise of option under share-based payment arrangement."}}},"auth_ref":{"r2","r13"},"us-gaap_PropertyPlantAndEquipmentNet":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"PropertyPlantAndEquipmentNet","crdr":"","debit","calculation":{"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED":{"parentTag":"us-gaap_Assets","weight":1.0,"order":2.0},"presentation":{"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"},"lang":{"en-us":{"role":{"terseLabel":"Property, plant and equipment-net of accumulated depreciation","label":"Property, Plant and Equipment, Net","documentation":"Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."}}},"auth_ref":{"r7","r401","r443","r451","r633"}}, "srt_RangeAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/srt/2024","localname":"RangeAxis","presentation":{"http://www.medifast1.com/role/DEBTDetails"},"http://www.medifast1.com/role/LEASESNarrativeDetails","http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Statistical Measurement [Axis]","label":"Statistical Measurement [Axis]"}}}},"auth_ref":{"r245","r246","r247","r248","r293","r300","r328","r329","r330","r338","r373","r411","r420","r437","r463","r464","r471","r476","r477","r528","r547","r551","r552","r581","r591","r592","r605","r613","r617","r624","r625","r629","r630","r635","r638","r705","r710","r751","r767","r768","r769","r770","r771"}}, "srt_RangeMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/srt/2024","localname":"RangeMember","presentation":{"http://www.medifast1.com/role/DEBTDetails"},"http://www.medifast1.com/role/LEASESNarrativeDetails","http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Range [Domain]","label":"Statistical Measurement [Domain]"}}}},"auth_ref":{"r245","r246","r247","r248","r293","r300","r328","r329","r330","r338","r373","r411","r420","r437","r463","r464","r471","r476","r477","r528","r547","r551","r552","r581","r591","r592","r605","r613","r617","r624","r625","r629","r630","r635","r638","r705","r710","r751","r767","r768","r769","r770","r771"}}, "srt_RepurchaseAgreementCounterpartyNameDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/srt/2024","localname":"RepurchaseAgreementCounterpartyNameDomain","presentation":{"http://www.medifast1.com/role/INVESTMENTSCollaborateArrangementDetails"},"lang":{"en-us":{"role":{"terseLabel":"Counterparty Name [Domain]","label":"Counterparty Name [Domain]"}}}},"auth_ref":{"r141","r142","r264","r288","r404","r421","r444","r598","r599"}}, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember","presentation":{"http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"},"lang":{"en-us":{"role":{"terseLabel":"Cash and Cash Equivalents [Domain]","label":"Cash and Cash Equivalents [Domain]","documentation":"Type of cash and cash equivalent. Cash is currency on-hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."}}},"auth_ref":{"r110"}}, "us-gaap_RestrictedStockMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestrictedStockMember","presentation":{"http://www.medifast1.com/role/EARNINGSPEPERSHARENarrativeDetails"},"http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails","http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails"},"lang":{"en-us":{"role":{"terseLabel":"Restricted Stock","label":"Restricted Stock [Member]","documentation":"Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."}}},"auth_ref":{"r22"}}, "us-gaap_RestructuringAndRelatedActivitiesAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestructuringAndRelatedActivitiesAbstract"},"lang":{"en-us":{"role":{"label":"Restructuring and Related Activities [Abstract]"}}}},"auth_ref":{"us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestructuringAndRelatedActivitiesDisclosureTextBlock","presentation":{"http://www.medifast1.com/role/SUPPLYCHAINOPTIMIZATION"},"lang":{"en-us":{"role":{"terseLabel":"SUPPLY-CHAIN-OPTIMIZATION","label":"Restructuring and Related Activities Disclosure [Text Block]","documentation":"The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."}}},"auth_ref":{"r240","r241","r242","r243","r244"}}, "us-gaap_RestructuringCostsAndAssetImpairmentCharges":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestructuringCostsAndAssetImpairmentCharges","crdr":"","debit","calculation":{"http://www.medifast1.com/role/SUPPLYCHAINOPTIMIZATIONSummaryofComponentsofSupplyChainOptimizationChargesDetails":{"parentTag":null,"weight":null,"order":null,"root":true},"presentation":{"http://www.medifast1.com/role/SUPPLYCHAINOPTIMIZATIONSummaryofComponentsofSupplyChainOptimizationChargesDetails"},"http://www.medifast1.com/role/SUPPLYCHAINOPTIMIZATIONSummaryofCondensedConsolidatedStatementofOperationDetails"},"lang":{"en-us":{"role":{"totalLabel":"Total supply chain optimization","terseLabel":"Total supply chain optimization","label":"Restructuring Costs and Asset Impairment Charges","documentation":"Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation."}}},"auth_ref":{"r6"},"us-gaap_RestructuringReserveAcceleratedDepreciation":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestructuringReserveAcceleratedDepreciation","crdr":"","debit","calculation":{"http://www.medifast1.com/role/SUPPLYCHAINOPTIMIZATIONSummaryofComponentsofSupplyChainOptimizationChargesDetails":{"parentTag":"med_NoncashChargesForSupplyChainOptimization","weight":1.0,"order":2.0},"presentation":{"http://www.medifast1.com/role/SUPPLYCHAINOPTIMIZATIONSummaryofComponentsofSupplyChainOptimizationChargesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Accelerated depreciation charges","label":"Restructuring and Related Cost, Accelerated Depreciation","documentation":"Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan."}}},"auth_ref":{"us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RetailRelatedInventoryPackagingAndOtherSupplies","crdr":"","debit","calculation":{"http://www.medifast1.com/role/INVENTORIESDetails":{"parentTag":"us-gaap_InventoryNet","weight":1.0,"order":2.0},"presentation":{"http://www.medifast1.com/role/INVENTORIESDetails"},"lang":{"en-us":{"role":{"terseLabel":"Packaging","label":"Retail Related Inventory, Packaging and Other Supplies","documentation":"Carrying amount as of the balance sheet date of items used in storage, presentation or transportation of physical goods that are targeted for sale to end-users."}}},"auth_ref":{"r666"}}, "us-gaap_RetainedEarningsAccumulatedDeficit":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RetainedEarningsAccumulatedDeficit","crdr":"","credit","calculation":{"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED":{"parentTag":"us-gaap_StockholdersEquity","weight":1.0,"order":2.0},"presentation":{"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"},"lang":{"en-us":{"role":{"terseLabel":"Retained earnings","label":"Retained Earnings (Accumulated Deficit)","documentation":"Amount of accumulated undistributed earnings (deficit)."}}}},"auth_ref":{"r46","r81","r449","r468","r470","r473","r486","r633"}}, "us-gaap_RetainedEarningsMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RetainedEarningsMember","presentation":{"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHGAINSTOCKHOLDERSEQUITYUNAUDITED"},"lang":{"en-us":{"role":{"terseLabel":"Retained Earnings","label":"Retained Earnings [Member]","documentation":"Accumulated undistributed earnings (deficit)."}}}},"auth_ref":{"r106","r144","r145","r146","r148","r153","r155","r157","r222","r223","r234","r343","r344","r347","r348","r349","r351","r352","r353","r359","r361","r362","r364","r366","r389","r391","r465","r467","r474","r775"}}, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RevenueFromContractWithCustomerExcludingAssessedTax","crdr":"","credit","calculation":{"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED":{"parentTag":"us-gaap_GrossProfit","weight":1.0,"order":1.0},"presentation":{"http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED"},"lang":{"en-us":{"role":{"terseLabel":"Revenue","label":"Revenue from Contract with Customer, Excluding Assessed Tax","documentation":"Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."}}},"auth_ref":{"r95","r96","r171","r174","r175","r178","r180","r181","r182","r183","r291","r292","r438"}}, "us-gaap_RevolvingCreditFacilityMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RevolvingCreditFacilityMember","presentation":{"http://www.medifast1.com/role/DEBTDetails"},"lang":{"en-us":{"role":{"terseLabel":"Revolving Credit Facility","label":"Revolving Credit Facility [Member]","documentation":"Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."}}},"auth_ref":{"us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability","crdr":"","debit","presentation":{"http://www.medifast1.com/role/LEASESSupplementalCashFlowInformationDetails"},"lang":{"en-us":{"role":{"verboseLabel":"Right-of-use assets obtained in exchange for lease obligations","label":"Right-of-Use Asset Obtained in Exchange for Operating Lease Liability","documentation":"Amount of increase in right-of-use asset obtained in exchange for operating lease liability."}}},"auth_ref":{"r397","r632"}}, "srt_ScenarioForecastMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/srt/2024","localname":"ScenarioForecastMember","presentation":{"http://www.medifast1.com/role/INVESTMENTSCollaborateArrangementDetails"},"lang":{"en-us":{"role":{"terseLabel":"Forecast","label":"Forecast [Member]"}}}},"auth_ref":{"r301","r684"}}, "srt_ScenarioUnspecifiedDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/srt/2024","localname":"ScenarioUnspecifiedDomain","presentation":{"http://www.medifast1.com/role/INVESTMENTSCollaborateArrangementDetails"},"lang":{"en-us":{"role":{"terseLabel":"Scenario [Domain]","label":"Scenario [Domain]"}}}},"auth_ref":{"r158","r301","r652","r684"}}, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock","presentation":{"http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables"},"lang":{"en-us":{"role":{"terseLabel":"Schedule of Accumulated Other Comprehensive Income","label":"Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]","documentation":"Tabular disclosure of the components of accumulated other comprehensive income (loss)."}}}},"auth_ref":{"r17","r756","r757"}}, "us-

gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": { "http://www.medfast1.com/role/INVESTMENTSTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Financial Assets Measured at Fair Value on a Recurring Basis", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": { "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": { "http://www.medfast1.com/role/INVESTMENTSCollaborateArrangementDetails", "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": { "r354" } }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": { "http://www.medfast1.com/role/EARNINGSPEERSHARETables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of the Computation of Basic and Diluted EPS", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": { "r686" } }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": { "http://www.medfast1.com/role/INVESTMENTSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]", "documentation": "Investment, Name [Axis]", "auth_ref": { "r218", "r219", "r220", "r346", "r653", "r654", "r655", "r741", "r742", "r743", "r744" } } }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": { "http://www.medfast1.com/role/INVENTORIESTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": { "r15", "r50", "r51", "r52" } }, "us-gaap_ScheduleOfInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentsLineItems", "presentation": { "http://www.medfast1.com/role/INVESTMENTSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investments [Line Items]", "label": "Schedule of Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590" } } }, "us-gaap_ScheduleOfInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentsTable", "presentation": { "http://www.medfast1.com/role/INVESTMENTSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investments [Table]", "label": "Schedule of Investments [Table]", "documentation": "Disclosure of information about investments owned by investment company." } } }, "auth_ref": { "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590" } } }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Activity", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": { "r83" } }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": { "http://www.medfast1.com/role/SUPPLYCHAINOPTIMIZATIONTables", "lang": { "en-us": { "role": { "terseLabel": "Summary of Components Optimization Charges", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": { "r26", "r76", "r77" } }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": { "r303", "r304", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331" } } }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": { "r11", "r12", "r82" } }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": { "http://www.medfast1.com/role/DEBTDDetails", "lang": { "en-us": { "role": { "terseLabel": "SOFR", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": { "r745" } }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://www.medfast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of 12(b) registered security." } } }, "auth_ref": { "r646" } }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://www.medfast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": { "r648" } } }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "lang": { "en-us": { "role": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "lang": { "en-us": { "role": { "verboseLabel": "Selling, general, and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": { "r159" } } }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "presentation": { "http://www.medfast1.com/role/SUPPLYCHAINOPTIMIZATIONSummaryofComponentsofSupplyChainOptimizationChargesDetails", "lang": { "en-us": { "role": { "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.medfast1.com/role/SUPPLYCHAINOPTIMIZATIONSummaryofComponentsofSupplyChainOptimizationChargesDetails", "lang": { "en-us": { "role": { "terseLabel": "One-time severance costs", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": { "r6" } } }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "lang": { "en-us": { "role": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": { "http://www.medfast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": { "r5" } } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "verboseLabel": "Award vesting period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": { "r618" } } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": { "r322" } } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in unit per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": { "r322" } } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."} } } }, "auth_ref": { "r320" } } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {

"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails": { "en-us": { "role": { "terseLabel": "Granted (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan.)" } } }, "auth_ref": { "r320" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails":
"http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails": { "en-us": { "role": { "terseLabel": "Unvested awards (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)", "periodEndLabel": "Outstanding at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": { "r317", "r318" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails": { "en-us": { "role": { "terseLabel": "Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares (Roll Forward)", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period (in usd per share)", "periodEndLabel": "Outstanding at beginning of period (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": { "r317", "r318" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value {Abstract}" } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": { "r321" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails": { "en-us": { "role": { "terseLabel": "Share-based compensation arrangement, fair value of awards vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": { "r324" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails": { "en-us": { "role": { "terseLabel": "Vested (in usds per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": { "r321" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails":
"http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails":
"http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONSummaryOfPerformancebasedShareAwardsDetails": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r303", "r304", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331" } }, "med_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesEarnedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.medfast1.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesEarnedPercentage", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails": { "en-us": { "role": { "terseLabel": "Additional shares earned (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Additional Shares Earned, Percentage", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Additional Shares Earned, Percentage" } } }, "auth_ref": { } }, "med_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesEarnedPerformancePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.medfast1.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesEarnedPerformancePeriod", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails": { "en-us": { "role": { "terseLabel": "Performance period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Additional Shares Earned, Performance Period", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Additional Shares Earned, Performance Period" } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails": { "en-us": { "role": { "verboseLabel": "Exercisable at end of the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": { "r311" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails": { "en-us": { "role": { "verboseLabel": "Exercisable at end of the period (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": { "r311" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodFotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodFotalIntrinsicValue", "crdr": "debit", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails": { "en-us": { "role": { "terseLabel": "Intrinsic value of options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": { "r324" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": { "r315" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails": { "en-us": { "role": { "terseLabel": "Awards granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": { "r313" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of options outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": { "r314" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": { "http://www.medfast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period (in shares)", "periodEndLabel": "Outstanding at end of the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": { "r309", "r310" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": {

```

http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Awards", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [ ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails", "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period (in usd per share)", "periodEndLabel": "Outstanding at beginning of period (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": { "r309", "r310" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued In Period", "auth_ref": [ ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUNAUDITED", "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued In Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": { "r31" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryOfPerformancebasedShareAwardsDetails", "lang": { "en-us": { "role": { "terseLabel": "Equity Award [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": { "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails", "lang": { "en-us": { "role": { "verboseLabel": "Exercised (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises In Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": { "r314" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails", "lang": { "en-us": { "role": { "verboseLabel": "Exercised (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": { "r315" } }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation, shares authorized under stock option plans, exercise price range, upper range limit (in usd per share)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": { "r32" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Award expiration period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r619" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": { "r31" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining contractual life of options exercisable (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r31" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining contractual life of options outstanding (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r84" } }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUNAUDITED", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "negatedLabel": "Net shares repurchased for employee taxes (in shares)", "terseLabel": "Shares withheld for employee taxes", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ ] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails", "lang": { "en-us": { "role": { "terseLabel": "Investments", "totalLabel": "Investment Securities", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": { "r91", "r92", "r668" } }, "med_ShortTermInvestmentsUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "ShortTermInvestmentsUnrealizedGainLoss", "crdr": "credit", "presentation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails", "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains (Losses), Total", "label": "Short-Term Investments, Unrealized Gain (Loss)", "documentation": "Short-Term Investments, Unrealized Gain (Loss)" } } }, "auth_ref": [ ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": { "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "lang": { "en-us": { "role": { "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": { "r70", "r138" } }, "us-gaap_StatementOfEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfEquityComponentsAxis", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUNAUDITED", "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": { "r10", "r44", "r47", "r48", "r106", "r128", "r129", "r130", "r144", "r145", "r146", "r148", "r153", "r155", "r157", "r172", "r222", "r223", "r234", "r290", "r343", "r344", "r347", "r348", "r349", "r351", "r352", "r353", "r359", "r360", "r361", "r362", "r363", "r364", "r366", "r382", "r383", "r384", "r385", "r386", "r387", "r389", "r391", "r403", "r454", "r465", "r466", "r467", "r474", "r522" } }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLID
```

"StatementTable", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUNAUDITED", "http://www.medifast1.com/role/EARNINGSPEERSHARENarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": { "r144", "r145", "r146", "r172", "r184", "r391", "r438", "r472", "r475", "r478", "r479", "r480", "r481", "r482", "r483", "r485", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r498", "r499", "r500", "r501", "r502", "r504", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r522", "r639" } }, "us-gaap-StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": { "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Shares", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": { "r10", "r43", "r44", "r81" } }, "us-gaap-StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUNAUDITED", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Options exercised by directors (in shares)", "negatedLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": { "r10", "r43", "r44", "r81", "r314" } }, "us-gaap-StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUNAUDITED", "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUNAUDITED", "label": "Options exercised by directors", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": { "r10", "r44", "r47", "r48", "r81" } }, "us-gaap-StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap-LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUNAUDITED", "totalLabel": "Total stockholders' equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": { "r44", "r47", "r48", "r73", "r487", "r503", "r523", "r524", "r633", "r645", "r679", "r700", "r755", "r775" } }, "us-gaap-StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity, Attributable to Parent [Abstract]", "auth_ref": { "us-gaap-SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information", "label": "Supplemental Cash Flow Information [Abstract]", "auth_ref": { "us-gaap-TextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TextBlockAbstract", "lang": { "en-us": { "role": { "label": "Text Block [Abstract]", "auth_ref": { "dei-TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": { "http://www.medifast1.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": { "us-gaap-TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain", "presentation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails", "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": { "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r285", "r289", "r365", "r377", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r455", "r621", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r634", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r695", "r696", "r697", "r698", "r747", "r750", "r751", "r752", "r753", "r754" } } }, "us-gaap-TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUNAUDITED", "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": { "r30" } }, "us-gaap-TreasuryStockRetiredCostMethodAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockRetiredCostMethodAmount", "crdr": "debit", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUNAUDITED", "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock retired from stock repurchases", "label": "Treasury Stock, Retired, Cost Method, Amount", "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method." } } }, "auth_ref": { "r10", "r29", "r44" } }, "us-gaap-TreasuryStockSharesRetired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesRetired", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUNAUDITED", "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock retired from stock repurchases (in shares)", "label": "Treasury Stock, Shares, Retired", "documentation": "Number of shares of common and preferred stock retired from treasury during the period." } } }, "auth_ref": { "r10", "r44", "r81" } }, "us-gaap-TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCANGESINSTOCKHOLDERSEQUITYUNAUDITED", "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock from stock repurchases", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": { "r10", "r30", "r81" } }, "us-gaap-TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": { "http://www.medifast1.com/role/INVESTMENTSCollaborateArrangementDetails", "http://www.medifast1.com/role/LEASESNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": { "r354" } }, "us-gaap-USGovernmentCorporationsAndAgenciesSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "presentation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails", "lang": { "en-us": { "role": { "terseLabel": "Government & agency securities", "label": "US Government Corporations and Agencies Securities [Member]", "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": { "r772" } }, "med-UncommittedIncrementalFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240630", "localname": "UncommittedIncrementalFacilityMember", "presentation": { "http://www.medifast1.com/role/DEBTDDetails", "lang": { "en-us": { "role": { "terseLabel": "Uncommitted Incremental Facility", "label": "Uncommitted Incremental Facility [Member]", "documentation": "Uncommitted Incremental Facility" } } }, "auth_ref": { "us-gaap-UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": { "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "lang": { "en-us": { "role": { "verboseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": { "r23", "r24", "r25", "r100", "r101", "r102", "r103" } }, "us-gaap-VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": { "http://www.medifast1.com/role/DEBTDDetails", "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": { "us-gaap-VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": { "http://www.medifast1.com/role/DEBTDDetails", "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": { "us-gaap-WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.medifast1.com/role/EARNINGSPEERSHAREComputationofBasicandDilutedEPSDetails": { "parentTag": "us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.medifast1.com/role/EARNINGSPEERSHAREComputationofBasicandDilutedEPSDetails", "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive common stock equivalents (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": { "r686" } }, "us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.medifast1.com/role/EARNINGSPEERSHAREComputationofBasicandDilutedEPSDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "http://www.medifast1.com/role/EARNINGSPEERSHAREComputationofBasicandDilutedEPSDetails", "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average shares of common stock outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": { "r161", "r166" } }, "us-gaap-WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "lang": { "en-us": { "role": { "verboseLabel": "Weighted average shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "auth_ref": { "us-gaap-WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.medifast1.com/role/EARNINGSPEERSHAREComputationofBasicandDilutedEPSDetails": { "parentTag": "us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "http://www.medifast1.com/role/EARNINGSPEERSHAREComputationofBasicandDilutedEPSDetails", "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average shares of common stock outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": { "r160", "r166" } } } } }

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

75ND.FJM\1G9J.EJG1.KH?OKHGXYA\(\$6<1;R.M)7-7\$VP.O9.P56A.N+P+AWK6KRG6G6H232.Z4Y.C#Y.LY.)DJPT<f&g:~Y\$34(>CHJ\$EV.RHM-M,4'CO-0"#O?N09=?
NCS<~N-9XP3>6~1P0D\$1XW1EQH?1:0Q:Z5.6.0D-M(C(WY0C92V*OD\$O(C~2GBY0+V>3;B@UCI-E9Y?>84BBW.\$%Z271+L&.>Z
M4&WEGC)<~P.07H8)CJW6?7/>~>~>1\$>E\$Y.1(0)V1Q1!<+V7D3./BIN-MIPB8173~.VVVTL\$+>~AMP:=CMSJG\$SR/W\$N+2QR45KQMZ*~1FCT&.UE-0-MR@*+IX/19BT
&N02Q00-1HFV1-K.WUT-M-15ZU1.PM.2Z0Y.Y~.M2M'V+1TZ4AHV0V<~5JQ4/M.DX.4OZ\$SA+2282UOTRM\$Y?CB<-C.DV2L'~GM+P+F40Y.MNNG\$H.H0B*KGU.
IEZ\$~2NCB0616D\$6V@EPADWV.E133Z5\$1ICOD46S'\$1~L-MK2464H0EE(68@T-M(XA1)F15H~.SP.O\$MA3>3.G#HP+0i&DHW\$M..R2M-F40Y1D7U1U@7RA~.=SDN-M-
7U8R.WA-0.V)=YP.4K4XT95L*~Y1)80*~\$8D.YOOS&.(IU3*~GSB-ZU5L-M3-6O)CYP@Q-IM97Z//B-RHO)8/U(M)&=)~9DTf17UW(W-1NYOZ2&RGA\CN0%L@-OPH*X'100DQ#B
L&-M-D5.9ENY1&X\$R5U0H0>~3."H8Y)H61@~PPDG@+CDB5+O3.H1P(Q>.>G&~M-R1U1\$M\$7.WG-M&<6QDD^1.DJZ41.BB6A4O&@&7AA+O>~1A0S-
~(4~\$&A12/730%71@+WX3K-M16L(5DIC30H1R+4'92)EA-X~NEW-Y1.<@/MJR3Z\$K*~ZB3A=10GOL\$A-M.(KTYVLE1+T0Z1VG6W.674R@QOY>YA/
==>4Y3JH'FLA'2VL~*XC8B-M-3)T1:09*Y0&~75PJ24<S1'CG&L4i>~H@<@SB7A~1V4.1O~\$Z.L(3H-M-GLP1C@KJ8R8'T\$10H8A1TH'LHGH
M1>H~J4<P\$E7H1%>5!S0513RWZ.RX2~7L1&<=+OBQ6.Y49S78YX'MZVY~1OE\$V=1.KYE471Y%CU06.&DFTFC2O.>8~?4(OG)RSK-M/Q3+Q/Z%#~\$ZT4J2S-B<~0C9?L13
M~.OKU18R..HY@:L18QR9DHNX\$8A1T2~6J8S.OET74Y18HVC17K)S#20(3ZBM2~1=I-PDY3HJE/I-MJ<L8H1QLB2D+~\$12@~6ZB13H\$A~JHHB~*X7+-
5UHK1.H.F@N0A)AX1VH-MJ2CQ.3TCFR0GQVPV~1+~1ZNO)BEH1OTU0HJD)D-60AP~W2/7YSB10/9FH-M@~0.F.(Q+~S936H0~5J01BPV1?>1SMR-1JR155H0~P#HIMEOLM)
MEG@F#E9Q24821SO1H0<~617D3\$NF18847~1H+Z+JHK5OZ-ER~>GWL1+~M'C3A1>~UJ..+P.A+HE32)LEWFH1+VTFY11<XXE.T6HRL*~ZNM-M0~614Z.9@~17?
GO\$JDG.)7J'B^\$!415U5.1+~(0IPMH+~BK)0.L.Z)1'R-MK47L%CO8+5@G/H-L8)\$Y16L8JF104D%.FI#SE-6<18~@5-MNH(35YQY1.G18E)<5*TO*(P-GM\$BE0(-D\$O-
~4MFIX/L'VOWLBD~2BQ4-MMM'T\$5N~WLOFAFA*TA)U!>~>2\$1E+HOZOE-M8-45KQO.'YQO'MD'G3C183BT7B17L2+P-JL4+~7A/OJ40M&(6N18'5B)\$M+U)K(M+IM:@P.
10+J10/HJ5.+K.C64B7.N+~.SHH-D~Q~<P\$>~1G>~@9*6-MJ&@PB'(C9~\$S\$M.D<>1LJZH8BMU.GF'Y=20GH/W.QJ1=U3\$+V.XWFRP.M6\$~.5'JOI MO4.C~
(#..+GZ8\$TFL041+~P#>S=675Z/DA1VH\$<~065.Z(=MKEMV\$17?>~\$DTFX~1%#JVP5D~*2Q=@1@4X1=19)1~"HTC'QO&Z?H%0.DF-M~*YRQ12HGQR(SOTOV8\$G9Y'7?
L1-80K#R#R%>~1%660IP5(V52.Z+~K~>X%M~1FORBSX~?>~\$QGBX&~..\$R97.Q.M6F1~).1B5-Q.DIMQ60P.1%VH<4@IB<2@<~>X\$>=@LPAHB.L@<+DV~M'KQ
M&S.@~n2/15L67KW@7K04~1C#RP9)9HP330.9\$>~>RT-020AP.WQIFA7RGSGCF1M(ZNL~L4)4HC7+G1E5_V~4-MR9JKO~8F+M6PHSN.R~9R1T7\$VWKKQJ_4+~
F0HWE/C@.(6..049P\$~N-M1~TH7R1+9W7?>Q~W9\$1G1.)=S>~1TTOQICGR1.L&C-810LD\$S\$9M14K2P3B~2G\$W0E0\$U~.2\$H4.V.\$4MA#~52>~^L1+~1@N7.WRR10.1
1+L1UGP34UFEKLS~N)P8U2=9'HSQ-B-M-P.'7-0JBDISA361A\$!&5L.PMM+K@CE7J.Y'MG+~1K1CT13+&~1/FPPIR8FPU~ANX~2CD2.Z.WWG~\$LF8'61@DPBY-MVBG-
7-P<~4C&~WZ!-N.6EO(17GO~42S'73~7BP1OKWM~!<~05\$EJARL\$*~@-MI<4H(QS..S\$5TR5F)OV2_@Y8-AM;<~>C~4HY(DGIND_9\$M~JY8!
<1>J3~(N2B63FZ1B3+~ULSDW~1R'2)SD&77H6JH4F.Q\$5N-MC=JY.C\$Q~*A+2~GK1413X*1L%~E1RZ5COUDH.6H1A&XUM@+1PU15/M'H/9~T&C.SD&@~93
NPG1~2N126~3W3K+~6'61>~MC>~1+STDM'Q1~G1+Y2G~X@W@U.PAJRE97L.M=1+@-BXB71QO7N-
M7PIA(1N7G\$-05UD51~)BO.\$<X)G&4OQ&T1~8Y4H6~*2K1=EQZ.MK5)EDH=HIE~1=Y64.2JH\$~B+RWM<~>QO&fH0'1.X<~G_X16.21O4UWUR..3#Q.4'2Z%~IRS
M'ZKK&+~1T0:C1THPFA&N.1'1BQ4)UGL@G<ZDWB~1'2>~KH5BYU5(C~1M)WTX100\$S@X(-2@7%)1X\$1+YU+FGTO-499G\$761*~(f&NDC8A(//..MP4HR~ULR@AB;75-
~A.912K1@_2Y83.1W3~.Y3X9)FS@d62=@BDDFK12\$1.M'GL-Q-DM<+1T(09=5.T'UPIX121(="G@EY@~243.U1R.R0E?\$H669A&C'W/
MIS#E&K(0)LRK1L812040615(IEZHR<~<~7A4(HG(C)K0W8A116%0..M841A)C)WRHH9QF1<~>41~@~8%K.MC&JX62~17)P~<~(M\$~ZL&C0/M?>
G\$~VU7PXX.Y+1HX8)RP+~D=KIGIE<~4MAGE%KYUWDB(01.G1..9.\$@PP-ERN9AEQOX12.419R-M~<F<~#4RRV3PH@6MA.PB/HIEG.)OY*~14GV6PFI/
MOD2FISQ:=1R8%9D8NG+~F#WAN.Y>EU(&H(8MD\$F16<5.8~5=1@Z(1'X1M>H15=(2%F6PQO-MC#_A0TK.(O&?C-41+7W1&U'19.D0*W'703~#JN:-
MV9A.PBGW00R3XVD.L=WO.LIC=36N15N2LZ660.9\$C=1ZFDBA.276E-MC33EKV@Y1YBK'08>..\$2>~<~14-MG7Z.E14WEY.F70~)XXIU7=WI=~Y163C(G:1H
B05\$>~R'XOFI@Y1J.MRQO.TD&27FD7H1+6N2U4H5&C2.IF4\$5Z461=JY\$<S'3TJ@GVPGV\$~0B-M1_0?~V'TX<1<03.P~\$3JOBX\$E56.F22C\$WUBOU\$UJ\$INSAF=-
ZLKVX-MW2QOB@G.W-A#3BNM&D1~#12>2BG12+5Y1T3>~<0F-M.1.58H4L.W@2UQC~(JG\$Y1~1~20)61K6C~.F=HUP1~PDVHDH3H1..M1%&XG1CU+~W9\$S(G>4<-
~WTB801\$S~==UO.O.3-Q\$FA~\$>)YH11\$M-X.LM-M(&F=)D(3@1IP55)@5J'R'1+1S1C0%7&1\$M.8~3)R6G1~1\$M2(5B)&O=X=6-PUC9)BD1%Q~MH(A<1(G7-
9.0W%~1CUB'0Y9CSROGO~VOC@+GNL01K'1K'2>~SC63&Y&J~M.'O1'Hf65CRH)~E>~&~R>G3YJG6\$US<~#<~4\$Sf(HE)T>@OZFEP.H'6-MJ?
VY*~QB1+0~FJ7YFKE~\$Q~S2)M(G-6@13H91)T.F\$NDS-WJFZ8:QH-MUY+HNARB~#8H1UEZ\$3\$Bf=1/GJ~BNQ6~G*~HD(KZ~<1F~U.9=RVGD16FN-M&23.Y*3A)80V;1
R_V1&4F2KJXR~XOFLS4APBTU0@54~X.W0(A1.9\$W@~MZFC=TMZ@TTCUBV~@LEF447Z@K2BHJA(U~*TAC~P~1~U~P~BS5
M'1~917F+01QA6.S1<~WBV4GYZ/4Z2FK'X~BGG@TA40=16Y86\$~W9@BIV-M7M9\$GI0TBHTP7.G~ZK5M>~7A!H&+DS+HM+GE^N^YVQLGZ+Z1)(JYG3)P\$~M8&1-

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g7*#3C21P MS'FHTFA.NAJ+YAS1.TVM8N15LDGDV2I'DLI;DV4Z<. HUN1S.OAOSGC<7 MJNXN919R4A.4.M63AZC4HXJGJGV9\I\WZ+4<4-JF1@JOIAQ7 M'TIOH&XV180E79M1N6.1J> ULVG&IDU<M9.N.E"Z;777G.A==%K M.NB..M3I>U03&D9&Y9JN+FO;L&9V1<@>.PV%K&V3VZ.IR W5OF0Y+1.SEL.M9T.O1.WFZY6P.4K4'JHFX1DIFZ'FMR;B'M'2K1H'Y'A.L#6#>1.LV *G12BO<D+K)< MR:NOY0&?T3D7N7K6#HCH;1>5BM2&E>N.U\$V.#V1ZB.MY18A;1D M4L12.D8WM\$Z#B-2'f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h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k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

[illegible]

01Q:TWLSEFQVSO=XYYX-MXZ=SDIOH^G7Z^HET-VH> G5U+V.W:R850A:GUOBCH7.WL^M5Z26VCW>2YM2W06G0A1#S9N1#^A&QV>V?@
UFPI40*0X09K>01HQ,OF+KAWD^8F57QF-MV2=LOIHW4M+AF(MPO2M1+31W2YMC6 5QM72SG1Y-MNM(N#-WKV9?OWSH:W)F+&+G9CFV4I087<#N:96DA
MV69#089EGYVY71P>7A2IG7=1DS/DS<^#CG<+1JM960M.C.R#V.S.N>-DIF5U0<^JSGIO M7U+R 9SKW0A+R=I9I+&UBN1AGNEFI2BD BL2SRRY<^6.5S
B55K<M-SOR/\$R#5EGJH)AOB.H+IH-8C2PD)XJ<YI M7R19W5F1<=>5015:KJLN LNN^CJD)Q25787EM58M54L-BH5S:BBG<C M5Y &IG^OK^F-
84L3<3K9YU+1NWA1EGGBH)GIZ>SL^QATV^E5^H72>IV+1FTLQK120P MONK6G1<=>7J.71(LGQ-S8S5HQ/AL0^9XYRT<^&6F#
FF>.>+3JAOQ(0LH<(DXT)H=H.0'0L'D3-0<^1X;IY 8C3((^XBD+^EN9VU/0\$+0.W1=+@L(CQ-MH1.VWR23K.8#>7WVW^X^S<S<AQD/L MIO 5E:|@<3PK^U^71^/X#RBL.L.M.
I+1BIOI^83MC+2^ZHI=P^=^U^I^KRTM::OUH|L^5:7R7F^W^MB.R?45OB9+<#<BWO^*::0.Y2VDFV^IAX+VFG-5ZCV=>?#B@ISOM1FW4>.@C
M+^WV101 59 T561FFX^I^K3<3>K|H|LP3T^H^OJB4KX0B.G<O^Q^#DAI- M83H+H+02U6V^M^7U^U^O^05^=<S1LW.LK#FNP>?FYV^I?@S4E9^4(5#9 M)P0VQ^)?
+OHHU/ R^A-KKIW5.K5>O.G2-YNCOZ52PU>WWDGQ^I^D<-4R5 MXP<8>9TSPBEH?@QD-P4H8.Z^Z^@4-BIF?2R+BU_1J5Z1VIESP>Y^Tz^M^O MW V^D)3TGT670^?Z
ZWUMZNV>NKK7 WW752D6HWYGVZV/LQ(C)C31D^EWN^M@B|C@^*^GLV7G<^HFAVZ-05>G^GMKHUVU04U>U^KW TINU>U^X^MZ MNZF6H^H4D0(Q>+<#74-
RW5H1(3M>+JL/M)M5RL0+VZIV M^7D6^AA^IV^CMBQI5?W5S<.&^4=JKZ?A182DI@U^B^N2>.>1^(\$F.B^DGN M^#5/W8I\$<^YKKHJLZ1G0Q-
NUTJH0Q>2L16MSTKRW+D4OUA.A^AUZHW>+I/ M1NNU@I^I92VH.O+<+Q+15=O>^>1^4Y14K^>T2P/H@8EIH7.9.RJU4>1 M0V>F^T? S^?YJH#=<
(CZT)54HE>ASZ6G(KH<FV3I>:KHP(C) K8BC4 MI<EGED.31^3S12>:DLA^4ID^IL^S^01 MHH 6M\$SXMI9>.<^5 E&9&1^I^L5>1LF3 I^L^M^WMW51 U>2G9^Z^+SA-ALVZ1W
71H7N6Z^<#<+<F M^<H2SD.EDE F51Y:SAHPY>=>YICIN).H2)7TZ+WT^WZ^8<^PS4G0^S^0/=<^GD^0. M^<=<EXO>WAIUGW+1 MBX7 (W9LU:St.U.G.4IN6H2ODI=22J9^Z^
(CF05T08E(B\$1I+H)R3C^F+8<#< MN1K=NL.P2R# 1Z<1^X^G^VPLEA4ICFK^W^<^D 20DH).(<S437 U<^M H JH1 JH0D77ZS1JH697
>CVUD4.H0S=1#U^HMFBJPW>8JKDNXG7 M(AZ:&+>PIHPY9^H|B>#01NVIF+<E3L8^H^A^O^<#^OT3SRZX8<^YT M0+X2^<88Z\$D@f@J H8I3214X<^YD&0GI<^>SNR^<B
8U^<+<W^M\$ MUV3.1(O>^>U^0:W85<48A1+<E5430G6I2LH1BYW+1N7IUS^WU1>A.WBU^<W^<+1+R-AE7ZISS^UQ3I30^2RL+1LV>#P060EI^I^F=X:X:U^U9+<51
M87704 U^W-HD1V2T^YGC+1>JQ(GE)F1YLV^GTEOMM^H2>=>E6S4F22F2I^M^<WBL>NABWUHFUHL MG3^AEV^EW^7SL7^>2L1ZIG&6^<W0XB^FAI^OCIMH^H85-
1.6KLW^<+<2&X^M.N9(OA#11PX^LCU@<^WEGOCVE3G^XK<+>Z>7^YH106^TQ63FDI>.<SXP MGKFI^H^I3W5>U^I^S3HX 85G6D^CG0Q^P51<KHHE6BXLU^X&
(b6+IQON1+M1>+<C(NVY^5V:AGS5M5ZU1X4H+83184#>1.H0Y2BFX=MGV^+71F2^D80Q:9015G3PX<6N^<H^OBI^CGR^Y8@E@T+>R^2A^A+12TXB+3^WQO^<
(M3.3L8RN-2)BM+<+9VRO-N^<#^%1^<EF>=>G^<V^9^6252^<K6>+<1^<MEQI/A+Z+>+J.AC.N^<P2<7S 1QOU\$<^<V^#<7T9.W&HO7+<ZUO^<+<X1>O M4+P067
<0<318^8YM3.31E.49>=<0N^Z^<+<910>Z2^<F0B7^<4NSF+<5 MX^T@<AUCYOA6M9G^N.CPN.K48Z1FMZNYGNO^G@EUL1A0421P1:IBYA^M^M8K\$M^06)VG)IS?<
(J&RRNE0G8R9>=<EURA067^B2IA>>XXMSD^H9(BGZ8QG1^R^M^A5:69B7H6((1^<2W^<0^<8^D^<GL^5^<4^<1^<3&SAWT^<UAMZB^X<^<S<^<I^<S7X9A^<S^<DMQ:8\$<GN1N2S/3^3 MP-I^<Z2S0A0U42Z2>.<PZVE.INPF:(<7H MIQ^U^UW1EL^<S^<94076: M&W+<+<1^<AYK05013>.<C^<05 14>2-
7&0I.BV4EXHAI^KO)G^A+<C296)S^M+<AKD0IMH=BL>R>2(C M-3Q2FW^#^OA/6HFH^N-B3VXG&+<+QVB^#FQCRIZ3^<1D^<2^<D5R4P^<6)BFI
M1EX7WD.^<K8KIHWN^H1^I<0X^P^G1B+<V.Y J99.DGL D-M+151^UO181.M@+NPEK=<C^U8>1L>M90S1\$SSC<^I@/F8^6/ARTFS)W6^7WBD04(IQ#
M4E611^W30R<0 QO5^>^4\$1^H10 (<^<5EHA^V/11 #/4 M-65D+31P.C0P.C.P7V^A^<YK:6S>25E36FRIOO^<Z^<KS2>01=N^<M&N^N(C
<0<^<YXIH.LBR>=<0NS0^P.GU-TN<(<980<CAD)9579U^E4.M67 CZ^<HGW<2L9L>^I^P70^<V.M7.\$Z3^I@>WUAY^W6^1 QS<1K^<R^<
M_S1_5VTDZA7QI^5VAV&<67K>S3HBDG^6Q22^P0X>2PZG 49F72G0+1 M8 P^MB=GWIKAQ^<55XQ=278U6^I^T^T^F^G^<WQHBAB)(<0D^217^#D<1<1
MY<0.9>=190F^<0/WO/FAP^D=PR9C^O31^<QOEF7CHL>C^1.7V^8XB12.SR=O.WM.M1:29I.S7^<V^<G^<GRR1P8C7Z9>1>2>.<DFZNG7U3^<07AU>D<6GNO^<S^<WW M1Z?<
#<QZDK>50.O/WAGZ^<O.KHCFXBPB.LK^<J^<YVY.S1YBGE8P3K^<7T3 MTS^UB3>1^<M0=>1=H2^<1^<IOMFYVWAZT.OIG7V3XX-WX<1H^LGN<3.M^M^1
I^HJH^M^E3LVIG<^OKZ2^I^T.(17GWWJVL^SVEA)2^<G^F^OX.O=2S.SY M54^HW0^<FG2P^KV^<Q^<T^<1^<6&XXP7G7P^<#1>QX:5151N^O.OH11^<
M1^<=3^<V^<#<M128/QOEP>=>Y^IM.S13U^<4F3R1319^0?<08C^H^<E M09L16X6=DK1S^I^H<420R5>U^Y^<Z/9131F^<N0^<1<=<0:QD?W3T)8?=<MI QG
YX^<8F6@E7E.FIRC31.77HUZ3Y9A> MO J^U4A=VL+<+Y^<1AT<=<0=0^<F^<GZ.YO1^<IPI.K^<FYRYVE^I^TE7K10 M(Q^<2S^<Q70ASCFP&1^<R^<#^<D-
<#<#M4Z^<SXSNQ/QL^<XEIH<=<(F9D& MX1^<1^<YGDGE^E0B>+<1YX5.U5CKKCP(9E4H=V^<VUTVQT^<1^<W3T1=<D^<Y^<#^<MR

[illegible]

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k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

(The following text is extremely dense and appears to be a mix of random characters and symbols, likely representing a corrupted or encoded document. It contains no meaningful information.)

MM&=4!IGP.G/=-1.KXXIYDZi\$Q+XF."DR.KX5\$.GHH.W#(1)8!DZK.3&NZ*M<2T4R*11L\$.F#M^1J.E6(GPG^A\$P1P#.T65!JH=0!0!9).G3.93!SS^Z6.MB!G.
R7W!K8A!N0+6.G.ATDYO02C2C*2GZ0!6PC^6.6?WDDPNOO!ISS>3F.8!C^ZTM.M\$C=-P.V.2M<@>=<-S!LE.A.M!C.PL88K!L203N!@S")\$E>3!<35D!V6!VP!SR^K6@8E!2@W9-
&2@QAI.M!5!2J!QXK!J\$.9!S@=>H!-0=Z9.84.9Y5!E!FD@>=<#SPZK?75L!QZXR.M.0DB.#>C.G9Y!Q.M0.C.9!6!1("4!4G+8+6!#.J4435!PFGLO7BIU!15X("M*K84.\$N86&R-
L!T.GWx3BD0=(866F+0*#M!E@.E!F58K+!^S24G5Z(W8+9ZD.MU.0?07P!T!F+SUX\$S".62F2!A!Q=#R"WVKT>J!>#82!+@%#0H#K!C!FX.M!D2.R!A!O!\$*S\$+0<SF(+&=
M!U?7.PL4!H8L!MEP!D!J\$E.AOC.M4354.D!>XGH!F(M.DE.S<2+!\$S018H!O.VYQ?>P!2!6!A?>Z2.M!Q#E6P7A!P#H@!A!S!<G@<Q!H#K!>2.BBF0.C?<GKK>AAH."CYLRB;?>
>7\$R+MN)8G<72J(+V<^9.)\$5!Q;W.O.Z\$O#H^>JG>3&V.4V0D23!UI/6@TGX*L!M<HFC!(TO!>A.C?TULW=RNV!B2!1(OA+@\$."H+=#!X!C3.4U=NEZ.&@VIB!O O
P?#YFG!+>WZ>2!<@=NAH>+8.HA!<A!54.2+7+1!Q!#>S08R!L!W!Z"OK!Q!E8!Q!MH\$O#D!T59!>I7-V<8C+UX?>U.G!6!M!<+!M!EDP8ZD3?Q#>DDG.6.EEH.Q
M!>=>F4B*V3@O!05>OAXN&4YQUA.H\$.Z0@G!C@8N2!J!\$.J\$W!A!>O6.MOSD!>7.TIN#L.W!6#7H!<A!<GKRIN3CX;.<#LRAU!<Y?P\$N.WY9Z!M.M.5Y3!<M!9PYW.
Z.S\$7Y!X-2BG.>5!4TQ4.L\$Q&9!54AZTHAK!4.2!H2.K!M349!P!T!>D.5F37+!T!S>L!Hr;12!YF<LE@P!VQ!6R!<2M.3^>P!Z7W.M9C!>!OOP.G7-
Q>S.Y>N>O@C!Y#<8PER7!ZSQS!P!4!J4M!R2!E!F4.M.K.#M&!<5!GOK!13.Y*=>U&^ZW!<2!506.R!<F!R.O258!FW!6+!R.S^4E>3K029!Z.M.1G!<E\$UJCL!R!IKO0C+U!G/N-D!<
H!4.7Y=0F4!6X.#MS#.02!Z!2!M3F.SCI!<V!X!DG^72!M!<A.IXSPD!+!F@Z!<O!EE!+!#<54!HD&#>=>WT>Y?0.MY6!<VYUN=R-R!E#B.
(U&Y!<AC!<4C0!<12>#!>9!LUR.WXXU!L!S!<X.M!<07!P!>!<BV.F!T43P!<B.#<G!<A!<=!S!J!<A!<KWR68.M!<P.C!<P!<H!Y!<L!R!<M!<7V!Z!<P.O!<M!<P!<5!<X6!<20!<@!<N!<"!<^<H!D!<
!525N.Z!R.BGTY!<T!<J!<MZP6.T!<D!<A!<G.OOKY!<P!<H30!<P!<.>@<^<GP<6!<Q!<HW!<N!<68!<15!<U!<T02!<V!<F!<68.M!<P8CF!<5!<K!<F!<BQ?<.
!C!<"!<BFEFG!<S!<Z!<E!<K!<N!<F!<F!<2!<+!<V7!<P!<A!<G!<B!<2!<D!<2!<J!<L!<6!<N!<W!<P!<P!<"!<O!<F!<L!<5!<1!<1!<Z!<D!<X!<D!<H!<M!<L!<P!<6!<F!<H!<K!<C!<S!<A!<B!<N!<P!<S!<Y!<2!<T!<P!<K!<K!<3!<6!<Q!<J!<W!<^<D!<S!<A!<H!<3!<C!<@>+!<V!<(<
<M!<X!<3!<L!<?<E!<V!<@!<Z!<3!<T!<F!<W!<8!<W!<V!<7!<P!<W!<4!<K!<L!<4!<P!<3!<J!<M!<A!<J!<E!<P!<C!<D!>+!<M!<D!<B!<R!<M!<L!<F!<6!<H!<4!<3!<E!<E!<Y!<^<P!<D!<H!<Y!<588!<D!<U!<W!<5!<4!<N!<@>=<9!<+!<V!<7!<F!<C!<G!<L!<=+!<G!
M.Y8A!<I5!<X!<X!<X!<N!<H!<U!<H!<5!<E!<30!<F!<L0!<W!<3!<E!<W!<Z!<Q!<N!<Z!<H!<U!<G!<3!<J!<M!<X!<F!<3!<X!<Y!<X!<G!<2!<P!<N!<B!<R!<B!<O!<S!<Y!<H!<X!<+!<3!<0!<^<X!<X!<A!<6!<A!<C!<V!<S!<G!<P!<M!<Q!<S!<Y!<43!<L!
%PH>V!<C!<D!<I!<G!<N!<A!<7!<J!<E!<H!<X!<S!<V!<Q!<E!<V!<I!<G!<N!<E!<^<C?<F!<O!<M!<N!<D!<2!<C!<W!<S!<9!<P!<L!<X!<X!<X!<R!<4!<Y!<B!<O!<W!<N!<T!<N!<C!<J!<O!<C!<0!<676>0!<^<P!<L!<5!<S!<G!<P!<G!<G!<@!<H!<M!<A!<H!<P!<U!<X!<V!<P!<D!
D!<@<X!<9!<Y!<74!<W!<4!<A!<K!<O!<7>*<S!<R!<C!<H!<W!<+!<T!<Y!<R!<M!<J!<M!<5!<M!<D!<2!<C!<Y!<N!<K!<Z!<O!<2!<9!<O!<M!<X!<W!<+!<O!<H!<5!<3!<Z!<H!<O!<S!<V!<K!<M!<P!<1!<9!<N!<Z!<C!<C!<C!<Y!<E!<W!<^<5!<7!<B!<+!<P!<4!
H!<P!<R!<L!<H!<X!<+!<Y!<#<2!<H!<I!<9!<Z!<M!<=>C!<O!<5!<D!<0!<S!<V!<7!<6>.<Q!<M!<U!<+!<3!<^<4!<X!<D!<P!<K!<R!<4!<O!<K!<2!<Z!<7!<O!<P!<8!<N!<V!<G!<4!<A!<M!<N!<+!<Z!<A!<M!<X!<M!<P!<3!<+!<N!<M!<O!<W!<O!<K!<Y!<3!<O!<X!<2!<+!<3!<C!<F!<4!<5!<2!<F!<Y!<P!<N!<M!<M!<H!<H!<K!<B!<J!<G!<M!<4!<U!<B!<L!<2!<S!<M!<C!<L!<F!<E!<U!<Q!<3!<O!<L!<O!<1!&

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~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f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

[illegible]

0000910329 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000910329 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000910329 us-gaap:RetainedEarningsMember 2022-12-31 0000910329 us-gaap:TreasuryStockCommonMember 2022-12-31 0000910329 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000910329 2023-01-01 2023-03-31 0000910329 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000910329 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000910329 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000910329 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000910329 us-gaap:CommonStockMember 2023-03-31 0000910329 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000910329 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000910329 us-gaap:RetainedEarningsMember 2023-03-31 0000910329 us-gaap:TreasuryStockCommonMember 2023-03-31 0000910329 2023-03-31 0000910329 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000910329 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000910329 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000910329 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000910329 us-gaap:CommonStockMember 2023-06-30 0000910329 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000910329 us-gaap:RetainedEarningsMember 2023-06-30 0000910329 us-gaap:TreasuryStockCommonMember 2023-06-30 0000910329 us-gaap:RestrictedStockMember 2024-04-01 2024-06-30 0000910329 us-gaap:RestrictedStockMember 2023-04-01 2023-06-30 0000910329 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0000910329 us-gaap:RestrictedStockMember 2024-01-01 2024-06-30 0000910329 us-gaap:RestrictedStockMember 2023-12-31 2023-12-31 0000910329 us-gaap:RestrictedStockMember 2022-12-31 0000910329 us-gaap:RestrictedStockMember 2023-01-01 2023-06-30 0000910329 us-gaap:RestrictedStockMember 2024-06-30 0000910329 us-gaap:RestrictedStockMember 2023-06-30 0000910329 srt:MinimumMember us-gaap:PerformanceSharesMember 2024-01-01 2024-06-30 0000910329 srt:MaximumMember us-gaap:PerformanceSharesMember 2024-01-01 2024-06-30 0000910329 us-gaap:PerformanceSharesMember 2024-01-01 2024-06-30 0000910329 med:GrantedInMarch2022Member med:MarketAndPerformanceBasedShareMember 2023-01-01 2023-03-31 0000910329 med:GrantedInOctober2021Member med:MarketAndPerformanceBasedShareMember 2024-04-01 2024-06-30 0000910329 med:MarketAndPerformanceBasedShareMember 2024-01-01 2024-06-30 0000910329 med:MarketAndPerformanceBasedShareMember 2023-01-01 2023-06-30 0000910329 med:OptionsAndRestrictedStockMember 2024-04-01 2024-06-30 0000910329 med:OptionsAndRestrictedStockMember 2023-04-01 2023-06-30 0000910329 med:GrantedIn2024Member us-gaap:PerformanceSharesMember 2024-04-01 2024-06-30 0000910329 med:GrantedIn2024Member us-gaap:PerformanceSharesMember 2023-04-01 2023-06-30 0000910329 med:GrantedIn2023Member med:MarketAndPerformanceBasedShareMember 2024-04-01 2024-06-30 0000910329 med:GrantedIn2022Member med:MarketAndPerformanceBasedShareMember 2024-04-01 2024-06-30 0000910329 med:GrantedIn2022Member med:MarketAndPerformanceBasedShareMember 2023-04-01 2023-06-30 0000910329 med:GrantedIn2021Member us-gaap:PerformanceSharesMember 2024-04-01 2024-06-30 0000910329 med:GrantedIn2020Member us-gaap:PerformanceSharesMember 2024-04-01 2024-06-30 0000910329 med:GrantedIn2020Member us-gaap:PerformanceSharesMember 2023-04-01 2023-06-30 0000910329 med:GrantedIn2020Member us-gaap:PerformanceSharesMember 2023-01-01 2023-06-30 0000910329 med:OptionsAndRestrictedStockMember 2024-01-01 2024-06-30 0000910329 med:OptionsAndRestrictedStockMember 2023-01-01 2023-06-30 0000910329 med:GrantedIn2024Member us-gaap:PerformanceSharesMember 2024-01-01 2024-06-30 0000910329 med:GrantedIn2024Member us-gaap:PerformanceSharesMember 2023-01-01 2023-06-30 0000910329 med:GrantedIn2023Member med:MarketAndPerformanceBasedShareMember 2024-01-01 2024-06-30 0000910329 med:GrantedIn2022Member med:MarketAndPerformanceBasedShareMember 2024-01-01 2024-06-30 0000910329 med:GrantedIn2022Member med:MarketAndPerformanceBasedShareMember 2023-01-01 2023-06-30 0000910329 med:GrantedIn2021Member us-gaap:PerformanceSharesMember 2024-01-01 2024-06-30 0000910329 med:GrantedIn2020Member us-gaap:PerformanceSharesMember 2024-01-01 2024-06-30 0000910329 med:GrantedIn2020Member us-gaap:PerformanceSharesMember 2023-01-01 2023-06-30 0000910329 med:MarketAndPerformanceBasedShareMember 2024-06-30 0000910329 us-gaap:PerformanceSharesMember 2024-06-30 0000910329 srt:MinimumMember med:OperatingLeaseArrangementForRealEstateMember 2024-06-30 0000910329 srt:MaximumMember med:OperatingLeaseArrangementForRealEstateMember 2024-06-30 0000910329 srt:MinimumMember med:OperatingLeaseArrangementForEquipmentMember 2024-06-30 0000910329 med:CashAndCashEquivalentsExcludingMoneyMarketFundsMember 2024-06-30 0000910329 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0000910329 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-06-30 0000910329 us-gaap:FairValueInputsLevel1Member 2024-06-30 0000910329 us-gaap:FairValueInputsLevel1Member 2024-01-01 2024-06-30 0000910329 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2024-06-30 0000910329 med:CashAndCashEquivalentsExcludingMoneyMarketFundsMember 2023-12-31 0000910329 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0000910329 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0000910329 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000910329 us-gaap:FairValueInputsLevel1Member 2023-01-01 2023-12-31 0000910329 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2023-12-31 0000910329 med:LifeMDMember 2023-10-01 2023-12-31 0000910329 med:LifeMDMember med:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementInitialMilestonePaymentMember 2023-12-31 0000910329 med:LifeMDMember med:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementSecondMilestonePaymentMember 2024-03-18 0000910329 med:LifeMDMember med:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementSecondMilestonePaymentMember 2024-01-01 2024-03-31 0000910329 med:LifeMDMember med:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementSecondMilestonePaymentMember 2024-04-01 2024-06-30 0000910329 med:LifeMDMember med:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementFinalMilestonePaymentMember 2024-06-05 0000910329 med:LifeMDMember med:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementFinalMilestonePaymentMember 2024-04-01 2024-06-30 0000910329 med:LifeMDMember srt:ScenarioForecastMember med:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementFinalMilestonePaymentMember 2024-07-01 2024-09-30 0000910329 us-gaap:RevolvingCreditFacilityMember med:AmendedCreditAgreementMember 2021-04-13 0000910329 us-gaap:LetterOfCreditMember med:AmendedCreditAgreementMember 2021-04-13 0000910329 med:UncommittedIncrementalFacilityMember med:AmendedCreditAgreementMember 2021-04-13 0000910329 srt:MinimumMember med:AmendedCreditAgreementMember 2021-04-13 2021-04-13 0000910329 srt:MaximumMember med:AmendedCreditAgreementMember 2021-04-13 2021-04-13 0000910329 med:AmendedCreditAgreementMember us-gaap:SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember 2024-01-01 2024-06-30 0000910329 med:AmendedCreditAgreementMember us-gaap:BaseRateMember 2024-01-01 2024-06-30 0000910329 med:AmendedCreditAgreementMember 2021-04-13 0000910329 med:AmendedCreditAgreementMember 2024-06-30 shares iso4217:USD iso4217:USD shares pure 0000910329 --12-31 2024 02 false 10-Q true 002-60-30 false 001-31573 Medfast, Inc. DE 13-3714405 100 International Drive Baltimore MD 21202 410 581-8042 Common Stock, par value \$0.001 per share MED NYSE Yes Yes Large Accelerated Filer false false false 10937418 168558000 296188000 343297000 645170000 45120000 85473000 92567000 188065000 123438000 210715000 250730000 457105000 131314000 172009000 250666000 364887000 7876000 38706000 64000 92218000 1296000 462000 2519000 281000 4070000 51000 1647000 53000 2774000 411000 872000 228000 10650000 39117000 936000 92446000 2496000 8837000 773000 22198000 8154000 30280000 163000 70248000 0.75 2.78 0.01 6.46 0.75 2.77 0.01 6.43 10937000 10888000 10923000 10876000 10937000 10917000 10967000 10923000 0.165 0.3 30 8154000 30280000 163000 70248000 32000 90000 43000 99000 28000 0 265000 0 4000 90000 222000 99000 8150000 30370000 59000 70347000 108016000 94440000 39603000 54591000 55489000 55601000 8728000 8727000 12479000 10670000 224315000 224029000 39921000 51467000 13417000 15645000 11770000 14650000 4108000 4117000 293531000 309908000 69148000 86415000 6031000 5885000 75179000 9230000 13069000 16127000 88248000 108427000 0.001 0.001 20000000 20000000 10937000 10896000 10896000 11000 11000 30401000 26573000 26000 248000 174845000 174649000 205283000 201481000 293531000 309908000 163000 70248000 6328000 6342000 2225000 2514000 4625000 3120000 51000 619000 74000 0 372000 0 9000 800000 1752000 0 11689000 0 14988000 49960000 1809000 3721000 206000 2142000 19430000 31851000 1000 3874000 20351000 107205000 17646000 0 16118000 0 3779000 3859000 5307000 3859000 36000 105000 833000 3238000 714000 36996000 0 3602000 1511000 43731000 43000 99000 13576000 59714000 94440000 87691000 108016000 147405000 504000 17520000 659000 18987000 10896000 11000 26573000 248000 174649000 0 201481000 8316000 8316000 59000 2171000 217000 1000 36000 36000 19000 817000 817000 226000 226000 10937000 11000 27963000 22000 182965000 0 210961000 8154000 8154000 2454000 2454000 16000 4000 4000 34000 34000 10937000 11000 30401000 26000 174845000 0 205283000 10928000 11000 21555000 24000 139852000 6398000 155044000 39968000 39968000 69000 606000 606000 4000 105000 105000 30000 3236000 3236000 3602000 84000 10000000 10000000 0 9000 9000 17994000 17994000 10887000 11000 19030000 33000 151826000 0 170900000 30280000 30280000 2000 2514000 2514000 2000 9000 90000 18221000 18221000 10889000 11000 21542000 123000 163885000 0 18561000 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt;text-align:justify">Basis of Presentationsans-serif;font-size:10pt;font-weight:700;line-height:120%>The accompanying unaudited condensed consolidated financial statements of Medfast, Inc. and its wholly-owned subsidiaries ("Medfast," the "Company," "we," "us," or "our") included herein have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for interim reporting and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, certain information and notes that are normally required by GAAP have been condensed or omitted. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included and management believes the disclosures that are made are adequate to make the information presented not misleading. The condensed consolidated balance sheet at December 31, 2023 has been derived from the 2023 audited consolidated financial statements at that date included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 ("2023 Form 10-K").</div><div style="margin-top:12pt;text-align:justify">Results of Operationssans-serif;font-size:10pt;font-weight:700;line-height:120%>The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of results that may be expected for the fiscal year ending December 31, 2024. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in the 2023 Form 10-K.</div><div style="margin-top:12pt;text-align:justify">Presentation of Financial Statementssans-serif;font-size:10pt;font-weight:700;line-height:120%>Presentation of Financial Statementssans-serif;font-size:10pt;font-weight:700;line-height:120%>The unaudited condensed consolidated financial statements included herein include the accounts of the Company. All significant intercompany accounts and transactions have been eliminated.</div><div style="margin-top:12pt;text-align:justify">Use of Estimatessans-serif;font-size:10pt;font-weight:700;line-height:120%>Use of Estimatessans-serif;font-size:10pt;font-weight:700;line-height:120%>The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</div><div style="margin-top:12pt;text-align:justify">Litigationsans-serif;font-size:10pt;font-weight:700;line-height:120%>The Company is, from time to time, subject to a variety of litigation and similar proceedings that arise out of the ordinary course of its business. Based upon the Company's experience, current information and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its results of operations, financial position or liquidity. However, the results of legal actions cannot be predicted with certainty. Therefore, it is possible that the Company's results of operations, financial condition or cash flows could be materially adversely affected in any particular period by the unfavorable resolution of one or more legal actions.</div><div style="margin-top:12pt;text-align:justify">Accounting Pronouncementssans-serif;font-size:10pt;font-weight:700;line-height:120%>Accounting Pronouncementssans-serif;font-size:10pt;font-weight:700;line-height:120%>Adopted in 2024</div><div style="margin-top:12pt;text-align:justify">Fair Value Measurementssans-serif;font-size:10pt;font-weight:700;line-height:120%>In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-03 - Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions ("ASU 2022-03") to (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for

equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. For public business entities, the amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company adopted the standard during the quarter ended March 31, 2024. The adoption of the standard had no material impact on the Company's financial statements.

The Company has not adopted any new accounting standards during the three months ended June 30, 2024.

Recently Issued Accounting Pronouncements - Pending Adoption

In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2023-09—Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) to enhance the transparency and decision usefulness of income tax disclosures, including jurisdictional information, by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disclosures. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024. Prospective application is required, though retrospective application is permitted. Entities are permitted to early adopt the standard. The Company did not early adopt for the 2024 reporting period. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.

Basis of Presentation

The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of results that may be expected for the fiscal year ending December 31, 2024. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in the 2023 Form 10-K.

Presentation of Financial Statements

The unaudited condensed consolidated financial statements included herein include the accounts of the Company. All significant intercompany accounts and transactions have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.

The Company is, from time to time, subject to a variety of litigation and similar proceedings that arise out of the ordinary course of its business. Based upon the Company's experience, current information and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its results of operations, financial position or liquidity. However, the results of legal actions cannot be predicted with certainty. Therefore, it is possible that the Company's results of operations, financial condition or cash flows could be materially adversely affected in any particular period by the unfavorable resolution of one or more legal actions.

Accounting Pronouncements - Adopted in 2024

In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-03—Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”) to (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security; (2) to amend a related illustrative example; and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. For public business entities, the amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company adopted the standard during the quarter ended March 31, 2024. The adoption of the standard had no material impact on the Company's financial statements.

The Company has not adopted any new accounting standards during the three months ended June 30, 2024.

Recently Issued Accounting Pronouncements - Pending Adoption

In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2023-09—Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) to enhance the transparency and decision usefulness of income tax disclosures, including jurisdictional information, by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disclosures. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024. Prospective application is required, though retrospective application is permitted. Entities are permitted to early adopt the standard. The Company did not early adopt for the 2024 reporting period. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.

INVENTORIES

Inventories consist principally of raw materials, non-food finished goods and packaged meal replacements, protein, and supplements held in the Company's warehouses and outsourced distribution centers. Inventories are stated at the lower of cost or net realizable value, utilizing the first-in, first-out method. The cost of finished goods includes the cost of raw materials, packaging supplies, direct and indirect labor and other indirect manufacturing costs. On a quarterly basis, management reviews inventories for unsaleable or obsolete inventories.

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

weight:400;line-height:120%;>Supplemental cash flow information related to the Company's operating leases was as follows (in thousands):

Six months ended June 30,	2024	2023
Cash paid for amounts included in the measurements of lease liabilities	\$3,141	\$3,387
Right-of-use assets obtained in exchange for lease obligations	\$3,141	\$3,387

As of June 30, 2024, the weighted average remaining lease term was 3 years, 5 months and the weighted average discount rate was 2.30%.

The following table presents the maturity of the Company's operating lease liabilities as of June 30, 2024 (in thousands):

	2024	2025	2026	2027	2028	Thereafter
Total lease payments	\$4,783	\$2,553	\$2,618	\$2,440	\$2,440	\$19,827
Less: imputed interest	-	-	-	-	-	-
Operating lease liability	\$4,783	\$2,553	\$2,618	\$2,440	\$2,440	\$19,827

P55M P102M P36M 1200000 1300000 2500000 2800000

</div>

[illegible]

[illegible]

[illegible]

[illegible]

Corporate bonds

Total

149,162

Net losses recognized during the period on equity securities sold

Three months ended June 30, 2024

June 30, 2024

The Company had \$65 thousand and \$0 realized gains for the three months ended June 30, 2024 and 2023.

The Company had \$74 thousand and \$0 realized gains for the six months ended June 30, 2024 and 2023.

During the fourth quarter of 2023, the Company entered into an agreement with LifeMD, Inc (Nasdaq: LFMD), a leading provider of virtual primary care, to purchase shares of common stock of LifeMD for \$10 million. The securities are subject to a registration rights agreement which stipulates that the registration of the securities is to be made as soon as practicable, but not later than 90 days following written demand by the Company. Written demand was made, and the securities registration remained in process as of June 30, 2024. The registration process was completed, effective July 18, 2024. In addition, the shares were subject to a 180-day lock-up period from the closing date of the agreement, December 11, 2023, which expired as of June 8, 2024. The fair value of the investment is recorded within the investment securities of the consolidated balance sheet.

Losses related to the Company's LifeMD investment for the three and six months ended June 30, 2024 and 2023 are summarized in the table below (in thousands).

	Three months ended June 30,	Six months ended June 30,
Unrealized losses recognized during the reporting period on equity securities still held at the reporting date	\$0	\$0
Realized losses recognized during the reporting period on equity securities sold	\$0	\$0
Net losses recognized during the period on equity securities	\$0	\$0

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]